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  Abstract 
Abstract
Introduction: Central nervous system tuberculosis (CNS TB) has a high 
mortality. Microglial derived matrix metalloproteinases (MMPs) are implicated in 
the intense inflammatory response to Mycobacterium tuberculosis (M.tb) as the 
blood brain barrier is rich in MMP substrates.  
Methods: In a cellular model of CNS TB human microglial cells were stimulated 
with M.tb and conditioned media from M.tb infected human monocytes 
(CoMTb). Gene expression of all 23 MMPs and the 4 tissue inhibitors of MMP 
(TIMPs) was analysed by real time RT-PCR and secretion by Luminex and 
Western blotting. MMP gene transcription regulation was studied by luciferase 
promoter reporter assays and NF?B/AP-1 ELISAs. MAP kinases were studied 
by Western blotting. Immunohistochemistry of CNS TB biopsies and ELISA 
analysis of cerebrospinal fluid (CSF) was performed. 
Results: CoMTb up-regulated expression of MMP-1, -3 and -9, which was 
suppressed by dexamethasone. In contrast CoMTb did not alter TIMP-1 and 
reduced TIMP-2, -3 and -4 expression. M.tb up-regulated MMP-1 and -3 
secretion. However, CoMTb drove MMP-1 and -3 secretion more potently than
M.tb but suppressed MMP-2 secretion. Nuclear NF?B p50-p65 heterodimers 
and AP-1 cJun/FosB increased in CoMTb stimulated cells, with concomitant 
degradation of I?B?. Mutation of NF?B and AP-1 sites in the MMP-1 promoter 
abrogated CoMTb promoter activity. CoMTb drove early p38 and ERK MAP 
kinase phosphorylation.  Chemical inhibition of both NF?B and p38 returned 
MMP-1 and 3 secretion to control levels but enhanced MMP-2 secretion that 
was also caspase 8 dependent. MMP/TIMP concentrations in CSF samples 
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from TBM patients were predictive of coma severity and outcome and 
demonstrated that dexamethasone preferentially suppressed MMP-9. 
Conclusions: In CNS TB unopposed MMP-1 and -3 expression and secretion 
are driven by M.tb-infected monocyte networks and regulated by p38, NF?B and 
AP-1. CSF MMP/TIMP concentrations predict disease severity and offer a 
mechanism for the beneficial effect of dexamethasone therapy. 
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Chapter 1 – Introduction 
Chapter 1 – Introduction 
The scourge of tuberculosis (TB) has been affecting humans since antiquity. 
Hippocrates considered TB (“phthisis”) as the most widespread disease of his 
time and the coughing of blood, associated with fever was considered almost 
always fatal. The ancient Greeks considered these symptoms due to an 
imbalance in the four humours. As it is now believed that tissue destruction 
caused by the host immune response to TB is responsible for many of the 
symptoms, signs and sequelae of infection the Greeks may well have been 
nearer the truth than they are given credit for. 
Worldwide Epidemiology of Tuberculosis 
TB is no less important today where 9 million new cases are thought to occur 
world-wide every year and 2 million die as a direct consequence of it [1, 2]. 
Rates of TB rose drastically in the late 1980s due to failing public health 
infrastructure and by 1993 the World Health Organisation (WHO) had declared 
TB a “global emergency” [3]. 13 years later, although incidence rates had 
started to level off it was still considered such a massive global problem that the 
“STOP TB” campaign was launched by WHO in 2006, setting ambitious targets 
in all aspects of TB diagnostics and treatment to be achieved within 9 years [4]. 
Halving TB prevalence and death rates by 2015 are also in the UN Millennium 
Development Goals. 
Sub-Saharan Africa has the highest incidence rates of TB infection (290 per 
100,000 population) but actual numbers of cases are higher in the more heavily 
populated Asian countries such as China and the Indian sub-continent, both of 
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whom report over a million new cases a year [5]. Vietnam, a country with a 
population of about 86 million people reported nearly 90,000 cases of smear 
positive TB in 2000 [6]. This puts it in the top 15 incidence countries in the 
world, yet its TB service is considered a success by WHO standards as number 
of cases put on short-course treatment have been over 70% since 1996 and 
reported cure rates are consistently over 85% [6].
Tuberculosis in the UK 
Introduction 
In the UK TB notification is regulated under the Public Health (Control of 
Disease) Act 1984 and Public Health (Infectious Diseases) Regulations 1988 
and co-ordinated by the Health Protection Agency (HPA), who produce an 
annual TB report from which the following is a summary of the most recent data 
[7].
Epidemiology 
8497 tuberculosis cases were notified to the HPA in 2006 in the UK, giving an 
overall incidence of 14/100,000. This represents a levelling off of TB incidence 
in the UK for the first time since the 1980s. The London region always accounts 
for the largest proportion of cases, 40% in 2006: an overall incidence of 
45/100,000. The majority of cases occur in young adults (aged 15-44 years) 
and 73% of cases were non-UK born. 56% of patients had pulmonary disease.
Central nervous system TB in the UK 2002-2006 
No breakdown of the figures for extra-pulmonary TB was given in the HPA 
annual report to estimate central nervous system (CNS) TB numbers. However, 
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I have been able to obtain the most recent HPA CNS TB data from 2002-2006 
(Table 1). This shows that there has been a 48% increase in the number of 
tuberculous meningitis (TBM) cases from 112 in 2002 to 166 in 2006 (the last 
year when data is available). In parallel a 46% increase in reported cases of 
“other CNS TB” (which equates to CNS tuberculomas as spinal TB is recorded 
as bone TB) over the same 5 year period. The number of cases of 
tuberculomas is lower than TBM: 48 rising to 70 cases over the same five year 
period. Therefore TBM accounts for a mean of 73% of all CNS TB when the 5 
year data is averaged (694/948 cases). In 2006 CNS TB made up 2.9% of all 
TB cases and 6.5% of all extra-pulmonary TB. 
Table 1. Number of tuberculosis cases with CNS disease: England, Wales 
& Northern Ireland, 2002 – 2006.
Year TBM CNSother Total*
2002 112 (72) 48 (28) 155
2003 116 (69) 54 (31) 168
2004 127 (74) 48 (26) 171
2005 173 (77) 57 (23) 225
2006 166 (72) 70 (28) 229
         *Some cases had site reported as both TBM and CNS other hence 
         the total is less than the sum. Numbers presented are n (%). 
         Source:  Enhanced Tuberculosis Surveillance as at 14/08/08, Health 
         Protection Agency Centre for Infections. 
Ethnic make-up of TB cases in the UK and drug resistance patterns 
In 2006 tuberculosis incidence was 95/100,000 among the non-UK born 
population compared to 4/100,000 among UK born persons. However, only 
20% of non-UK born cases arrived in the UK in the two years prior to their 
diagnosis, suggesting that port of entry screening for active disease alone will 
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not pick up enough cases to affect on-going transmission. Among the non-UK 
born population, most cases belonged to the South Asian group (45%), but the 
highest incidence rate was among those belonging to the black African ethnic 
group (395/100,000), which is higher than the WHO TB rate for sub-Saharan 
Africa. 7.7% of TB isolates were resistant to at least one first line drug and 6.9% 
were isoniazid resistant. Multi-drug resistance remained low at about 1.1%. 
Death and TB in the UK 
Among cases with treatment outcome reported (88% of all cases from 2005 – 
the most recent data available) 453 patients with TB in any site died whilst on 
treatment, giving a death rate of 7%. However, most deaths were in the over 65 
years age group (25% deaths) and it can be assumed that some patients were 
dying with, not because of, TB. Nevertheless the HPA considered that TB was 
causative of death in 31% of cases, equating to 140 deaths per year. A 
significant rise in the number of HIV-TB co-infected cases will have contributed 
to this [8]. 
CNS TB and death 
Unpublished data from the treatment outcome database was also obtained from 
the HPA to give crude CNS TB related death rates (Table 2). CNS TB 
accounted for 15% (21/140) of TB deaths in 2005. Although the number of 
deaths is small ranging between 11 and 21 per year the overall 5 year averaged 
death rate from CNS TB in the UK is still high at 16% (99/618). Rates of death 
from TBM are lower than those reported from the developing world literature, 
which probably reflects better access to intensive care, radiological and 
neurosurgical services.
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Tuberculomas appear to run a more benign clinical course with an 11% total 
death rate (19/174), which is lower than the TBM rate of 18% (83/457, p=0.03 
for group comparison by ?2 test). No data on HIV status, severity of disease at 
presentation or time to diagnosis were available to assess either the impact of 
HIV or whether UK doctors are performing well at diagnosing CNS TB. 
Table 2. Number of deaths among tuberculosis cases with CNS disease: 
England, Wales & Northern Ireland, 2002 - 2006#. 
TBM CNS other Total*
Year Total # Deaths(%)** Total
# Deaths
(%)** Total
# Deaths
(%)** 
2002 101 12 (12) 37 6 (16) 134 16 (12) 
2003 107 26 (24) 45 6 (13) 150 32 (21) 
2004 107 27 (25) 40 4 (10) 143 30 (21) 
2005 142 18 (13) 52 3 (6) 191 21 (11) 
         # among cases with treatment outcome reported (hence numbers less than table 1). 
         * some cases had site reported as both CNS meningitis and CNS other. 
         ** died before completing TB treatment. 
         Source:  Enhanced Tuberculosis Surveillance as at 14/08/08, Health Protection Agency Centre for Infections. 
The HIV epidemic and TB – global perspectives 
The onset of the HIV epidemic has further fuelled the rise in TB incidence as 
rates of TB mimic those of HIV and HIV is the strongest risk factor known for the 
reactivation of latent TB disease [9]. Without anti-retroviral therapy 
immunosuppressed HIV positive patients have a 10% annual risk of reactivating 
latent disease, whereas HIV negative counterparts carry a 10% lifetime risk 
[10]. It is estimated that about 10% of all new TB and 12% of TB deaths are 
attributable to HIV co-infection. This is quite geographically biased though as in 
Africa it is over 30% but in most developed nations well below 10% where 
antiretroviral medication is more readily available. TB treatment success rates 
are similar between HIV positive and negative patients, but the former are at a 
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higher risk of reinfection and death. For example in a cohort of South African 
miners 13.7% of HIV positive patients with active TB died, compared to only 
0.5% of those HIV negative patients [11].
TB Pathogenesis 
Mycobacterium tuberculosis (M.tb) is an aerobic, non-spore forming acid fast 
bacillus that principally infects humans. Spread from person to person is due to 
inhalation of airborne particles containing bacilli coughed from the lungs of an 
infectious person. They are small (1-5 ?m) so they can remain airborne far 
longer than droplets that spread other respiratory illnesses such as influenza. 
The initial infection is thus pulmonary, which can present with a productive 
cough, fever, weight loss and sometimes haemoptysis (“primary progressive 
TB”). However, initial infection is usually asymptomatic leading to latent 
infection. It is during this early asymptomatic phase that a transient low level 
bacteraemia leads to dissemination of bacilli around the body.
Latent infection occurs when the infection is self-contained by complex immune 
mechanisms. Once alveolar macrophages phagocytose M.tb the bacilli can 
inhibit IFN-? signalling and arrest the formation of phago-lysozomes. 
Phagosome acidification is the final step to successful intracellular killing of 
pathogens. Thus infection can remain dormant for many years, with viable non-
replicating bacilli remaining within macrophages. Recent evidence suggests this 
may be mediated by Rv3671c, a pathogen gene encoding a membrane-
associated protein of previously unknown function. M.tb mutants with this gene 
deleted were unable to grow in acidified broth and failed to maintain intra-
bacterial pH in IFN-? activated macrophages and in mice [12]. In normal 
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circumstances infected macrophages process M.tb peptides and present them 
on cell membrane expressed class I and II major histocompatability complex 
(MHC) molecules. However, it is believed mycobacteria remain in phagosomes 
and do not gain access to the cytosolic MHC-I presentation pathway. In addition 
M.tb drives apoptosis in adjacent non-infected macrophages, thereby reducing 
antigen presentation [13]. So how is efficient T-cell cross-priming achieved?
Some authors believe non-infected macrophages and dendritic cells (DC) ingest 
the apoptotic remnants (vesicles) of dead cells and after endosomal processing 
presentation of antigen to T-cells occurs [14]. Certainly these apoptotic vesicles 
are immunogenic and can be used to “vaccinate” mice protecting them against 
subsequent infection [15]. Additionally this process leads to presentation of 
mycobacterial lipid to CD1 restricted T-cells via CD1b molecules (expressed by 
DCs but not macrophages), an important further source of a Th-1-like T-cell 
response. Others, however, consider that autophagy occurs. This innate 
immune response to intracellular pathogens is induced in vivo by IFN-? and in 
vitro by drugs like rapamycin. It allows the host to overcome mycobacterial 
phagosome maturation block, leading to cytosolic processing of mycobacterial 
antigen and successful presentation of antigen on MHC molecules [16].  
Either way cytolytic CD8+ and Th-1 polarised CD4+ T-cells are stimulated by 
M.tb infected macrophages and DCs. CD8+ T-cells then lyse and kill some of 
the infected macrophages by inducing apoptosis and using molecules like 
granulysin. Both types of T-cell secrete IFN-? in response to engagement of TB 
antigen/MHC to the appropriate T-cell receptor and are co-stimulated by 
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macrophage derived IL-12 and -18. As this system does not eliminate all viable 
bacilli a granuloma forms, with central coalesced monocytes (multinucleate 
giant cells) surrounded by a mixed T-cell population and a fibrous cap of 
stromal cells. Macrophages are sustained in the granuloma by a complex cell 
mediated immune (CMI) response involving secreted chemokines, IL-2, TNF-?
and IFN-? [17]. If the centre of the granuloma becomes necrotic then caseation 
is said to have occurred as the material has a cheese-like appearance. It is this 
process that drives local tissue destruction. 
Reactivation can take place at anytime in a person’s life once they are latently 
infected due to defects developing in the innate and adaptive immune response. 
About 5-10% of those latently infected will reactivate disease at some time in 
their life. Well described immune defects include HIV infection, corticosteroid 
therapy, poorly controlled diabetes mellitus, cancer, renal failure, vitamin 
deficiencies, anti-TNF-? therapies (increasingly used in the treatment of 
connective tissue diseases, such as rheumatoid arthritis) and other inheritable 
abnormalities in both cytokine production and receptor function (e.g. involving 
IFN-? and IL-12) [18-23]. Geographical genetic dispositions exist too, such as 
polymorphisms in the zinc transporter solute carrier family 11 member 1 
(SLC11A1: formally NRAMP1, natural resistance-associated macrophage 
protein-1) [24]. 
Clinical features of active disease 
TB presents in a myriad of ways but the hallmark is one of tissue destruction, 
often in excess of bacillary load. In about 50% of cases recurrent pulmonary 
infection occurs, often with destructive cavitatory lesions in the lungs where 
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M.tb can freely replicate leading to cough and haemoptysis. Cervical 
lymphadenopathy can breakdown leading to scrofula, more common in children 
and young women. Pleural disease presents as breathlessness caused by an 
effusion. Fever of unknown origin associated with disseminated infection, or 
“miliary TB”, is so named because the pulmonary infiltrates look like millet seed 
[25]. Disease of the central nervous system (CNS) is considered below and is 
more common in children and HIV patients. TB of the spine (Pott’s disease), 
which can lead to paraplegia, is the commonest form of bony involvement. 
However, TB appears to be able to infect almost any part of the body as the 
vast back catalogue of case reports atone to [26-33]. 
Diagnosis is often based upon clinical suspicion as culture (where available) 
takes several weeks and smear is insensitive. The tuberculin skin test (injection 
of a bleb of purified protein derivative intradermally) can be helpful if strongly 
positive but can be negative in active disease and is confounded by previous 
BCG vaccination or exposure to environmental mycobacteria. Interferon-?
release assays (IGRA) are based on stimulating whole blood with M.tb specific 
peptides (early secretory antigenic target, ESAT-6 and culture filtrate protein-10, 
CFP-10) not found in M. bovis BCG due to deletion of region of difference 1 
(RD-1). They have proved more useful in diagnosing latent than active disease 
and are not confounded by BCG vaccination [34]. 
Treatment
Latent disease can be treated with one or two drugs for 3-6 months. Treatment 
of symptomatic disease is more complicated with anti-mycobacterial antibiotics 
needed for at least six months. Combinations of three or four drugs, such as 
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isoniazid, rifampicin, pyrazinamide, streptomycin and ethambutol are used for 
two months with a further four months of isoniazid and rifampicin. Extensive 
tissue destruction (such as pulmonary cavitation or cranial nerve palsies) 
develop over the long periods of time that disease is present before treatment is 
commenced. Furthermore exposure of antigen to the immune system at the 
onset of treatment can lead to worsening of symptoms before cure. This 
situation is complicated by drug-drug interactions, poor absorption and 
resistance of M.tb isolates to these drugs. Resistance to isoniazid and 
rifampicin is defined as multidrug resistant TB (MDR-TB). If isolates are 
resistant to all first line drugs, fluoroquinolones and second line injectables (e.g. 
kanamycin) it is defined as extensively drug resistant TB (XDR-TB). MDR-TB 
and XDR-TB carry a poorer chance of cure but individualised treatment can be 
efficacious [35]. However, with HIV co-infection and no anti-retroviral therapy 
XDR-TB is almost universally fatal [36]. 
Resistance can be present in the infecting organism or develop during 
treatment due to poor compliance. Drug resistance is currently only a 
consequence of TB resurgence and poor treatment, not yet a cause of rising 
rates. In today’s global world, like in many areas of microbiology, the rise of 
organisms resistant to drugs considered the backbone of TB treatment since 
the late 1940’s threatens to return us to the pre-antibiotic era [37]. Although new 
drug classes are being developed and older drugs, such as the 
fluoroquinolones, being tested in TB novel approaches to treatment are urgently 
needed. It is in this context that the study of TB immunology and in particular 
the host response to infection by M.tb has an important role to play.
19
Chapter 1 – Introduction 
CNS TB – specific aspects 
Epidemiology 
Accurate estimates of the burden of tuberculous disease due to involvement of 
the CNS are difficult to obtain because the greatest number of cases of TB are 
in the developing world where access to diagnostic tools and central record 
keeping are limited. Therefore the best estimates are from the USA where 1.2% 
of all TB reported to the CDC involved the meninges, making up 5.9% of extra-
pulmonary TB [38]. Worldwide, using this rate to extrapolate, this equates to 
approximately 20,000 cases a year. However, this is likely to be an 
underestimate as the US has a lower burden of HIV positive TB cases, where 
CNS TB is more likely to occur. Thus the UK data presented above broadly 
reflects US figures. Other risks reported for CNS TB include excess ethanol 
use, immunosuppression and carcinomas.  
Pathogenesis 
TB affects the central nervous system as meningitis (TBM), CNS tuberculomas 
and rarely as a brain abscess. Classic experiments, using intra-carotid injection 
of bacilli in guinea pigs and rabbits by Rich and McCordock in 1933 
demonstrated that the local rupture of a granuloma into the subarachnoid space 
was the most likely explanation for spread of disease into the CNS, rather than 
blood-borne bacilli crossing the blood brain barrier (BBB) directly [39]. 
Nevertheless M.tb bacilli are able to penetrate and cross brain endothelial cells 
in vitro, but these endothelial models do not have complete BBB structure [40]. 
Rich and McCordock confirmed their animal model work with an extensive 
review of TBM patients’ post-mortems, showing that in almost all cases they 
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could identify a specific point where a granuloma was juxtaposed to 
subarachnoid tissue [39].
Once M.tb has reached the CNS leucocytosis of the CSF, a prominent feature 
of TBM, occurs. This is mediated by pro-inflammatory cytokines, chemokines 
and matrix metalloproteinase (MMP) release [41-43]. TNF-? plays a central role 
in BBB breakdown and immunopathology in TBM. Rabbits inoculated intra-
cisternally with a virulent strain of M. bovis had increased survival rates when 
thalidomide, a drug with anti-TNF-? secretion activity, was co-administered with 
anti-tuberculosis drugs [44, 45]. In the same rabbit model, using an M. bovis
BCG strain overexpressing murine TNF- ?, higher CSF concentrations of TNF-?
were correlated with higher CSF white cell counts and increased tissue 
destruction [46]. However, modulation of TNF-? in CNS TB patients has proved 
disappointing [47, 48]. 
CSF IL-6 concentrations were independently associated with severe TBM in a 
study of patients with TBM from Vietnam but there is no published mechanism 
to explain this effect [49]. In the same study HIV positive patients with lower 
CSF IFN-? concentrations had poorer clinical outcomes, with IFN-? levels 
mirroring lower peripheral and CSF CD4 counts [49]. Subsequently CD3+CD4+ 
lymphocytes and monocytes predominate in HIV negative TBM but CSF 
neutrophils are an early feature of TBM, suggesting these cells may play an 
important role in the pathogenesis of TBM [50, 51]. Although treatment is 
effective in many patients with CNS TB it is clear that inflammation takes much 
longer to abate. Many months after treatment has commenced patients still 
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have evidence of BBB dysfunction and elevated CSF concentrations of many 
inflammatory molecules [50, 52]. 
Toll like receptors (TLRs), pattern recognition molecules used by the innate 
immune system, are known to sense mycobacteria. TLR2, 4 and 9 have all 
been implicated in the immune response to TB [53-56]. TLR2 genotype 597CC 
was associated with susceptibility to TBM, especially when patients had miliary 
disease, suggesting it controls the pathogen’s ability to disseminate [57]. 
Patients with TLR2 597TC allele were more likely to be infected with M.tb of 
East Asian/Beijing genotype, with the Euro-American lineage of M.tb appearing 
to cause pulmonary rather than meningeal disease. Host and pathogen 
genotypes may depend upon the geographical regions where they co-evolved 
as often these associations are not repeated in other parts of the world [58].
Not all CNS tissue destruction is host mediated though. M.tb strain background 
affects phenotype. East Asian/Beijing genotype was associated with shorter 
duration of illness and fewer CSF leucocytes [59]. Different strains of M.tb
caused varying amounts of CNS damage in the rabbit TBM model, in part 
mediated by pathogen polyketide synthase-derived phenolic glycolipid (PGL) 
[60]. The W-Beijing family is said to be the only group of M.tb strains able to 
synthesise PGL, perhaps explaining the more aggressive clinical phenotype 
seen with this strain [61-63]. Silencing the pks1-15 gene, required for the 
synthesis of PGL, in H37Rv M.tb does not give a pathogen with the same 
phenotype as that originally described for the HN878 isolate [62]. Perhaps this 
is because pathogen strain may also affect host type I interferon induction and 
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have negative effects on pro-inflammatory signalling pathways via production of 
negative regulators of cytokine pathways such as suppressors of cytokine 
signalling (SOCS) [64]. What becomes clear from these data is that pathogen 
stimulated, host driven tissue destruction is central to many of the clinical 
problems observed in CNS TB. 
Clinical features 
TBM presents as the classic triad of fever, neck stiffness and headache in up to 
90% of patients unless aged over 60 years [65-67]. Additional factors that aid a 
diagnosis of TBM over the main differential of bacterial meningitis (BM), 
especially where prior antibiotics have been administered, are being younger 
and HIV positive. Duration of illness is usually greater than 10 days in TBM. In 
contrast it is usually only 2-3 days in BM [68, 69]. Cranial nerve palsies are 
statistically more common in TBM (~25% patients) but occur in BM frequently 
too. HIV infection does not appear to affect clinical presentation, although co-
existent extra-pulmonary TB disease may be clinically apparent [66, 70, 71]. 
Diagnosis 
CSF opening pressure is raised during lumbar puncture (LP) and total white cell 
count is usually less than 900 cells/?L. It can be over 10,000 cells/?L in BM, 
which is usually accompanied by a systemic leucocytosis unlike TBM. Although 
neutrophils predominate early in both diseases, it is rare for an LP to be done at 
this time in TBM so a mononuclear cell infiltrate is usually apparent. When 
clinicians are uncertain of the diagnosis a repeat lumbar puncture 48 hours after 
the first LP is usually unchanged in TBM where anti-tuberculosis treatment has 
not been administered. In BM this second LP would usually demonstrate a fall 
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in opening pressure, CSF white cell count, lactate and protein but a rise in the 
CSF:blood glucose ratio and the proportion of CSF lymphocytes [65]. 
TST and IGRA appear to be less useful in the diagnosis of TBM than latent TB, 
in keeping with findings for active pulmonary disease [49, 72, 73]. It is known 
that malnutrition (leading to micronutrient deficiencies) and HIV affect the TST, 
both risk factors for TBM [74-76]. Rates of TST positivity in TBM vary between 
20-50% in most series, despite high levels of BCG vaccination [77, 78]. CSF 
has been used with the IGRA kits to diagnose TBM [79]. Sensitivity in this small 
series was 84% and specificity 92% but culture positivity was only 16%, 
meaning a large number of diagnoses were based on clinical features. 
However, it does suggest that the CNS TB immune response is tissue specific, 
analogous to findings in pulmonary TB where peripheral blood, but not 
pulmonary, responses to mycobacterial antigens are often negative [80, 81] . 
CSF smear, performed on fresh CSF, stained for acid fast bacilli by the Ziehl-
Neelsen method is the initial diagnostic test performed in most laboratories. 
Centrifuging more than 6 mls of CSF for 15 minutes at 3000g, then viewing 
areas of high cellularity for at least 30 minutes yielded a smear sensitivity of 
58% in a study of over 100 patients, confirming the published evidence from 50 
years previously [68, 82]. Even so this is not always possible where only a small 
volume of CSF has been taken from the patient, e.g. in cases of suspected 
paediatric TBM. Smear alone will also give no information about M.tb drug 
susceptability.
24
Chapter 1 – Introduction 
The gold standard of TBM diagnosis is therefore culture of M.tb from the CSF, 
which is very dependent upon the laboratory’s experience of CNS TB cases. 
Therefore published rates of sensitivity vary between 20-90% [82, 83]. CSF is 
more likely to be smear and culture positive in HIV positive patients and when 
CSF neutrophils predominate [51, 66, 70]. M.tb has a doubling time of about 
one day and so grows in 28-42 days on standard solid media, like Löwenstein-
Jensen; too slowly to influence the early management of patients with 
suspected TBM. Using liquid culture systems reduces time to positive culture, 
has an increased sensitivity and can be used to perform direct sensitivity testing 
by introducing anti-tuberculosis drugs into culture medium. However, these 
automated systems are prohibitively expensive for most laboratories in low 
income settings. In addition the increased sensitivity is at the cost of increased 
contamination from bacterial overgrowth and cross-contamination from other 
positive specimens being handled in the laboratory concurrently. More recently 
microscopic observation drug sensitivity assay (MODS), known to work well 
with respiratory specimens from suspected TB patients, has been validated in 
TBM [84-89]. MODS is a liquid culture system, developed with low income 
settings in mind, that utilises the characteristic beaded appearance of M.tb
observed down a light microscope to enhance the speed of diagnosis. Anti-
tuberculosis drugs are included in Middlebrook liquid culture medium in some 
culture wells allowing direct sensitivities to be read by observing a lack of 
growth. MODS out-performed standard liquid culture giving a positive result in a 
median of only 6 days compared to 16 days using the best liquid system [84]. 
The main drawback is that it is heavily reliant upon personnel as plates need 
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viewing by a trained technician every few days, but in low income settings this is 
currently more economical than computer assisted systems. 
PCR techniques are no more sensitive than a well performed CSF smear but 
require addition expertise, finance and time. Laboratory contamination has been 
a particular problem using such a highly sensitive system too. The role of PCR 
appears to be in confirming a diagnosis of TBM and suggesting possible drug 
resistance as specificity and positive predictive values are high [90]. Many other 
laboratory tests for TBM have been assessed: detection of anti-mycobacterial 
specific antibodies, secreted/released mycobacterial antigen, tuberculostearic 
acid and detection of lymphocyte inflammatory molecules (e.g. adenosine 
deaminase) with variable success dependent upon whose hands the test is in 
[91]. Unlike the MODS technique test success appears to be difficult to transfer 
between laboratories and may be also vary dependent upon the population 
being tested. 
Both computerised tomography (CT) and magnetic resonance imaging (MRI) 
are useful tests in the diagnosis of TBM. In unselected patients with CNS 
symptoms of meningitis it is not possible to diagnose TBM confidently on 
neuroimaging alone as the differential diagnosis is wide, including non-
infectious causes such as sarcoidosis, vasculitis and tumours. Where clinical 
suspicion and other tests are suggestive a combination of basal enhancement, 
hydrocephalus and evidence of infarction appears to be the best indicator of 
TBM in children and adults [92-96]. In older adults and HIV positive patients 
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imaging is less good, perhaps due to a poorer inflammatory response in the 
subarachnoid space [97, 98]. 
The diagnosis of tuberculomas or TB brain abscesses is more difficult as clinical 
features usually include evidence of a space occupying lesion and so LP is 
rarely undertaken. CNS imaging series confirm that any number of lesions may 
be apparent. Only 30% have solitary lesions and lesions can be of any size [99-
101]. Confusing the diagnosis with other infectious causes of multiple CNS 
mass lesions such as cysticercosis, a common cause of epilepsy in South 
Americans and Indians, is well described [102]. TB can still be a surprising 
finding for surgeons biopsying a mass lesion thought to be a tumour [103]. 
Histopathology of excised tissue reveals typical granuloma formation and acid 
fast bacilli in some cases [104]. Concurrent TB discovered elsewhere occurs in 
about 25% cases of CNS TB so is worth investigating for. 
Prognosis and outcome 
Absolute numbers of cases with CNS involvement are much lower than other 
forms of TB. Nevertheless these manifestations account for a large percentage 
of the attributable morbidity and mortality of TB disease with overall global 
mortality from CNS TB estimated at 60-70% although rates in the UK presented 
above are lower [66, 69, 105]. In a paper reporting on 292 post-mortems 
performed in patients dying from TB performed between 1972 and 1976 in India 
TBM was the main cause of death in both children (70% deaths) and adults 
(55%). Isolated TBM was more common in adults than children (50% versus 
22% respectively). TBM affected all age groups equally, unlike miliary disease 
which was almost twice as common in the under 15 year old group (39.5% 
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versus 23.9% respectively). BCG vaccination appeared to protect children from 
TBM as is generally thought to be the case [106]. Like the UK data above 
tuberculomas seem to have a more benign course in this series as only 3% of 
autopsied patients had them as the main finding. Although this paper gives no 
indication to the denominator value of how many other deaths due to TB were 
not autopsied during the same period it gives an insight into how over 
represented CNS TB is in TB mortality figures. 
Once diagnosed with TBM or CNS tuberculomas patients have a risk of 
mortality of 20-40% if HIV negative, rising to 80% if co-infected despite the use 
of dexamethasone [71, 107]. Neurological disability is seen in up to 50% of all 
survivors of CNS TB followed-up long-term [108, 109]. This is partly because 
they have a broad differential diagnosis and treatment is often delayed. 
Repeatedly clinical stage, extent of coma and focal neurological signs on 
admission to hospital are predictive of poor outcome from TBM [110-112]. 
Laboratory parameters can also predict outcome: high initial CSF 
concentrations of lactate and protein, low numbers of CSF white blood cells (in 
particular neutrophils) and low CSF glucose levels are associated with poorer 
outcome [52, 67, 73, 113]. Single drug resistance in M.tb isolates does not 
affect outcome but MDR-TB can [113-115]. There are no data currently on 
XDR-TB.
Treatment 
Therapy, when started, is prolonged and frequently complicated by worsening 
of symptoms before recovery [83, 95, 116]. This is likely to be due to an 
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increase in tissue destruction driven by an enhanced inflammatory reaction to 
revealed mycobacterial antigens [117]. Such a reaction is especially poorly 
tolerated in the CNS where there is less room for expansion of lesions and 
development of hydrocephalus may be a pre-morbid event in parts of the world 
where access to neurosurgery is sparse [118].
As tissue destruction is widely apparent in CNS TB concomitant steroid therapy 
might be beneficial. Clarification that adjunctive steroid therapy reduces 
mortality is only available in TBM [119].  In a randomised, placebo controlled 
trial of 545 patients receiving intravenous dexamethasone at a starting dose of 
0.4mg/kg/day receipt of dexamethasone led to a 30% reduction in death rate 
over placebo but no effect on the numbers of severely disabled patients was 
observed [107]. Additionally the same authors found less clear benefit of 
dexamethasone in HIV positive patients. Similar evidence for a beneficial effect 
of dexamethasone in children has been reported [120, 121]. The mechanism for 
this effect has not been described despite extensive analysis of CSF 
inflammatory mediators [50]. There are no randomised, controlled trials of the 
effect of steroids in treating CNS tuberculomas but anecdotal evidence has 
persuaded physicians to use them in this setting, supported by the benefits in 
TBM and the high likelihood that concurrent meningeal disease may be present
with tuberculomas. Clearly a trial is long overdue in this setting.
Oral anti-tuberculosis therapy is generally administered for 9-12 months, 
although there is no evidence for the efficacy of prolonging treatment for more 
than six months. As in pulmonary TB four drugs, tapered to two after two 
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months seems to be the consensus view. Usually therefore isoniazid, rifampicin, 
ethambutol and pyrazinamide are commenced but regimens vary [91]. When 
injectables are needed streptomycin, isoniazid, rifampicin, fluoroquinolones and 
second line agents such as capreomycin and aminoglycosides are available. 
Intrathecal administration of therapy is only possible with good neurosurgical 
input and seems to be reserved for intractable MDR TBM [122]. All four first line 
drugs cross an inflamed BBB but rifampicin and ethambutol are less good at 
crossing the BBB as treatment continues but steroids do not seen to have an 
influence on CSF penetration of anti-tuberculosis drugs [123-125].
Neuroinflammation 
In order to understand the context of the pathogenesis of CNS TB presented 
above more fully a more general introduction to neuroinflammation is helpful. 
Inflammation is a complex set of interactions between soluble molecules and 
cells arising in all tissues in response to trauma, infection, ischaemia, toxins or 
autoimmune injury. This process has evolved to lead to elimination of the 
invading pathogen and to healing [126]. Neuroinflammation is no different in 
many respects but has certain unique features that set it apart from systemic 
inflammatory processes. 
The Blood Brain Barrier 
The BBB is the highly specialised interface between the CNS and the rest of the 
body, allowing a microenvironment for efficient neural function (Figure 1). It is 
composed of endothelial cells joined by high resistance tight junctions, astrocyte 
foot processes interfacing with brain capillaries and pericytes (macrophage 
lineage cells), which are embedded in the basal lamina [127, 128]. This is a
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Figure 1. Schematic representation of the blood brain barrier (BBB). Astrocyte foot processes make intimate contact with
the basal lamina, which divides them from pericytes and endothelial cells lining brain capillaries. Basal lamina is made up
of type IV collagen, laminin, aggrin and fibronectin. Microglial cells, seen engulfing Mycobacterium tuberculosis, do not
make up the BBB but are found in adjacent brain parenchyma. Endothelial cells are tightly opposed by tight junctions
(occludens, cadherins and claudin molecules link the cell membrane to the intracellular actin cytoskeleton) and cell-
lamina interactions with aggrin. 
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complex mix of extracellular matrix, such as type IV collagen, laminin, 
fibronectin and aggrin [129]. Tight junctions in endothelial cells are made up of 
transmembrane claudin and occludin molecules, linking to intracellular zonula 
occludens (ZO-1 to 3) molecules that in turn bind the actin cytoskeleton. 
Junctional adhesion molecules (JAM-A to C) help maintain the integrity of the 
BBB. The tight junction system is so efficient even Na+ and K+ ions have to 
cross intracellularly as resistance across the cells is >1000 ohm cm2 (usually 2-
20 ohm cm2) [128]. 
“Immune-privilege” in the CNS 
The BBB functions to keep the CNS an “immuno-privileged site” by acting as a 
physical barrier to infiltrating leucocytes and immune mediators. This is 
reflected by the lack of resident lymphocytes within the CNS, although immuno-
surveillance does occur in the resting state [130]. In addition it serves to 
emphasise the importance of microglia in protecting the CNS during the initial 
stages of any inflammatory insult such as infection because they are the only 
professional immune cells present. Nevertheless a diverse spectrum of 
organisms can invade the CNS, causing meningitis or encephalitis which 
typically is accompanied by an intense inflammatory response. This suggests 
that this “immune-privilege” is only sustainable in the resting state. 
Leucocyte migration across the BBB 
Leukocyte-endothelial interactions at the BBB are essential for trafficking of 
leucocytes into the CNS, which occurs by a process of transmigration [43]. 
Endothelial anchored chemokines initiate leukocyte integrin aggregation and 
conformational change, leading to leukocyte arrest within the brain capillary 
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system at inter-endothelial junctions. Leukocytes then extend protrusions 
through the inter-endothelial junctions, in search of chemokine gradients that 
drive transmigration. Extravasating cells accumulate in the perivascular space 
by the basal lamina (sometimes called the glia limitans). It is here that MMPs 
may be involved as leucocytes traverse the glia limitans into the brain 
parenchyma. Some Mmp null mice have significantly attenuated BBB disruption 
in response to inflammatory stimuli, also seen with broad spectrum MMP 
inhibitors [131, 132]. 
Microglia 
Introduction 
Better insight into immune responses in the subarachnoid space and brain 
parenchyma might help develop more efficacious adjuvant therapeutic 
approaches to a variety of CNS inflammatory disorders [133]. Relatively little is 
known about effectors of tissue destruction in CNS disease but innate immune 
responses are likely to be key [52]. Microglia are the resident macrophages of 
the CNS, most likely of mesodermal monocyte-lineage in origin and are 
therefore the principle CNS innate immune cell [134-137]. Although more 
predominant in white matter, microglia are found throughout the CNS and in 
some areas are as numerous as neurons [138]. Although far outnumbered by 
astrocytes and oligodendrocytes they can make up to 17% of CNS cells in the 
resting situation [138]. The microglial cell has a scavenger role to maintain 
homeostasis when quiescent, so-called ramified cells, but like all sentinel cells it 
is pre-stationed to sense inflammation. Microglia are activated by many stimuli, 
including LPS, cytokines and amyloid-related proteins, to secrete an array of 
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inflammatory mediators including IL-1?, TNF-?, chemokines, growth factors and 
MMPs, although probably not interferons [139, 140]. Microglia express a wide 
range of cell surface molecules including MHC I and II, integrins, complement, 
cytokine/chemokine, CD68, CD14 and mannose receptors [141]. All nine Toll-
like receptors (TLR) are expressed at high levels, whilst astrocytes and 
oligodendrocytes, the other CNS glial cells, primarily express only TLR2 and 
TLR3 [142, 143]. In addition microglia can take on the functional characteristics 
of dentritic cells in order to present antigen to Th1 lymphocytes during 
inflammation [144]. 
Microglia as effectors of CNS inflammatory disease 
Microglia are implicated in the pathogenesis of a number of non-infectious CNS 
diseases, the most notable being multiple sclerosis (MS) and Alzheimer’s 
disease. MS is an adaptive immune response driven inflammatory disorder 
leading to demyelination of neuronal sheaths. However, the damage to neurons 
is effected by T-lymphocyte activated infiltrating macrophages and microglia 
engulfing and degrading myelin [145]. In addition these cells secrete neuronal 
pro-apoptotic mediators and proteases, including MMPs, that not only degrade 
myelin basic protein but cause BBB breakdown [131]. Alzheimer’s disease 
appears to be more dependent upon a microglial innate immune response 
because ?-amyloid reactive T-cells are scarce in the early stages of disease 
[133, 146-148].
Thus microglia have the ability to become the effectors of CNS tissue 
destruction [149]. Breakdown of microglial control mechanisms play a central 
part in development of disorders such as HIV-associated encephalitis and 
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Alzheimer’s disease [149-151]. There is gathering evidence that regulation of 
CNS inflammation may have clinically beneficial effects in these diseases and 
that this may be modulated via disruption of microglial function [152, 153]. The 
exact mechanisms of neuronal death during CNS inflammation are complex but 
frequently involve microglia. Many insults such as infection, hypoxia, acidosis 
and toxic molecule secretion occur simultaneously, derived from different cell 
types. For example HIV infected microglial/macrophage secreted proMMP-2, 
activated by neuronal MMP-14, cleaves the astrocyte derived chemokine 
CXCL12 (SDF-1), which is itself neurotoxic [151]. Additionally microglial 
secreted molecules such as TNF-? are known to be pro-apoptotic to neuronal 
cells. Control of inflammatory responses in microglia is known to be via IL-10 
and TGF-? as well as exogenous neuroregulators such as neurotrophins [139, 
154].
Although direct microglial responses to pathogens and inflammatory molecules 
occur monocyte-microglial networks are likely to be important in CNS TB. 
Peripheral monocytes traffic into the CNS due to BBB breakdown, following 
chemokine gradients and secreting a number of pro-inflammatory cytokines that 
can affect microglia as outlined already. Also once matured into macrophages it 
is hypothesised that peripheral monocyte-derived macrophages have a more 
inflammatory phenotype than their CNS counterpart microglia [155]. However, 
as deciphering the origin of mature macrophages once in the CNS is not 
possible this remains speculation. In summary microglia have a complex role 
during CNS inflammatory immune responses acting as effectors, controllers and 
the controlled. 
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Microglia and CNS TB 
M.tb causes a meningo-encephalitis clinically and histopathologically. 70% of 
patients who initially present with features of meningitis will have radiological 
evidence of parenchymal involvement at some stage of their illness [95]. 
Microglia are infected by M.tb more readily than the most abundant glial cells 
astrocytes. When infected there are also more intracellular bacilli per cell than in 
astrocytes suggesting an active phagocytic process in microglia is occurring 
[156]. In vitro infection of microglia and astrocytes resulted in the secretion of a 
wide array of pro-inflammatory cytokines such as IL-1?, TNF-?, IL-6, CCL2, 
CCL5 and CXCL10 in microglia, whereas astrocytes only secreted CXCL10 
[156, 157]. TNF-? expression has been shown to be biphasic in microglia 
suggesting a down-regulatory interaction between host and pathogen, 
supported by the observation that non-pathogenic mycobacteria did not up-
regulated TNF-? secretion at all [158]. Nevertheless the CNS TB granuloma 
would appear to be little different from those in other organs. Primary porcine 
microglia, infected with M. bovis, rapidly formed multinucleated giant cells in a 
TNF-?, CD14 and CD18 (?2 integrin) dependent fashion [159]. Consistent with 
the immune-privilege hypothesis are data that suggest non-opsonised M.tb is 
readily phagocytosed by microglia in a CD14 dependent manner, obviating the 
need for an active humoral immune response in early CNS TB [160]. Of note 
dexamethasone has a potent down-regulatory effect on cytokine secretion in 
M.tb infected microglia but not on phagocytic ability [156]. 
Animal models of CNS TB 
The study of CNS TB has been somewhat hampered by differences between 
human and murine CNS responses to M.tb challenge. In addition it has proven 
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difficult to establish CNS disease models from latent infection. Mice need to 
have an intra-cisternal injection of live bacilli in most models. Human microglia 
do not produce nitric oxide (NO) in response to M.tb infection, a distinct 
difference from mouse models of TBM, which are poor mimics of human 
disease [161]. Therefore the recent report that iNOS null mice infected with M.tb
developed serious clinical manifestations and granulomatous lesions containing 
tubercle bacilli throughout the meninges, much more in keeping with human 
form of the disease than previous mouse models, may allow further in depth 
studies [162]. Currently therefore the rabbit remains the best model of CNS TB 
as very little research has been performed in non-human primates despite some 
evidence that macaques may develop TBM in response to low doses of intra-
tracheally administered M.tb [163-165]. 
Matrix metalloproteinases 
Introduction 
Events leading to CNS inflammation, from any stimulus, involve multiple steps, 
cells and mediators. One such important group of mediators, acting as effectors 
of inflammation, are the proteases. Proteases are classified into four groups by 
the biochemistry of their active site: aspartic, cysteine, serine and metallo- 
proteases.  Aspartic and cysteine proteases are lysosomal and have an optimal 
pH of 2-5 and 3-6 respectively.  Although Cathepsin S maintains some activity 
at neutral pH these proteases are most important in extracellular tissue 
destruction only in highly acidic pericellular compartments. Serine proteases are 
active at neutral pH and are secreted by inflammatory cells but are rapidly 
depleted within 24 hours [166].  Only the MMPs are sustainably released and 
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active at neutral pH. MMPs are a family of 23 zinc dependent, calcium requiring, 
proteases which degrade extracellular matrix and can cause tissue destruction. 
MMPs perform multiple roles in development, reproduction and the normal 
immune response such as facilitating leucocyte recruitment, cytokine and 
chemokine processing, defensin activation and matrix remodelling [167]. MMP 
activity is controlled at the transcriptional level and by four tissue inhibitors of 
metalloproteinase (TIMP-1 to -4), as well as by compartmentalisation and 
secretion of pro-forms (zymogens). MMPs have already been implicated in the 
aetiology of a broad range of destructive inflammatory diseases such as 
rheumatoid arthritis [168], sarcoidosis [169] and atherosclerosis [170] as well as 
CNS disorders like multiple sclerosis [171] and HIV encephalitis [151]. 
Generally increased MMP activity is felt to be detrimental in pathological 
conditions but higher MMP concentrations can inhibit tumour progression and 
be beneficial for host response to infection [172, 173].
The origin of MMPs lies in the 1962 discovery by Gross and Lapiere of a 
collagenolytic enzyme responsible for tail involution in tadpoles whilst working 
on mechanisms controlling metamorphosis in amphibians [174]. Subsequently 
22 more MMPs have been described in humans, all involved in the turnover of 
ECM. Nine are encoded on chromosome 11 at 11q14.3–23.2 suggesting 
evolution of some MMPs has occurred by gene duplication [175].
Structure 
Structure of the MMPs follows a similar pattern and is summarised in figure 2 
[167, 176-181]. The pro-domain is ~80 amino acids long and contains the 
consensus sequence PRCXXPD (with X denoting any amino acid), where the
38
39
Chapter 1 - Introduction
Figure 2: Schematic structure of major MMP groups. MMP groups are shown divided by differences in domain
structure, which do not predict substrate affinity (see table 3). Thiol group and zinc ion interaction folds 
pro-domain into catalytic site: SP, signalling peptide; Pro, prodomain; SH, thiol group; Fur, furin cleavage site;
Catalytic, catalytic domain; Zn, zinc 2+ ion; Hinge, hinge region; Haemopexin, haemopexin domain; TM,
transmembrane domain; GPI, glycosylphosphatidylinositol phosphate; Fibronectin repeats, fibronectin domains
for gelatin binding.
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cysteine residue (C) interacts with the zinc ion in the catalytic domain to 
maintain the zymogen form. The catalytic domain (160-170 residues) contains 
that zinc ion (Zn2+) in the active site, ligated to three conserved histidine 
residues in the sequence HEXGHXXGXXHS/T. The glutamic acid residue (E) in 
this catalytic motif provides the nucleophile that severs peptide bonds by 
promoting the attack of a water molecule on the carbonyl carbon of the 
substrate. The structure of the hydrophobic pocket gives substrate specificity. 
The backbone structures of the MMP catalytic domain are similar to those of the 
astacin-, adamolysin- and serralysin-family metalloproteinases, as well as 
certain snake venom MMPs [179]. The adamolysins are so called because they 
consist of A Dysintegrin and Metalloproteinase (ADAMs, 13 members) and A
Dysintegrin and Metalloproteinase with Thrombospondin repeats (ADAMTS, 19 
members).
MMPs have a proline-rich hinge region, important in activation events. This is 
up to 75 residues in length and has some homology to type V collagen. All but 
MMP-7 possess a C-terminal haemopexin-like domain (200 residues) which 
functions in substrate recognition and delivery to the active site [182]. Terminal 
cysteine residues are joined in the haemopexin domain leading to a final folded 
structure resembling four propellers. Signal peptides, about 17-20 amino acids 
in length, function to allow export from the endoplasmic reticulum. Only MMP-17 
does not have a signal peptide.
MMPs can be divided into a number of subgroups dependent upon substrate 
specificity that is reflected in different additional domains. For example the 
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gelatinases (MMP-2 and 9) have a gelatin binding domain made of three 
fibronectin repeats. Other major groups are the interstitial collagenases (MMP-
1, 8 and 13), stromelysins (MMP-3, 10 and 11), matrilysins/elastases (MMP-7, 
12 and 26) and membrane-type MMPs (MT1-6 MMP). The latter of which 
posses a furin cleavage site necessary for intracellular activation, needed to 
deliver active enzyme to the membrane. Interactions with other membrane 
molecules such as integrins means that secreted MMPs can also be membrane 
associated thus keeping high concentrations of protease locally. For example 
MMP-9 binds membrane expressed CD44. CD44 is the principle cell surface 
receptor for hyaluronate thus juxtaposing substrate and enzyme more efficiently 
[183]. Not all enzymes are categorisable in this manner, mainly because their in 
vivo substrates are yet to be determined (see table 3 for further details of MMP 
substrates and groupings). 
Control of MMP secretion and activity.  
MMPs are potent proteases thus the body needs to retain tight control over 
them. As already stated control is at four major points: gene regulation, 
secretion of pro-forms requiring activation, compartmentalisation (where and 
how MMPs are released e.g. membrane association versus secretion) and 
physiological inhibitors. Signalling events up-stream of gene expression are 
important points of control for secretion of MMPs, which if identified might better 
enable targeted modulation of MMPs in disease. Cytokines, TLRs, mitogen 
activated protein kinases (MAP kinases) and nuclear transcription factors are all 
possible targets. 
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Table 3. Summary of major MMP groups and published substrates. 
Name Alternative name ECM substrate Other substrates CNS substrate/role 
Collagenases 
MMP-1 Collagenase-1 Type I, II, III collagen, aggrecan
Neuronal apoptosis, 
brevican, tenascin 
MMP-8 Collagenase-2 Type I, II, III collagen, aggrecan Brevican, tenascin 
MMP-13 Collagenase-3 Type I, II, III collagen, aggrecan Brevican
Gelatinases 
MMP-2 Gelatinase A 
BM, Type IV, V & XI 
collagen, gelatin, aggrecan, 
laminin
CCL-7, CXCL12, ?-amyloid Neuronal apoptosis, dystroglycan, brevican 
MMP-9 Gelatinase B 
BM, Type IV, V & XI 
collagen, gelatin, 
fibronectin, laminin 
Latent TGF-? & VEGF, ?1-
proteinase inhibitor, 
CXCL8, CXCL1, 4 & 11, ?-
amyloid 
BBB breakdown, zona 
occludens-1, myelin 
formation, cerebellar 
maturation, dystroglycan, 
NG2
Stromelysins 
MMP-3 Stromelysin-1 Fibronectin, laminin, type IV collagen, aggrecan 
Latent TGF-?, E-cadherin, 
IL-1?, ?-amyloid 
Neuronal growth & 
apoptosis, NTs, myelin, 
occludins, claudins, 
brevican, tenascin 
MMP-10 Stromelysin-2 Laminin ProMMP-1, 7, 8 & 9 Brevican
MMP-11 Stromelysin-3 Type VI collagen, aggrecan, laminin Apoptosis
Matrilysins 
MMP-7 Matrilysin 
Elastin, gelatin, fibronectin, 
type IV collagen, aggrecan, 
laminin
E-cadherin, syndecan-1, 
pro-defensins, FasL 
(CD95L), latent TNF-?,
CXCL1
Synaptic plasticity, NTs, 
brevican, tenascin 
MMP-26 Endometase Fibrin, fibronectin, vibronectin, gelatin Serpins
Membrane-type 
MMP-14 MT1-MMP Type I, II, III collagen, laminin, aggrecan 
ProMMP-2, syndecan-1, 
SLPI, DR-6, CCL7 Tenascin
MMP-15 MT2-MMP Fibrin, aggrecan, laminin, perlecan ProMMP-2, anti-apoptotic Tenascin
MMP-16 MT3-MMP
Type III collagen, 
fibronectin, gelatin, laminin, 
vibronectin
ProMMP-2
MMP-24 MT5-MMP Proteoglycans ProMMP-2, cadherins Axon pathfinding, synapse plasticity & remodelling 
… table 3 continues 
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Table 3 (continued) 
GPI anchored 
MMP-17 MT4-MMP Gelatin ProMMP-2, ADAMTS4 activation Expressed in neurons 
MMP-25 MT6-MMP Type-IV collagen, gelatin, fibronectin, fibrin, laminin 
?1-proteinase inhibitor, 
ProMMP-2
Others 
MMP-12 Metalloelastase Type V collagen, laminin, elastin, fibronectin 
Latent TNF-?, CXCL11, ?1
proteinase inhibitor, EGFR, 
OMP A, CXCL1-3, 5, 6 & 8, 
CCL2, 7, 8 & 13 
Macrophage migration, 
myelin formation 
MMP-20 Enamelysin Type V collagen, aggrecan, amelogen, ameloblastin     
MMP-19 RASI1 
Type IV collagen, 
aggrecan, laminin, 
fibronectin, gelatin 
T-cell development,
IGFBP-3 
Expressed in MS lesions, 
tenascin
MMP-21   Gelatin     
MMP-28 Epilysin Casein   Myelin degradation 
Notes: MMP-4-6 do not exist. MMP-18 only found in Xenopus sp. MMP-22, 23 and 27 no published information. IGFBP-
3, Insulin-like growth factor binding protein-3; DR6, Death receptor-6; SLPI, Secretory leucocyte protease inhibitor; 
EGFR, Epidermal growth factor receptor; OMP A, Outer membrane protein A ( of E. coli); NTs, neurotrophins. 
Cytokines and chemokines 
TNF-? and IL-1? are key pro-inflammatory stimuli leading to MMP secretion. 
Most MMPs can be induced by these molecules but the range of MMPs 
secreted is often cell-type dependent. Local autocrine and paracrine networks 
involving TNF-? have already been described in M.tb induced MMP secretion 
[184]. Many MMP promoters have IL-1? transcription factor binding sites, such 
as activator protein-1 (AP-1) [185]. IL-1? and TNF-? synergise with other 
cytokines such as oncostatin M, a member of the IL-6 superfamily, that signal 
via Janus kinase (JAK) / signal transducers and activators of transcription 
(STAT) and the MAP kinase pathways, to up-regulate MMPs [186]. 
Molecules that principally target TNF-? and IL-1? are already in use in the clinic 
in chronic inflammatory conditions such as rheumatoid arthritis, psoriasis, 
Crohn’s disease and ankylosing spondylitis. Currently based on monoclonal 
Chapter 1 – Introduction 
antibody technology these drugs have proved extremely efficacious. MMPs are 
implicated in the pathogenesis of all these diseases and anti-TNF-? is known to 
reduce MMP secretion in patient samples and in vitro, but a causal link is yet to 
be proven [187, 188]. Anti-TNF-? therapy has been used as an adjuvant for the 
treatment of TBM but with little success [47, 48, 189]. Indeed one of the adverse 
events of drugs such as infliximab is TB reactivation. This is more frequently 
seen than opportunistic infection, demonstrating the importance of this molecule 
in TB host defence [18]. Whether the disorganised granuloma structure seen in 
biopsies from patients with anti-TNF-? associated TB is related to that seen in 
Mmp9 null mice is not clear [190]. 
IFN-?, a major activator of macrophages, suppresses MMP secretion in a 
number of models, opposing TNF-? driven gene expression. This can be via a 
direct effect on TNF-? driven Ets-1 and NF?B binding to the MMP-3 promoter or 
via IFN specific JAK/STAT pathways involving the sequestration of the co-
activator CBP/p300 by IFN-? induced STAT1 [191]. TGF-?, IL-4 and 10 all down 
regulated MMP secretion in the same way they do for other molecules. TGF-?
signals via smads, which can sequester the nuclear-located CBP/p300 histone 
acetyltransferase, leading to less IL-1?-induced MMP-1 transcription [192]. It is 
also worth remembering that cytokine-MMP interactions can be bi-directional as 
MMP processing of cytokines affects the inflammatory milieu (described in 
detail later). In certain circumstances pro-inflammatory signals such as TNF-?
can down-regulate MMP secretion acting at the gene expression level, so once 
again cell and disease specific control exists [193]. 
44
Chapter 1 – Introduction 
IL-17 is an important cytokine in autoimmune disease. IL-17 can drive MMP 
secretion from a number of different cell types. IL-17 is also known to drive 
TNF-? and IL-1? from macrophages offering an indirect mechanism of MMP up-
regulation [194]. Although levels of IL-17 producing regulatory ?? T-cells are 
higher in TB patients than controls but currently there are published links 
between IL-17 and MMPs in TB [195]. 
CCL2 (MCP-1), CCL4 (MIP1?), CCL5 (RANTES), CXCL8 (IL-8), and CX3CL1 
(Fractalkine) can all cause MMP secretion from microglial cells [196]. HIV 
infected leucocytes require additional CCL2 to up-regulate MMP-2 and -9 
secretion in order to cross the BBB, an important step in the development of 
HIV related CNS dysfunction [197]. Chemokine processing by MMPs is an 
important feature of many inflammatory processes and is discussed in detail 
later.
TLRs
TLRs are a group of nine pattern recognition molecules crucial for the 
subsequent release of many cytokines in response to infectious challenge. The 
most well-defined is the interaction between TLR4 and lipopolysaccharide 
(LPS), a key component in the cell wall of gram negative bacteria, leading to 
MyD88/NF?B dependent TNF-? release. Stimulation of any TLR can lead to 
MMP secretion. TLR2, 4 and 9 have already been implicated as important in the 
host response to M.tb. Microglia are known to express a wide variety of TLRs, 
whereas astrocytes and oligodendrocytes express mainly TLR2 and 3, meaning 
that microglia are better placed to respond in initial innate responses to invading 
pathogens [142]. In neuroinflammation MMPs can be up-regulated before pro-
45
Chapter 1 – Introduction 
inflammatory cytokines such as TNF-? suggesting innate mechanism are 
functioning early in disease [198]. 
Growth factors and hormones 
A large number of growth factors stimulate MMP secretion e.g. epidermal 
growth factor (EGF), nerve growth factor (NGF) and platelet derived growth 
factor (PDGF). Vascular endothelial growth factor (VEGF) is an important 
growth factor in stimulating vascular growth and vascular permeability in normal 
physiology and in the development of tumour blood supply. Mammary tumour 
secreted VEGF can induce MMP-9 secretion from T-cells and MMPs in turn can 
affect VEGF function [199]. MMPs have important roles in uterine remodelling 
during normal menstrual cycling, pregnancy and delivery suggesting oestrogen 
and progesterone levels affect MMP function. 
Cleavage of other cell surface molecules such as peroxisome proliferator-
activated receptors (PPAR) and integrins leads to intracellular signalling and 
can result in MMP secretion. PPAR? agonist (-glitasones) already have a 
clinical role in the treatment of insulin resistance in diabetes. In a murine model 
of cerebral ischaemia pioglitazone reduced delayed neuronal damage through 
inhibition of active MMP-9 secretion [200]. 
Cell-cell and cell-matrix interactions 
Cell-cell and cell-matrix interactions are mediated by integrins and cadherins. 
For example fibroblasts grown in a 3-D collagen matrix will often produce a 
different spectrum of MMPs than those grown on tissue culture plastic as 
functional interplay exists specifically between matrix collagen and fibroblast 
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expressed integrins. This interaction is responsible for subsequent MMP-14 
secretion as neither 2-D gels nor gelatin (degraded collagen) were able to 
substitute for intact collagen in this process [201]. ?3?1 integrin signalling has 
been described to affect mRNA stability of MMP transcripts in keratinocytes 
using actinomycin-D chase experiments so signalling crosstalk mechanisms are 
important too [202]. Pericytes appear to be important modulators of endothelial 
and astrocyte MMP secretion in the context of BBB function. Removal of 
pericytes from astrocyte co-cultures reduced subsequent MMP expression and 
activity [203].
Direct control of gene expression 
Although there are many stimuli to MMP/TIMP secretion the final common 
pathway is often via alterations in gene transcription and stability. Gene 
transcription is modulated by a variety of processes such as MAP kinases, 
JAK/STATs, transcription factor binding to cis-acting elements, histone 
(de)acetylation, DNA methylation and mRNA stability. A number of these factors 
are important in the control of MMP/TIMP gene expression, dependent on the 
cell examined. 
The MAP kinase pathway involves a phosphorylation cascade of a series of 
protein kinases, with signalling leading to 10,000-fold amplifications. Three main 
pathways exist:
i. Stress activated protein kinases (SAPK) also known as extracellular 
signal-regulated MAP kinases (ERK) play a role in cell turnover and 
phosphorylation of a number of transcription factors and microtubule 
associated proteins. 
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ii. The p38 MAP kinase subfamily regulates cell differentiation, apoptosis 
and is important in cellular response to inflammation. Many cytokines 
signal via p38 and this pathway can be activated via TLRs in response to 
bacterial pathogen stimulation. p38 is also known to affect gene 
expression kinetics by post transcriptional regulation of mRNA stability. It 
has four subunits ?, ?, ? and ?.
iii. c-Jun N-terminal kinase (JNK) acts ultimately via the phosphorylation of 
the c-Jun subunit of the transcription factor AP-1.  
All MAP kinase pathways can ultimately phosphorylate transcription factors 
increasing their ability to drive gene transcription. p38 has been described as an 
important point of divergence between MMP and TIMP secretion in 
tuberculosis. Pulmonary epithelial cells secreted MMP-1 in response to M.tb
infected monocyte derived cytokines. Blockade of p38 led to abrogation of 
MMP-1 but an increase in TIMP-1 secretion [204]. Astrocyte MMP-9 secretion 
has been confirmed in brain biopsies from CNS TB patients and in vitro MMP-9 
secretion was dependent upon an IL-1?/MAP kinase/AP-1 pathway. p38 MAP 
kinases also increase the cellular amount of the AP-1 proteins indirectly by 
increasing transcription from the c-jun and c-fos promoters. p38 inhibitors have 
reached phase II clinical trials in cardiology so exploring these pathways in TB 
seems appropriate. 
Transcription factors 
Specific sequences in gene promoters, cis-acting elements, can bind 
transcription factors leading to up-regulation of RNA polymerase activity. Three 
distinct structures of the promoter region are found in MMP genes. Most (e.g. 
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MMP-1, -3, -7, -9, -12, -13, -19 and -26) have a TATA box (-30 bp from the 
transcriptional start site) and a proximal AP-1 site (-70 bp). Some (e.g. MMP-8, -
11 and -21) have a TATA box but no AP-1 site. MMP-2, -14 and -28 lack both, 
often leading to high levels of constitutive expression, controlled by the 
ubiquitous Sp family of transcription factors, which bind to a proximal GC box 
[205]. The TATA box contains a conserved A-T rich sequence (usually 
TATAAAA) which plays an important role in the transcription of eukaryotic 
genes by RNA polymerases. 
MMP secretion is often dependent upon NF?B and AP-1 but PEA3, Sp-1, b-
catenin/Tcf-4 are also important in [206]. NF?B is a transcription factor held in 
the cytoplasm complexed with its inhibitor I?B. Upon phosphorylation of the 
I?B? and I?B? subunits by I?Kinase1 (IKK1) and IKK2 the p65 (RelA) subunit of 
NF?B is released and I?B proteins are ubiquinated and degraded. p65 
dimerises with itself or another NF?B subunit, usually p50, and translocates to 
the nucleus. Here it binds to the specific up-stream promoter regions of genes 
increasing mRNA transcription. NF?B has a number of subunits (p50, p65, 
RelB, cRel and p52) and it is the exact make-up of these subunits at the 
promoter that differentially affect gene transcription. p65 is known to be up-
regulated in microglia infected with M.tb and many MMP genes have NF?B
consensus sites in their promoter, although there is little literature on 
M.tb/NF?B/MMP pathways [156]. Transcription factors rarely act in isolation, for 
example NF?B and Sp-1 are both required for efficient MMP-9 transcription and 
AP-1 and PEA3 are commonly required for other MMP gene transcription [207]. 
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MMP promoter polymorphisms and TB 
Single nucleotide polymorphisms (SNP) in MMP promoters are responsible for 
different levels of protein expression. The guanosine insertion at -1607 in the 
MMP-1 promoter creates an Ets-1 binding site (5'-GGA-3') and leads to 
increased MMP-1 secretion, which subsequently has been linked to increased 
risk of a number of cancers [208]. In tuberculosis patients with cavity formation, 
an increasing trend of the 1G allele frequency was observed but no increased 
risk of TB disease per se over controls was seen [209]. A more recent 
publication studied patients with endobronchial TB lesions and found that those 
with the 1G genotype had a 9-fold greater risk of developing subsequent 
tracheobronchial stenosis [210]. In contrast to the original study monocytes 
stimulated by IL-1? ex vivo in 1G patients demonstrated higher basal and higher 
up-regulation of MMP-1 secretion than 2G patients. So although risk of TB 
disease is not affected by MMP-1 promoter polymorphisms disease phenotype 
is. Data for other MMP promoters in TB are not published. 
Epigenetic regulation of MMP gene transcription 
Chromatin remodelling by histone acetylation and DNA methylation is an 
important control point in gene transcription. Deacetylation of histones allows 
chromatin to coil more tightly leading to a less permissive state for transcription 
factor access to the basal transcriptional polymerase machinery and thereby 
effects reductions in gene transcription. Histone modifications occur mainly via 
histone H3 or 4 acetylation, methylation, or phosphorylation. Chromatin 
remodelling can be investigated using inhibitors of histone deacetylases 
(HDAC) such as trichostatin and sodium butyrate. MMP-1 and 13 expression 
can be blocked in this way but MMP-10 expression is promoted. The final 
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common pathway for the action of the PPAR agonists mentioned above is felt to 
be at this point, involving an interaction between HDACs and AP-1 binding to 
the SW1/SNF chromatin remodelling complex. Increased promoter MMP-3 and 
9 methylation caused suppression of secretion in lymphoma and colonic 
carcinoma cells so the generalisability of the findings is unclear since many 
MMP promoters contain few CpG islands available for methylation [206].  
Post-translational modification of MMP mRNA 
There is evolving evidence for post-translational modification of MMP mRNA as 
an important mechanism of control. Sequence specific elements at the
AU-rich (ARE) 3' or 5’-untranslated regions (UTR) of numerous genes control 
the decay of their mRNAs by deadenylation. This is strongly attenuated by 
activating the p38 MAP kinase pathway, which allows Hu family proteins to bind 
the ARE. HuR 3’-UTR binding is responsible for increased stability of MMP-9 
transcript in response to ATP/IL-1? in renal mesangial cells [211]. The 3’-UTR is 
also responsible for ribosomal engagement and subsequent efficiency of protein 
synthesis.
MicroRNAs 
Micro-RNAs (miRNAs) are short (21-23 bp) RNA molecules that are involved 
with control of mRNA translation and degradation [212]. Incomplete base pair 
hybridisation between miRNAs and mRNA 3’-UTR leads to an as yet unknown 
mechanism of translational arrest. Complete sequence homology and binding at 
the 3’-UTR is a characteristic of small interfering RNAs (siRNAs) that lead to 
degradation of message. MicroRNA-21 (MiR-21) is elevated in glioblastoma 
cells, known to use MMPs to expand. Silencing of MiR-21 down-regulates 
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TIMP-3 expression, thereby affecting net-proteolytic ability of the tumour [213]. 
No data exist for host cells, miRNA and M.tb.
Dexamethasone
Corticosteroids are known to affect MMP gene transcription directly, both via 
nuclear localisation and binding to glucocorticoid response elements, as well as 
by direct inhibition of NF?B DNA binding, called transrepression. 
Dexamethasone also increases the expression of MAPK phosphatase-1, an 
enzyme that opposes TNF-? induced p38 and JNK MAP kinase activity, without 
affecting nuclear levels of NF?B [214, 215]. 
MMP activation 
MMPs are usually secreted as pro-forms or zymogens, which is appropriate for 
potent proteases. They can be activated in a number of ways. Intracellular 
activation by furin pro-protein convertases allows delivery of fully active 
membrane bound MMPs (MT-MMPs) to the cell surface [216]. MMP-2/-
14/TIMP-2 interact in a mechanism involving TIMP-2/MMP-14 delivery of pro-
MMP-2 to another MMP-14 molecule for pro-domain cleavage. Neutrophils 
release oxidants that activate MMPs by a non-proteolytic mechanism. Cleavage 
at residues 35-40 of the pro-domain lend the MMP the ability to cleave itself 
intra-molecularly via the “cysteine switch” mechanism. Once the Cys-Zn2+ bond 
in the active site is disrupted proteolysis can occur. Many MMPs can activate 
one another, particularly MMP-3 [217]. There are reports that the MMP-3 
activated product of MMP-1 is a more potent collagenase than the autolytic 
process produces [178]. All of these mechanisms and those involving 
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organomercurials have only been described in vitro and await confirmation in
vivo.
TIMPs  
There are four members of the tissue inhibitor of metalloproteinase (TIMP) class 
of molecule. TIMP-1 to -4 are all between 184 and 194 amino acids long [218]. 
TIMP-1 can inhibit all MMPs by specific 1:1 stoichiometric inhibition. TIMP1 null 
mice have impaired learning and memory, as well as increased resistance to 
pseudomonal infection. Timp2 null mice have motor defects. TIMP3 null mice 
develop alveolar cell damage and an emphysema-like disease, associated with 
elevated ADAM17 activity, which leads to increased free TNF-?. Timp4 null
mice have no currently described phenotype suggesting some redundancy in 
substrate inhibition. Less is known about the role of TIMP-4 although levels are 
suppressed in some forms of meningitis. Astrocytes and microglia do not 
express TIMP-4 in culture [219, 220].  
Control of TIMP secretion is similar to MMPs although basal secretion is often 
much higher, presumably acting as a mechanism of mopping up excess 
protease before it can do damage. TIMP-1 levels were suppressed in M.tb-
infected monocyte-epithelial cell networks and TIMP-1 secretion did not 
increase in line with MMP-9 in similar monocyte-astrocyte network experiments 
[204, 221]. Independent of their inhibition of MMPs TIMPs have mitogenic 
action and regulate survival and apoptosis [185].
Physiological inhibition of MMPs can be performed by non-specific anti-
proteases such as ?2-macroglobulin, a large molecule consisting of four 
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identical 180 kDa sub-units. Thrombospondins (TSP1 and 2), secreted by 
astrocytes, increase the quantity of synapses in vitro and in vivo. TSP1 and 
TSP2 bind the fibronectin repeats in the catalytic domains of pro-MMP-2  and -9 
and inhibit their activation [222]. 
Substrate specificity of MMPs 
Defining the substrates of a particular MMP to a degree of certainty is difficult 
therefore data in table 3 is from all sources available in the literature. In the 
strictest sense only evidence of substrate cleavage in vivo and loss/gain of 
function with transgenic mice is acceptable. In vitro MMPs cleave all known 
components of the extracellular matrix (ECM) at neutral pH (an important factor 
in collagen breakdown). In these model systems overlapping substrate affinity 
can occur as a laboratory phenomenon because often only the MMP catalytic 
site will have been expressed. Specificity in secretion, or compartmentalisation, 
leads to tissue restricted expression in vivo (e.g. MMP-12 is mainly expressed 
by macrophages). Variable substrate affinity means that in vivo substrate 
availability may dictate MMP substrate choice, but there will be some 
redundancy in the system. 
i) Knockout mice 
To date 14 single and some double MMP murine knock outs have been bred, all 
surviving to birth and most having mild phenotypes until exposed to an 
inflammatory challenge [223]. Only Mmp14 null mice die early (3-12 weeks), 
due to defects in type I-III collagen degradation. Mmp2 null mice have subtle 
defects in bone morphology but more extensive mammary gland defects, 
mirrored in Mmp3 null mice. The Mmp20 null mouse displays multiple dental 
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defects, including enamel hypoplasia [224]. Mmp9 null mice have vascular 
remodelling and growth-endplate defects due to inappropriately high galectin-3 
levels, a pro-apoptotic molecule [225]. In various models of CNS inflammation 
these knockouts show less immunopathology, BBB breakdown and cellular 
infiltration [41, 131, 226]. However, this is at the cost of impaired response to 
invading pathogens [172]. In the only published paper concerning M.tb and
Mmp null mice defective granuloma formation with poor macrophage 
recruitment to the lungs was reported in Mmp9 null mice [190]. There are MMP 
homologues in lower order organisms, for example drosophila have only two 
MMP genes. Like their murine counterparts the knockouts survive to the larval 
stage, when defects in epithelial cell detachment from ECM become apparent 
[227].
Although Timp null mice have been discussed above one with a CNS 
phenotype warrants further discussion. Timp3 null mice have reduced cerebral 
infarct size compared to wild type controls with TIMP-3 expression up-regulated 
on apoptotic neurons in wild type controls. As TIMP-3 can inhibit MMP-3 driven 
FasL cleavage on neurones this offers a putative mechanism for the null 
phenotype protection [228]. However, the authors did not investigate whether 
unopposed ADAM17 TNF-? release, also pro-apoptotic to neurons, was also 
partly responsible for this mechanism. 
ii) Human genetic defects in MMP genes 
Defects in human MMP genes have been described leading to rare skeletal 
diseases. Torg, Winchester and Nodulosis-Arthropathy-Osteolysis syndromes 
are a heterogeneous group of conditions now felt to be due to defects in the 
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MMP-2 gene. A homozygous recessive nonsense mutation in the MMP-2 gene 
has been described in consanguineous families leading to stunting, arthritis and 
osteolysis [229]. An autosomal dominant missense mutation in the MMP-13 
gene is responsible for causing a condition called the Missouri variant of 
spondyloepimetaphyseal dysplasia (SEMDMO) [230]. These patients have 
defective growth and modelling of vertebrae and long bones caused by defects 
in type II collagen processing. A phenylalanine substitution for a serine residue 
in the pro-region of MMP-13 means it is auto-activated and degrades not only 
itself but full length MMP-13 produced from the normal allele intracellularly. Only 
inactive enzyme fragments are secreted. A mutation in the intron 6 splice 
acceptor (AG to TG) of the MMP-20 gene leads to a dental disorder called 
amelogenesis imperfecta [224]. Patients have thin enamel leading to multiple 
chipped teeth like the null mice. No defects in host immune response have been 
described in any of these MMP defective patients but they have not specifically 
been examined. 
iii) Chemokine & cytokine processing by MMPs 
Chemokine and cytokine stimulation is known to lead to MMP secretion but 
MMPs have an important role in processing these molecules to modulate their 
effects [231]. Epithelial injury promotes MMP-7 synthesis and MMP-7 releases 
CXCL1 (GRO?) from syndecan-1 sequestration leading to neutrophil 
recruitment at the site of injury [232].  MMP-9 activates CXCL8 (IL-8) by amino-
terminal processing but inactivates both CXCL1 and 4 (PF4) [233]. MMP-9 
cleaved CXCL8 is 10 times more potent a stimulus to neutrophil recruitment 
than the full length peptide suggesting a positive feedback loop exists as the 
secretion of both molecules will occur in areas of inflammation. The monocyte 
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chemoattractant CCL7 (MCP-3) is a substrate of MMP-2 and -14 with the 
cleaved product acting as a competitive antagonist to the parent molecule [234]. 
proTNF-? is usually cleaved by ADAM17 to its 17 kDa active form. In vitro this 
can be performed by MMP-1, -2, -3 and -9 but it is questionable whether it 
happens in vivo. However, MMP-7 or -12 release of macrophage bound TNF-?
may be an important homeostatic or inflammatory mechanism [235]. M.tb and 
LPS specifically up-regulate macrophage MMP-7 but not ADAM17 secretion in
vitro and TNF-? autocrine loops are important in monocytic cells for MMP 
secretion [184, 236]. 
An increasing area of research is now centred on the role of MMPs in the 
resolution of inflammation. Those same MMPs that were responsible for tissue 
destruction during the inflammatory process can also aid in its down-regulation. 
MMP-9 is a known TGF-? activator, which can lead to detrimental effects in 
oncology [237]. However, this same mechanism probably evolved to enable a 
negative feedback mechanism whereby TGF-? down-regulates MMP-9 
secretion [238]. Similarly IL-1? is a potent stimulus of MMP-3 secretion, which in 
turn activates other IL-1? molecules in a caspase-1 independent manner. 
However, the biologically active IL-1? is itself degraded by MMP-3 [239]. Mmp8
null mice are at increased risk of chronic skin inflammation in poorly closing 
experimental wounds [240]. These mice had reduced neutrophil influx 
suggesting that MMP-8 mediates early acute inflammation, essential for rapid 
resolution of inflammation. 
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iv) Cell surface molecule cleavage 
During normal wound repair MMP-7 enables leucocyte trafficking between 
loosened epithelial cells by cleavage of E-cadherin [241]. Cadherins are 
transmembrane proteins that mediate Ca2+ dependent cell–cell adhesion. N- 
and E-cadherin are found concentrated around CNS synapses and function in 
synapse plasticity. MMP-24 (MT5-MMP) can cleave N-cadherin leading to 
intracellular signalling thereby affecting synaptic adhesion [242]. MMP-7 
cleavage of membrane bound FAS ligand (CD95L) is also an important step in 
the pro-apoptotic pathway of epithelial cells [243]. Neutrophil recruitment is an 
important step in pulmonary inflammatory processes. Pulmonary epithelial cell 
epidermal growth factor receptor (EGFR) cleavage by MMP-12 (macrophage 
elastase) led to CXCL8 secretion [244]. 
v) Role of MMPs in host defence to pathogens 
Innate immune responses to invading pathogens are a key initial defence 
mechanism. Evidence of a direct anti-microbial effect of MMPs is rare but in a 
murine model of E.coli sepsis and bone marrow transplantation MMP-12 
appeared to have an anti-microbial effect [245, 246]. MMP-12 was found to kill 
E. coli by degrading outer membrane protein A, localized on the bacterial 
surface, mediated by the haemopexin domain. Indirect mechanisms are more 
common. MMP-7 activates gut epithelial secreted pro?-defensins, important 
anti-microbial peptides involved in gut protection from enteric bacteria [247]. 
Minocycline, an MMP inhibitor, impeded African trypanosome invasion of the 
brain by reducing parasite migration across the BBB [248]. MMP-9, MMP-3, and 
MMP-7 but not MMP-2 or MMP-12 are needed for murine resistance to 
Pseudomonas aeruginosa corneal infections [249]. Other mechanisms are 
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unexplained such as Mmp9 null mice being protected against endotoxic shock 
[250].
MMPs in TB
TB is an inflammatory disease and a number of MMPs have been described in 
its pathogenesis, although the majority of evidence surrounds MMP-9.
i) Murine studies of TB 
There are relatively few published murine studies of MMPs and TB. Infection of 
BALB/c or severe combined immunodeficiency (SCID) mice with M.tb induced 
substantial increases in MMP-9 activity in infected tissues. In vitro this was 
mediated via TNF-? and IL-18, but down-regulated by IFN-? [251]. This latter 
effect has been reported in monocytes, where it is mediated by caspase-8 in a 
non-apoptotic manner [252]. Dissemination of M.tb occurred earlier in C57BL/6 
TB resistant mice compared to the TB susceptible CBA/J strain. Nonspecific 
blocking of MMPs in C57BL/6 mice reduced early haematogenous spread of the 
bacilli, although this was not MMP-9 dependent. Mmp9 null mice instead 
showed poor macrophage recruitment to the granuloma, which had a 
disorganised appearance [190].
ii) MMP-9 & TB 
MMP-9 is quantitatively the most significant MMP released by macrophages 
and concentrations are increased in lungs and pleural fluid of TB patients [253, 
254]. Serum MMP-9 concentrations may be raised and associated with disease 
severity [255]. In vitro, MMP-9 is secreted from monocyte cell lines in response 
to stimulation by a number of TB components such as lipoarabinomannan 
(LAM), a process dependent upon the transcription factor AP-1 [253, 256]. 
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MMP-9 activity was also dependent upon mannose receptors but not ?-glucan
receptors. Multinucleate giant cells in tuberculous lymph-node biopsy samples 
expressed high MMP-9 levels adjacent to areas of necrosis, confirmed in vitro 
[257]. Regulation of MMP-9 secretion by live M.tb in monocytic cells is 
dependent upon autocrine and paracrine networks involving TNF-? [184].
MMP-9 is secreted from pulmonary epithelial cells in networks involving 
monocyte derived cytokines synergising with M.tb antigen, although in this case 
not LAM dependent [258]. In a mouse mycobacterial model, cytokine-
dependent MMP networking effects also appear key in control of MMP gene 
expression and secretion [251].  
iii) MMP-1, -3 and -7 
Investigation of gene expression of all known MMPs, ADAMs and TIMPs using 
real-time PCR focusing on the role of primary macrophage-derived MMPs 
showed that MMP-1, -7 and -9 mRNA were up-regulated. There was also 
limited up-regulation of MMP-3 and -10 mRNA. In the same study M. bovis BCG 
did not up-regulate MMP-1 secretion as potently as M.tb but both strains 
increased MMP-7 secretion. MMP-1 is a potent collagenase, an important 
structural component of lung tissue. This divergence may explain why M.tb
causes lung cavitation but other non-tuberculous mycobacteria do not.
In the same study investigation of down-stream signalling pathways showed 
that only secretion of MMP-1 was prostaglandin dependent. MMP-1 was also 
secreted by monocytes but at lower concentrations and delayed compared to 
MMP-9 [259]. In monocytes protein kinase C, protein kinase A and tyrosine 
kinases controlled secretion. Work with respiratory epithelial cells showed that 
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MMP-1 up-regulation and TIMP-1 suppression in response to M.tb may be a 
more ubiquitous response. In the lung epithelium, this is driven by a monocyte-
dependent network involving IL-1 and TNF-?, key cytokines in the immune 
response to M.tb, as well as GPCR [204]. 
The granuloma is surrounded by a cap of stromal cells, mainly of fibroblast 
origin. In response to networks involving monocyte derived oncostatin M and 
TNF-? MMP-1 and -3 are secreted without a compensatory rise in TIMP-1 [186]. 
There is very little other data on MMPs in TB, except in the context of CNS TB 
which is specifically discussed below.  
MMPs in CNS disease 
MMPs can degrade brain extracellular matrix and components of the BBB 
basement membrane such as type IV collagen, laminin and fibronectin (Table 
3). There are many cellular sources of MMPs in the CNS as all CNS cells have 
been described to secrete MMPs or TIMPs. MMPs are important in 
neurogenesis and axonal development as neural stem cells express MMP-2 
and all four TIMPs, although the exact mechanism is undefined [185]. Mmp null 
mice do not appear to have prominent neurological phenotypes at birth but the 
literature is currently slender. As in other areas of embryogenesis MMPs may 
be more important postnatally, as MMP-9 is implicated in postnatal cerebellar 
maturation [260]. Axonal elongation and guidance involves MMPs. MMP-3 can 
be localised to the neural growth cone and inhibition is detrimental to this 
process. Other factors important in neural development such as neurotrophins 
(NTs) can induce MMP secretion. Neuronal guidance during embryogenesis is 
an MMP dependent process. Netrin-1, an axon outgrowth-promoting factor 
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originally isolated from chick brain, binds deleted in colon cancer (DCC) 
receptors. MMP shedding of DCC receptors has been proposed as a 
mechanism of axonal guidance [261].  
i) Microglial MMP secretion 
The MMP milieu of any specific condition and its temporal phase will define 
which molecules are active at any one time as the product of one set of cells 
may activate those of another. During neuroinflammation infiltrating leucocytes 
will be an external source of MMPs but their relative contribution over resident 
CNS cells is unclear. Activated monocytes and neutrophils tend to produce 
quantitatively and qualitatively more MMPs than T- or B-cells. In a study of 
MMP secretion from healthy blood donors leucocytes were stimulated with a 
variety of inflammatory ligands appropriate for the cell stimulated. Ex-vivo MMP-
2, -11, -17, -26 and -27 were enriched in B cells, while MMP-15, -16, -24 and -
28 were prominent in T-lymphocytes. Monocytes and neutrophils produced a 
wider array of MMPs: MMP-1, -2, -3, -9, -10, -14, -17, -19 and -25 [262]. In a 
separate study LPS stimulation of adult human brain microglia showed 
increased mRNA of MMP-1, -3, -8, -10, and -12, qualitatively similar to other 
leucocytes (B- and T-lymphocytes, monocytes and neutrophils) tested in the 
same way, but produced transcript in much greater quantities. In addition MMP-
7, -13, -14, and -19 mRNA rose to a lesser extent and MMP-15, -16 and -21 
transcript levels fell [263]. 
ii) Mechanisms of CNS damage by MMPs 
Association of high MMP expression during neuroinflammation is not evidence 
of causation. More compelling evidence is that injection of MMP-7, -8 and -9 
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directly into the brain of laboratory animals led to inflammation and that MMP-7 
and -9 can cause myelin breakdown and axonal injury [264, 265]. Myelin basic 
protein fragments, produced from MMP-3 cleavage, are known to be potent T-
cell stimuli [145]. Integrin cleavage can lead to apoptosis in the CNS driven by 
cells sensing they are no longer attached to basement membrane (“anoikis”) 
[266]. Inhibitors of MMP-9 reverse the neuronal apoptotic effects of MMP-9 
[267]. MMP-1 was toxic to human neurons grown in dissociated cultures and IL-
1? could stimulate the secretion of MMP-1 from astrocytes [268]. An indirect 
interaction involving apoptotic neuronal release of MMP-3, which in turn 
activates microglia by an unknown mechanism to produce pro-inflammatory 
cytokines, has also been described [269]. 
iii) Multiple sclerosis 
Stimulated peripheral leucocytes from multiple sclerosis (MS) patients secrete 
more MMP-2 and -14 compared to controls [262]. MS is the prototypical CNS 
MMP-mediated disease and MMP inhibition in preliminary safety trials have 
reported promising results [171, 270]. Treatment of MS patients with the 
immunomodulatory drug IFN-? reduced CSF MMP concentrations, restored 
BBB integrity and increased peripheral TIMP-1 levels [271, 272]. In vitro this is 
mirrored by reduced MMP-9 secretion from IFN-? stimulated leucocytes, 
although MMP-9 itself can cleave IFN-? [273]. CSF MMP-9 concentrations 
correlate with the frequency of inflammatory MS lesions on brain scans and 
MMP-9 concentrations are reduced by high dose steroid therapy in relapsing 
and remitting MS [274]. Mmp9 null mice have a better outcome from 
experimental autoimmune encephalitis (EAE), the best animal model for MS 
[275]. EAE animals also show reduced levels of MMP-15 to -17 but the 
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significance of this is unclear. MMP-7 has also been described in MS lesions 
from postmortem studies [276]. 
iv) HIV dementia 
HIV dementia was a common condition prior to anti-retroviral therapy. HIV itself 
can cause encephalitis at all stages of disease, including at seroconversion. 
Chronic disease is characterised by microglial activation, BBB breakdown and 
neuronal loss that leads to dementia [42].The description of MMP-2/MMP-
14/CXCL12 (SDF-1) mediated neurotoxicity has already been discussed briefly 
but the mechanism warrants discussion as neuronal loss is key to deterioration 
in HIV dementia [151]. The cleaved product of CXCL12 only lacked 4 N-terminal 
amino acid residues. However, it failed to bind to its cognate receptor (CXCR4) 
but bound CXCR3 instead. Stimulation of this receptor then led to neuronal 
apoptosis [277]. 
v) Alzheimer’s disease 
As has been alluded to already Alzheimer’s disease is now felt to be an 
inflammatory disorder [150]. Evidence in clinical studies suggests protection 
from onset in aspirin takers is mediated by a reduction in neuroinflammation 
[152]. ?-amyloid protein can activate microglia to secrete pro-inflammatory 
cytokines known to influence MMP secretion from CNS cells. In addition it 
directly stimulates MMP-3, MMP-12 and MMP-13 secretion from the same cells 
[148]. However, some MMPs, notably MMP-2, -3 and -9 can also degrade ?-
amyloid so the exact role of MMPs in this disease is unclear.  
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vi) Cerebral ischaemia 
During cerebral ischaemia a number of MMPs are known to increase. Neuronal 
nitric oxide synthase co-localised and activated MMP-9 that then induced 
apoptosis of neurons in a murine model of ischaemia [278]. MMP-9 seems to be 
activated by MMP-3, that is itself neurotoxic in other models [217, 279]. Again 
the temporal aspect of which MMP is expressed when is important. Treatment 
with MMP inhibitors 7 days after inducing stroke in mice suppressed 
neurovascular remodelling, perhaps by effects on VEGF, leading to increased 
brain injury and impaired recovery [280]. 
vii) Meningitis 
In the UK an estimated 10,000 cases of meningitis occur every year. However, 
most will be of viral aetiology,  caused by enteroviruses such as echovirus and 
Coxsackie viruses [281]. Bacterial meningitis, usually cause by Neisseria
meningitidis or Streptococcus pneumoniae has a much poorer outcome and is 
accompanied by more severe tissue damage. Fungal meningitis is rare outside 
of the context of immunosuppression, particularly HIV disease. TBM is 
discussed below. Steroids are currently recommended as adjuvant therapy for 
pyogenic meningitis suggesting that interrupting the inflammatory process is 
beneficial [282, 283].
MMP concentrations are raised in the CSF of meningitis patients. Children with 
viral disease have high MMP-9 but also TIMP-1 concentrations [284]. High 
concentrations of MMP-8 and -9 were associated with increased BBB 
permeability and poorer neurological outcome [285]. In this study CSF white cell 
counts did not correlate with MMP concentrations and so the authors concluded 
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that CNS cells were a significant source of MMPs but other studies contradict 
this result [286]. MMP-8, -9 and -13 were up-regulated in a study of viral and 
bacterial meningitis in children [287]. There is less evidence in other forms of 
meningitis but MMP-9 seems implicated in fungal and parasitic (eosinophilic 
meningitis) disease [219, 288]. One of the problems with the published data is 
that very few of the 23 MMPs known are measured in these studies. 
Animal models of pyogenic meningitis demonstrate that MMPs are important in 
tissue destruction. Murine models of meningococcal and pneumococcal disease 
have shown MMPs to be important and inhibition by non-specific mechanisms 
such as doxycycline (a broad spectrum MMP inhibitor) or steroids was 
beneficial [289-292]. However, one report of reduced host defence to 
pneumococci in Mmp9 null mice urges caution [172]. Fungal meningitis in a 
rabbit model and eosinophilic meningitis in a mouse both implicate MMP-9 in 
driving tissue destruction [293, 294]. 
MMPs and leucocyte trafficking into the CNS 
As described above the BBB is a complex mix of cellular and matrix 
components (Figure 1). Leucocytes traffic into the CNS during periods of 
neuroinflammation in response to chemokine gradients. The influence of MMPs 
on these molecules has been discussed, but the cleavage of CXCL8 by MMP-9 
into a more potent form will influence neutrophil trafficking more than T-cells. 
Further examples of chemokine/MMP processing, although not CNS specific, 
reveal the complexity of these interactions with one set of leucocytes often 
influencing another. Macrophage derived MMP-12 inactivated CXCL1-3, 5, 6 
and 8 and the monocyte chemotactic proteins CCL2, 7, 8, and 13 generating a 
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host of CCR antagonists. This offers a down-regulatory role for macrophages in 
inflammation, as Mmp12 null mice had increased levels of neutrophils and 
macrophages in lungs [295]. T-cell recruitment to the lung is affected in the 
same way. CXCL11 (I-TAC) was processed by the PMN-specific MMP-8, 
macrophage-specific MMP-12 and the more ubiquitously secreted MMP-9 [296].
MMP influence on the BBB via loosening of cell-cell contacts by cadherin 
cleavage has been discussed but other mechanisms are known. Dystroglycan, 
a transmembrane receptor that anchors astrocyte endfeet to the basement 
membrane via laminin binding, is cleaved by MMP-2 and -9. Mmp2Mmp9 null 
mice were protected from neuroinflammation in an EAE model [226]. The 
balance between MMPs and TIMPs has also been shown to be important for 
BBB breakdown. TNF-? stimulation of porcine choroid plexus epithelial cells led 
to a dramatic decrease in electrical impedance, mediated by fluxes in MMP-3 
and -9. Although TIMP-1 levels were high there was no change in its secretion 
in response to TNF-? but TIMP-3 levels were suppressed leading to a net 
increase in MMP activity [297]. 
The biggest role for MMPs described in the literature regards their degradation 
of the BBB basal lamina, the specialised basement membrane that acts as both 
a physical barrier and cellular structural support. It is composed of a number of 
known MMP substrates, in particular type IV collagen (a known substrate of 
MMP-2, -3, -7, -9 and -19) [291], fibronectin (MMP-3, -7, -9, -12, -19, -25 and -
26) [298], aggrecan (MMP-1, -2, -3, -7, -8, -9, -11, -13, -14, -19, -20, MT1-MMP 
and MT2-MMP) [299] and laminin (MMP-2, -3, -7, -9, -11, -12, -19 and MT6-
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MMP) [222]. The MMP cellular source is likely to depend upon the stage of 
inflammation but CNS parenchymal cells are known to contribute and their 
products interact with leucocyte derived molecules [217, 228, 300]. Mmp3 null 
mice were protected from the effects of intracerebral LPS by reductions in tight 
junction protein cleavage, specifically occludin (a 60 kDa membrane protein), 
claudin-5 and laminin degradation [301]. This was associated with less CNS 
neutrophil trafficking, perhaps mediated by MMP-3 controlled reduction in MMP-
9 activity. MMP-9 is implicated in other studies showing decreased BBB 
permeability with less occludens-1 cleavage, a murine tight junction protein. 
However, in this model with Mmp9 null mice occludin was not affected [131]. 
Indirect effects of MMPs on the BBB have been demonstrated in MS via IL-1?
activation of the hypoxia inducible factor (HIF)-VEGF axis [302]. MMPs can 
influence this indirectly via VEGF processing [303]. 
MMP substrates in the brain parenchymal will be universally expressed proteins 
such as collagens as well CNS specific molecules. Pyramidal neurons, 
important in the control of motor function, are embedded in perineuronal nets 
composed of brevican (a member of the lectican family of chondroitin sulphate 
proteoglycans) and the glycoprotein tenascin-R. In vitro brevican is cleaved by 
MMP-1, -2, -3, -7, -8, -10, and -13 but not MMP-9 [304]. Tenascin is also 
cleaved by MMP-1, -3, -7, -8, -13, -19, MT1-MMP and MT2-MMP [299]. 
MMPs as effectors of repair in CNS disease 
MMPs have accepted roles in the regenerative processes involved after CNS 
injury. Most of the published evidence regards MS and spinal cord trauma and 
many of the mechanisms have already been covered: cell survival can be 
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dependent upon MMP driven apoptosis (FasL is expressed on CNS cells), MMP 
driven integrin signalling allows cell trafficking, growth factor release from ECM 
stimulates recovery and MMP/NTs direct axonal regeneration. 
MMPs are known to be involved in myelin formation. Myelin is the insulation laid 
down around axons by oligodendrocytes that allows saltatory conduction to 
occur. Oligodendrocytes express MMP-9 as they put out cellular processes 
during remyelination so they can recontact cells. Mmp9 and Mmp12 null mice 
have poor process formation. MMP-9 clears a proteoglycan, NG2, that acts as a 
barrier to oligodendrocyte maturation. In addition MMP-9 cleavage of CXCL1 
(GRO?) is a controlling step in this maturation process. 
Demyelination in CNS TB 
Although not common white matter changes are described in CNS TB. 
Perivascular demyelination is felt to be due to a hypersensitivity reaction to TB 
antigen, perhaps in the same way reversal reactions occur in leprosy [305]. This 
“allergic tuberculous encephalopathy” is characterised by cerebral oedema, 
myelin pallor (because of loss of myelin sheaths) and perivascular macrophage 
infiltration [306]. The demyelination is proposed to be as a consequence of 
delayed hypersensitivity and may also manifest clinically as radiculomyelopathy.  
The evidence for this was published in 1975 [307]. Guinea pigs were sensitized 
to tuberculin and then either live or killed sonicated tubercle bacilli, tuberculin, or 
tuberculin purified protein derivative (PPD) was injected into the central or 
peripheral nervous system. Local inflammatory reactions were produced and 
demyelination was consistently observed. As there is similarity in this 
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neuropathology to leprosy it is of some interest that MMPs are now the focus of 
research in this disease. It has been reported that myelinated axons, infiltrating 
macrophages, Schwann cells, endothelial cells, and perineural cells stain 
positive for MMP-2 and -9 in neuritic leprosy biopsies [308].  
MMPs as therapeutic targets 
Given the amount of evidence that MMPs are involved in the pathological 
processes in a number of important diseases it may be surprising that MMP 
inhibition is not included in treatment regimens for any of them currently [309]. 
Only one compound is licensed in the US, Periostat for treatment of periodontal 
disease. A number of non-specific MMP inhibitors reached phase III trials in 
oncology in the late 1990s. Unfortunately there were a number of important 
safety issues surrounding unexpected musculoskeletal side effects that led to 
the early termination of many trials [173]. Based mainly on being hydroxamic 
acid analogues these peptidomimetics chelate zinc ions in the MMP active site. 
A compound called BMS-275291 has been tried in early breast cancer, Kaposi’s 
sarcoma (KS), late stage prostate and non-small cell lung cancer all to no avail. 
Marimastat has been used in gliomas with no observed efficacy too. 
It is now thought that being so non-specific other proteases, principally the 
ADAM and ADAMTS families, were also affected leading to the observed side 
effects. In addition most patients had late stage cancers that were unresectable, 
unlike the murine models used to test the drugs where early stage disease was 
usually studied. Some of the early trials compared MMP inhibition to placebo 
and so measurement of hard clinical endpoints were difficult because these 
drugs do not cause shrinkage of cancer, being only designed to prevent 
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metastasis and local expansion. Subgroup analyses did show promise, 
especially for early disease. More specific drugs have been developed, such as 
tanomastat which targets MMP-2 and -9 and Metastat (COL-3) has shown 
promise in a Phase I trial treating KS. 
Outside of oncology there is more optimism. Two non-controlled efficacy finding 
trials in MS using minocycline have reported promising evidence of reduced 
relapses [270, 310, 311]. Other CNS conditions such as stroke and trauma 
where murine studies have shown efficacy with early treatment are good 
candidates for trials of this nature. What is clear from these trials is that the 
timing of delivery of inhibition is crucial and can only be decided after a full 
understanding of pathology. MMPs have both detrimental and beneficial effects 
dependent upon where they are and at what stage the disease is at. More 
specific drugs will become available. In addition targeting the stimulus to MMP 
secretion or MMP substrate may represent a better pharmaceutical option. 
MMPs and CNS TB 
Much less is known about MMPs in CNS TB. CSF levels of MMP-2 and -9 are 
raised in TBM with no concomitant rise in TIMP-1 or -2, suggesting that in 
excess MMPs lead to a matrix-degrading phenotype with breakdown of the BBB 
[288, 312, 313]. Elevated CSF MMP-9 concentrations were associated with 
local tissue damage and patient death. Initial high concentrations of MMP-9 fall 
during TBM treatment, although not to baseline levels months later, suggesting 
ongoing BBB permeability [52, 312]. This permeability required host-cell actin 
cytoskeletal rearrangements in an in vitro model of TBM and was associated 
with pathogen as well as host transcriptional changes [40]. Whether M.tb is truly 
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neurotropic is a matter of ongoing research but RFLP analysis of isolates from a 
small number of CNS TB patients revealed 13 distinct restriction patterns 
compared to pulmonary patients [314]. The strain differences in the rabbit 
model of TBM and the Beijing strain association with shorter duration of illness 
have already been discussed but there are no data to support or refute MMP 
involvement in this area of the literature.
M.tb-infected monocytes drive a network involving IFN-?, TNF-?, IL-1? and 
NF?B resulting in increased astrocyte MMP-9 secretion without altered TIMP-
1/2 secretion indicating a role for glial cells in the development of the matrix 
degrading phenotype present in CNS TB [221, 315]. This is mediated via 
transcriptional control involving AP-1.
Therefore, in summary, microglia and MMPs are central to the pathogenesis of 
neuroinflammation. Microglial derived MMPs have been implicated as effectors 
of this process but there are no publications specifically discussing the role of 
microglial derived MMPs in CNS TB.  
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Hypothesis and aims 
This project aimed to investigate the hypothesis that interactions between cells 
of mononuclear and glial lineage are critical for the up-regulation of MMPs 
during the development of an inflammatory response to M.tb in the CNS.  
I hypothesised that microglia might control the CNS immune response to M.tb
infection via the production of a different spectrum of MMPs compared to 
monocyte/macrophages and other glial components. In addition, by 
investigating intracellular signalling mechanisms, targets subsequently 
amenable to specific manipulation via small molecules might be identified. 
The specific aims were to: 
1. Develop an in vitro model of CNS TB that could be used to investigate 
monocyte-microglial interactions leading to MMP/TIMP secretion. 
2. Investigate signalling pathways for the MMPs identified as key, 
specifically to look at the MAP kinase and NF?B pathways. 
3. Confirm these findings in patients by using immunohistochemical 
analysis of archived brain biopsies and quantification of CSF MMP/TIMP 
concentrations.
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Chapter 2 – Materials & Methods 
Standard tissue culture chemicals were purchased from Sigma-Aldrich (Poole, 
UK), tissue culture plastic from TPP (Trasadingen, Switzerland) and tissue 
culture medium from Invitrogen (Paisley, UK) unless otherwise stated.
M.tb culture and colony counting 
The virulent M.tb strain H37Rv Pasteur and a green fluorescent protein (GFP) 
expressing variant (a gift of Dr Brian Roberson, Imperial College) were cultured 
from frozen stocks in Middlebrook 7H9 broth (BD Biosciences, Oxford, UK) with 
10% OADC enrichment medium (BD Biosciences), 0.2% glycerol, and 0.02% 
Tween 80 in a rocking incubator. An optical densitometer (Biowave Cell Density 
Meter, WPA, Cambridge, UK) was used to assess growth of M.tb. M.tb was 
passaged regularly by sonicating to reduce clumping and pipetting 100-400 ?L
of stock with an optical density (OD) of 0.4 – 0.8 into 2 mls complete 7H9 broth. 
Stocks of M.tb were replaced every two months. Experiments were performed 
with cultures having an OD of 0.6 sonicated for 30 seconds. This has previously 
been shown to correspond to 108 colony forming units/ml (cfu/ml) and the mid 
log-growth phase. The endotoxin level was <0.03 ng/ml LPS as previously 
measured by amoebocyte lysate assay (Associates of Cape Cod, East 
Falmouth, MA, US). Multiplicity of infection (MOI) used in each experiment was 
checked by performing colony counts: 100?l of experimental broth was serially 
diluted eight times in 900?l 7H9 and 10?l was plated from each dilution, in 
triplicate, on Middlebrook 7H11 agar (BD Biosciences) containing ADC 
enrichment medium (BD Biosciences) and amphotericin 2.5 μg/ml. After two 
and four weeks triplicates of the dilution with individual colonies were counted, 
74
Chapter 2 – Materials & Methods 
averaged and the appropriate calculation performed to give a final cfu/ml and 
hence MOI for the experiment.
Monocyte isolation and M.tb infection 
Peripheral blood mononuclear cells (PBMCs) were isolated from single healthy 
blood donor residual buffy coats (UK Blood Transfusion Service) using Ficoll-
Paque (GE Healthcare, Little Chalfont, UK) density gradient centrifugation. Cells 
were diluted 50:50 with room temperature HBSS and layered onto 15mls Ficoll-
Paque. After a 30 minute spin at 480g the buffy coat layer was pipetted off and 
washed with medium a total of 5 times, with a 5 minute 308g spin cycle 
between washes. Between washes 3 and 4 monocytes were counted after a 5 
minute incubation at 37oC using a Neubauer chamber slide. Monocytes adhere 
and appear granular and larger than non-adherent cells such as lymphocytes. 
Once resuspended in RPMI 1640 containing 2mM glutamine and 10 ?g/ml
ampicillin (non-mycobacteriocidal at this concentration) monocytes were plated 
at a density of 250,000 cells/cm2. After one hour of adherence at 37oC and 5% 
CO2 cells were washed three times with warmed medium. This protocol has 
previously been demonstrated to give cell purity >95% by anti-CD14 flow 
cytometry [204]. 
Monocytes were infected with M.tb or 7H9 medium alone at an MOI of 1. At 24 
hours the cell culture medium was collected and filtered via a 0.2-?m pore size 
sterile filter (Anopore, Whatman, Brentford, UK or Nalgene, Hereford, UK) 
inserted into a 50 ml centrifuge tube and spun in a sealed bucket benchtop 
centrifuge for 1 minute at 2000 rpm to remove infectious particles. This 
conditioned medium from M.tb infected monocytes was termed CoMTb and 
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conditioned medium from uninfected, control monocytes was termed CoMCont. 
Several batches of CoMCont and CoMTb were produced. To increase 
homogeneity between experiments where possible different CoM batches were 
pooled, aliquoted and stored at -20oC.
Microglial cell culture and M.tb infection 
SV40 large antigen transformed human CHME3 microglial cells (a gift of 
Professor Marc Tardieu, Paris, France and Dr Nicola Woodroofe, Sheffield 
Hallam University, UK) were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% foetal calf serum (FCS, Biosera, UK) and 
3mM glutamine in a humidified incubator with 5% CO2 at 37oC [196, 316]. For 
experiments cells were seeded the day previously at 35-50,000 cells/cm2. On 
the day of experiment, which were performed in macrophage serum free 
medium (MSFM), cells would be 80-100% confluent (equating to 65-85,000 
cells/cm2). Cell culture medium was harvested at the specified time points and 
centrifuged for 5 minutes at 12,000g to remove cellular debris and samples 
were frozen at -20oC for later analysis. In direct infection experiments, M.tb was 
removed by filtration of all samples through a 0.2-?m pore size Durapore sterile 
filter (Millipore, Watford, UK) to remove infectious particles but retain MMPs 
[317]. Preparation of conditioned medium from infected microglia was 
performed as for CoMTb above, except cells were infected at an MOI of 10 in 
MSFM. It was termed CoMicTb and control medium CoMicCont.
Primary astrocyte cell culture and M.tb infection 
Pure cultures of primary human foetal astrocytes (a gift of Professor V. Wee 
Yong, University of Calgary, Canada) were obtained as described previously 
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and maintained in Minimum Essential Medium (MEM) containing 0.1% 
dextrose, 1mM sodium pyruvate, 0.1mM non-essential amino acids, 0.2mM 
glutamine and 10% FCS (Biosera) [318]. Flasks were coated with 10 ?g/ml
polyornithine to aid adhesion. Cultures had been shown to be >99% pure by our 
collaborators by immunostaining with antibody to the astrocyte specific cell 
surface expressed glial fibrillary acidic protein [318]. Preparation of conditioned 
medium from confluent M.tb infected astrocytes, termed CoATb, was as per 
CoMTb above, except an MOI of 10 and serum free MEM were used. Control 
medium was termed CoACont. 
Preparation of nuclear & cytoplasmic extracts 
Nuclear and cytoplasmic extracts were prepared using a commercial kit (Active 
Motif, Rixensart, Belgium) according to the manufacturer’s instructions. In brief 
a confluent 60mm dish of CoM stimulated cells was washed and scraped in 1ml 
ice-cold phosphate buffered saline with phosphatase inhibitors and centrifuged 
for 5 minutes at 700 rpm at 4oC. Supernatant was discarded and the pellet was 
resuspended in 250?l of 1x hypotonic buffer and incubated on ice for 15 
minutes. 25?l detergent was added and the mixture vortexed and centrifuged 
for 30 seconds at 14,000g in a centrifuge cooled to 4oC. The supernatant 
(cytoplasmic extract) was transferred to a pre-cooled microtubule and stored at 
-80oC. The pellet was resuspended in 50?l complete lysis buffer (10mM DTT, 
Lysis buffer AM1 and protease inhibitor cocktail) and placed on a rocking 
platform at 150rpm for 30 minutes incubated on ice. The resultant nuclear 
extract was obtained by vortexing, centrifuging for 10 minutes at 14,000g and 
storing the supernatant in the same way.
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Bradford total protein concentration assay 
In order to ensure equal total protein loading of samples between wells in 
subsequent western and ELISA assays of cell lysates a Bradford assay was 
used to calculate total protein concentration in samples. A standard curve was 
produced between 0 and 1000 ?g/ml using a commercial protein assay 
standard and 200 μL of a 1:5 dilution of developing reagent (both Bio-Rad, 
Hemel Hempstead, UK). Unknown samples were assayed in duplicate at 
dilutions that allowed calculation of their concentration from the linear part of the 
standard curve. Absorbance was read at 580 nm on a spectrophotometer (Bio-
Tek, Winooski, Vm, US). 
Zymography
Introduction 
Zymography is substrate based SDS-PAGE electrophoresis. The zymographic 
process activates pro-enzyme MMPs by releasing the cysteine switch in a non-
proteolytic manner, so that gel impregnated substrate degradation allows the 
detection of both pro- and active enzymes of each MMP being analyzed [319]. 
Consequently, zymography provides data on all the potentially active MMP 
present in the sample analysed.  Enzyme activity is seen as white bands on 
Coomassie blue stained gels [320]. In this case the use of 11-12% 
polyacrylamide gels allows 50-100 kDa proteins to appear in the middle of the 
gel after 2-4 hours of running time. The molecular weight of each band will give 
an indication of which MMP is causing proteolysis in the gel, but the exact 
identification needs to be confirmed by running a recombinant MMP standard 
and by a second laboratory method such as western blotting. Gels were 
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analysed densitometrically by digital image capture (UVP Transilluminator, 
Cambridge, UK) and by Scion Image Analysis software (NIH Image version 
1.61, Bethesda, MD, US).  
Casein zymography  
5?l of loading buffer (0.25M Tris pH 6.8, 50% glycerol, 5% SDS and 
bromophenol blue crystals) was mixed with 20?l cell culture medium and loaded 
into precast 12% casein gels (Invitrogen). Gels were run at 125V for 2.5 hours 
immersed in zymography running buffer (25mM Tris, 190mM glycine and 0.1% 
SDS). After one hour in 2.5% Triton-X gels were transferred to collagenase 
buffer (55mM Tris base, 200mM sodium chloride, 5mM calcium chloride and 
0.02% Brij; pH 7.4-7.6) for 40 hours incubation at 37oC. Gels were developed 
with 0.2% Coomassie blue (Pharmacia Biotech, Sweden) for one hour before 
destaining in acetic acid/methanol/water (1:3:6). A 5 ng MMP-1 standard 
(Oncogene, Merck, Germany) was run on each gel to allow for between gel 
variations after construction of a standard curve between 0 and 12.5 ng (Figure 
3A). Although three bands are seen on the zymogram only the top band, which 
is the full length protein, was used to standardise. The lower two bands are 
autolytic fragments of MMP-1 retaining caseinolytic activity. The lower level of 
sensitivity for this assay was 1.56 ng total MMP-1 per well.  
Gelatin zymography 
5?l of loading buffer was mixed with 20?l cell culture medium and loaded into a 
15 well 11% polyacrylamide gel (National Diagnostics, Hull, UK) impregnated 
with 0.12 mg/ml gelatin. Gelatin gels were cast in the laboratory on the day of 
use and overlaid with a 4% stacking gel. Gels were run at 180V for 3.5 hours
79
80
Chapter 2 - Materials & Methods
Figure 3. Recombinant human MMP standard curves. A, MMP-1 was serially diluted and analysed by casein
zymography. 5ng MMP-1 was used in subsequent experiments. Three bands are seen on the zymogram: the
top band is the full length protein and the next two are autolytic fragments retaining catalytic activity. B, 
MMP-9 was serially diluted and analysed by gelatin zymography. 0.2ng MMP-9 was used in subsequent
experiments. Points represent mean values ± SD of triplicate samples, representative of at least duplicate
experiments performed in triplicate.
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immersed in zymography running buffer. After one hour in 2.5% Triton-X gels 
were transferred to collagenase buffer for 24 hours incubation at 37oC. Gels 
were developed with 0.2% Coomassie blue with concomitant destaining in
acetic acid/methanol/water as previously described. A 0.2ng MMP-9 standard 
(Oncogene) was run on each gel to allow for gel to gel variability after standard 
curves were run with 0.0125 to 0.2 ng total recombinant MMP-9 (Figure 3B). 
The unknown band OD values were then expressed as a percentage of the OD 
for the standard. The lower level of sensitivity for this assay was 25 pg total 
MMP-9 per well. Hence weight for weight gelatin zymography is about 60 times 
more sensitive than casein zymography. 
Optimisation of collagenase buffer pH 
Biochemical theory suggests MMPs perform better at pH 5.5 yet their optimum 
working pH for zymography is said to be pH 7.5 [178]. An experiment to 
optimise the pH of the collagenase buffer used to incubate the gels overnight 
was performed. Identical casein gels containing two concentrations of 
recombinant MMP-1 (25 and 2.5 ng) were run as described above. One gel was 
incubated in collagenase buffer at pH 5.5 and the other at 7.5 (Figure 4). 
Sample values were normalised to the pH 7.5 25ng MMP-1 OD value. A 93.9% 
reduction in band intensity was seen with use of pH 5.5 collagenase buffer for 
the 25ng sample. The 2.5ng sample was below the level of sensitivity of the 
zymogram at pH 5.5. Therefore pH 7.5 buffer was subsequently used in all 
experiments.
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Figure 4. The effect of collagenase buffer pH on MMP-1 zymographic bands. 25 and 2.5 ng of recombinant human
MMP-1 was run on two separate casein zymograms. The gels were then incubated for 40 hours in collagenase buffer
adjusted to pH 7.5 (dark grey bars) and 5.5 (light grey bars). Collagenase buffer at pH 7.5 was better than 5.5 for
supporting enzymatic activity of MMP-1 and was used in subsequent experiments.
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Western Blotting 
MMP-1
Standard western blotting was performed. For MMP-1 40?L of cell culture 
medium was heat denatured with 1x loading buffer (10% glycerol, 5% 2-ME, 2% 
SDS, 0.06M Tris pH 6.8 and bromophenol blue) and loaded onto 10% 
polyacrylamide gels, run at 200V in running buffer (25mM Tris base, 192mM 
glycine and 0.1% SDS) for 3.5 hours. Gels were electro-transferred to a 
nitrocellulose membrane (GE Healthcare) and blocked for one hour in 5% milk 
protein / 0.1% Tween 20. Overnight incubation in 1:1000 sheep anti-MMP-1 
primary antibody (The Binding Site, Birmingham, UK) was followed by washing 
and incubation with 1:2000 donkey anti-sheep peroxidase-conjugate secondary 
antibody for an hour (The Binding Site). Bands were visualised by 
chemiluminescence with the ECL plus system (GE Healthcare) according to the 
manufacturer’s instructions.
MMP-3
MMP-3 western blotting was performed using 1:5000 rabbit anti-MMP-3 primary 
(Chemicon, Millipore) in 5% bovine serum albumin (BSA) and 1:2000 HRP-
linked anti-rabbit secondary (Cell Signalling Technology, Danvers, MA, US) in 
5% milk protein.
I?B? and ?-actin
For cytoplasmic I?B? Western blots cytoplasmic extracts were prepared and 
15?g protein aliquots were processed and probed with 1:1000 rabbit anti-I?B?
primary antibody (Chemicon, Millipore, UK) and 1:2000 HRP-linked anti-rabbit 
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secondary (Cell Signalling Technology). For cytoplasmic ?-actin I?B?
membranes were striped for 15 minutes with Restore Plus Western Blot 
Stripping Buffer (Pierce Biotechnology, Rockford, IL, US), reblocked with 1x 
TBS, 5% milk protein / 0.1% Tween 20 and probed with 1:1000 mouse anti-?-
actin primary (Sigma) then 1:5000 anti-mouse secondary (Jackson, West 
Grove, PA, US).
MAP kinase 
For MAP kinase experiments cells were lysed using 200?l of SDS sample buffer 
(62.5mM Tris pH 6.8, 2% SDS, 10% glycerol, 50mM DTT and 0.01% 
bromophenol blue) and immediately frozen at -80oC. 40?l aliquots were 
processed on western gels as described and probed with 1:1000 rabbit primary 
antibodies to both phosphorylated and unphosphorylated variants of p38 or 
ERK MAP kinase. A 1:2000 dilution of anti-rabbit HRP-linked secondary 
antibody was used (all Cell Signalling Technology). 
Analysis of MMPs by Luminex multianalyte technology 
Casein zymography gives a semi-functional analysis of caseinolytic MMPs, 
assessing all potentially active enzyme in any one sample. However, total 
enzyme concentration (pro-, active and degraded) is not assessed by this 
method. Therefore some samples were analysed for MMP secretion using 
Fluorokine multianalyte profiling kits (R&D Systems, UK) that is similar in 
principle to an ELISA but read using flow cytometry laser based technology on a 
Luminex machine. Luminex relies on the conjugation of fluorescent dye 
impregnated beads coated with primary antibody to the analyte of interest. As 
the beads for each analyte have slightly different quantities of two fluorescing red 
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dyes the Luminex dual laser system detects which bead is passing through the 
reader using the red 635nm solid state laser and how much phycoerythrin (PE) 
the bead is coated with (proportional to analyte quantity as secondary antibody 
is conjugated to it) using the green 532nm Nd-Yag laser.  
Standard curve, diluted samples and bead mixtures were loaded onto a 
permeable membrane bottomed 96-well plate (Millipore) and left for two hours. 
Excess standard/sample was washed three times with 250 μL 1x PBS/1% 
Tween 20, aspirated through the membranous bottom of the 96-well plate using 
a vacuum manifold after each wash, thereby retaining the beads/bound analyte 
but removing excess sample/standard or wash. Biotinylated secondary antibody 
was added for one hour and washed in the same way. Streptavidin-PE 
conjugate was then added for 30 minutes, the plate washed and beads finally 
resuspended in 100 μL wash. Sample concentrations were detected using the 
Luminex platform Bio-Plex 200 system (Bio-Rad) and Bio-Plex manager 
software (version 5.0) was used to construct standard curves and calculate 
unknowns. The minimum level of detection for MMP-1 was 10 pg/ml, MMP-2 
80 pg/ml and MMP-3 15 pg/ml. 
MMP/TIMP & TNF-? ELISAs 
MMP-1, -2, -3, -7, -8, -9, -10, TIMP-1, -2, -4 and TNF-? levels in cell culture 
medium and CSF were also sometimes measured by standard ELISA 
technology (R&D Systems, UK) using the manufacturer’s instructions to prepare 
a standard curve. MMP-1, -2, -7 and -10 had primary antibody pre-coated onto 
the plate but MMP-3, -8, -9, TIMP-1, -2 and -4 were paired antibody kits. The 
primary antibody concentrate was diluted to 2?g/ml in 1x PBS and 100 μL used 
85
Chapter 2 – Materials & Methods 
to coat the 96 well flat bottomed plate overnight at room temperature. After 
washing three times in 1x PBS/0.05% Tween 20 the plate was blocked for one 
hour with 1x PBS/1% BSA and a seven point standard curve produced by serial 
dilutions. The samples and standards were left for two hours at room 
temperature, the plate washed and 50ng/ml biotinylated secondary antibody 
added for two hours. After three further washes 100 μL streptavidin-HRP 
conjugate was added and developed using a stabilised hydrogen peroxide 
solution (R&D Systems). The reaction was stopped by addition of 50 μL 2M 
sulphuric acid and read at 450nm, using a 540nm reference wavelength to 
correct for refractive errors. The lower level of sensitivity for the ELISAs were 
156 pg/ml for MMP-1 and 7, 78 pg/ml for MMP-2 and 10, and 31 pg/ml for TNF-
?, MMP-3, 8, 9, TIMP-1, 2 and 4. 
Freeze-thaw cycle stability of MMPs 
As any one experiment may be used for analysis of multiple MMP/TIMPs I was 
concerned that freeze-thawing samples might affect concentrations of MMPs 
differentially depending upon analyte and detection methodology. Therefore 
three samples from CoMTb stimulated microglia were aliquoted and subjected 
to between 1 and 9 freeze-thaw cycles. Samples were removed from the 
freezer for two hours then refrozen for 22 hours. Samples were then analysed 
by casein, gelatin zymography and MMP-3 ELISA. There was no detectable 
decrease in MMP stability over the 9 cycles (Figure 5). The most any sample 
was freeze-thawed during the laboratory work towards this thesis was 7 times.
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Size exclusion fractionation of CoMTb 
In order to decipher which pro-inflammatory molecules within CoMTb were 
responsible for secretion of various MMPs/TIMPs a holistic approach to 
detection was taken by fractionation of CoMTb using Microcon centrifugal filter 
units (Amicon, Germany) that specifically allow solutes through a membrane 
based on molecular weight. 500 μL of CoMTb was pipetted into a 10 kDa - 
Micron YM-10 regenerated cellulose membrane spin column and centrifuged at 
14,000g for 20 minutes. The filtered solute (480?l-490?l) contained the <10 kDa 
fraction and the retentate >10kDa. The columns were then turned upside down 
and spun at 1,000 rpm for 3 minutes to recover the retentate. Retentate (10-
20?l) was reconstituted in RPMI (480?l-490?l) and labelled as the >10kDa 
fraction. To ensure sterility in cell culture medium both fractions were 
reconstituted to 500 μL using sterile RPMI as used in preparation of CoMTb and 
sterilised by centrifugation (14,000g, 30 seconds) through a Micron 0.22?m
Ultrafree filter column (Amicon).
Modified Kinyoun staining of M.tb infected cells 
Initial experiments showed that microglia and especially monocytes adhered 
better to plastic coated than glass slides. Therefore cells were plated onto 4 well 
Lab-Tek Permanox chamber slides (Nunc, Roskilde, Denmark) and infected 
with M.tb for two hours as described above. M.tb and culture medium were 
aspirated off and cells were then fixed in 4% paraformaldehyde for 30 minutes 
and rinsed once in 1x PBS. A modified Kinyoun stain was used to estimate 
infection rates of microglia and monocytes. Fixed slides were flooded with 
carbol-fuchsin solution for 3-5 minutes without heating, washed briefly with tap 
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water, decolourised with 3% acid-alcohol (HCl:C2H5OH) and counter stained 
with methylene blue. After air drying the slides were viewed under a 100x oil 
immersion microscope. Approximately 100 cells were viewed under high power 
in each of the four different chambers and a mean and standard deviation 
calculated for the percentage of cells associated with M.tb.
Confocal microscopy 
Microglial cells and monocytes were plated onto 4 well Lab-Tek Permanox 
chamber slides (Nunc) and infected with M.tb as described above. M.tb and 
culture medium was aspirated off and cells were fixed in 4% paraformaldehyde, 
rinsed once in 1x PBS and permeabilised for 10 min in 0.2% Triton-X 100 in 1x 
PBS in the dark to preserve GFP expression. After three washes with 1x PBS 
cells were incubated for 10 minutes at room temperature in the dark with a 
TRITC-Phalloidin conjugate (Invitrogen) at 1:500 dilution (final concentration 
250 ng/ml) to bind F-actin. After three further washes cells were mounted with 
700?l Dakocytomation S3023 mountant (Dako, Glostrup, Denmark), covered 
with a 22 mm x 50 mm coverslip and left overnight to harden.
Confocal microscopy was performed as previously described, using a Zeiss 
laser-scanning microscope LSM 510 equipped with a 63x oil immersion 
objective (Karl Zeiss Inc, Thornwood, NY, US) [321]. Laser excitation at 488 nm 
and 532 nm was used.  Images were collected as horizontal sections taken at 
0.1?m intervals through whole cell volumes. Images from representative areas 
of individual cells (top, middle and bottom) were taken and Y-Z projections of 
these cell areas were then compiled as composites of the relevant Z-sections 
using ImageJ software (NIH, Bethesda, MD, US). The composites were 
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imported into Adobe Photoshop CS3 (Adobe Systems Inc, San Jose, CA, US) 
and recreated as pseudo colour overlays (phalloidin staining in red and M.tb-
GFP staining in green). 
Gene expression analysis by real time quantitative PCR 
Microglia were lysed with TRI Reagent and total RNA was extracted using a 
standard chloroform-phenol-isopropanol protocol using phase-lock-gel tubes 
(Eppendorf, Cambridge, UK) [322]. The RNA was further purified by a DNAse 
step using a commercial kit (Ambio, Austin TX, US). cDNA was prepared from 
1?g RNA measured using an Eppendorf Biophotometer, ensuring that the 
absorbance at 260nm was between 0.1 and 1.0. Reverse transcription of 1?g
RNA used a 20 μL reaction volume. Initially 2 μL of random primers (Invitrogen) 
were annealed to RNA for 10 minutes at 65oC. 200 units of SuperScript III 
reverse transcriptase (Invitrogen) was added with 1st stand buffer, dNTPs, DTT 
and RNAse inhibitor to the annealed RNA/random primers and incubated at 
37oC for an hour. After 15 minutes denaturing at 75oC samples were spun and 
diluted to a final cDNA concentration of 0.5ng/?L for subsequent use.
Quantitative polymerase chain reactions (qPCRs) were done in a 25 μL reaction 
volume in 96 well plates with a Stratagene Mx3000P machine (Stratagene, La 
Jolla, US) using 5ng cDNA, Brilliant II qPCR mastermix (Stratagene) and MMP 
primers and probes as described previously [323]. The cycle threshold (CT) at 
which amplification entered the exponential phase was determined and this 
number was used to indicate the amount of target RNA in each sample. The 
MMP CT calculated was also normalised to ribosomal 18s cDNA that was run 
concurrently.
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Immunohistochemistry
Paraffin embedded brain biopsies from five non-immunosuppressed patients 
with biopsy-proven CNS M.tb infection, two non-infected post-mortem negative 
controls and two positive controls (patients who had undergone temporal 
lobectomy epilepsy surgery) were immunostained for the microglial marker Iba-
1 (rabbit polyclonal, WAKO Pure Chemical Industries Ltd, Osaka, Japan), MMP-
1 (mouse monoclonal, Calbiochem, Merck, Nottingham, UK), cJun (rabbit 
polyclonal, AbD Serotech, Kidlington, UK), p65 (rabbit polyclonal, Santa Cruz 
Biotechnology, Santa Cruz, Ca, US) and phospho-p38 (mouse monoclonal, 
Sigma). Sections of 5 ?m thickness were dewaxed in xylene and rehydrated in 
decreasing alcohols to water. Endogenous peroxidase activity was blocked with 
0.3% hydrogen peroxide in 1x PBS (pH 7.4) for 30 minutes. Antigen retrieval of 
sections was performed by steaming for 20 minutes in citrate buffer (0.01M 
citrate pH 6.5) and sections blocked with 10% normal goat serum for 10 
minutes (Vector Laboratories, Burlinghame, CA, US). The primary antibodies 
(Iba-1 at 1:400, MMP-1 at 1:150, p65 at 1:100, cJun at 1:200 and p38 at 1:200 
dilutions) were applied for 16-20 hours at 4oC after optimisation in placenta 
(MMP-1) or tonsillar tissue (p65 and cJun). Iba-1 and p38 had already been 
optimised in the laboratory using glioblastoma sections. On the following day 
staining was visualised using biotinylated secondary antibodies with an avidin-
biotin horseradish peroxidase complex (Vectastain Elite ABC kit, Vector 
Laboratories, Burlingham, CA, US) applied onto tissue sections for 45 minutes 
at 23˚C. The reaction product was revealed with 2 μg/mL 3, 3’-
Diaminobenzidine (DAB) and 0.0075% hydrogen peroxide in PBS. p65 and 
cJun were developed using components of the Super Sensitive Polymer HRP 
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IHC Detection System (BioGenex Laboratories, Dan Ramon, CA, US). Between 
each step in the immunostaining procedure sections were washed with PBS 
three times for five minutes. Finally the slides were counterstained with 
hematoxylin, dehydrated in graded ethanol, cleared in xylene and coverslipped 
in Di-n-butylPhthalate (DPX). Negative controls included omission of the 
primary antibody. 
Immunofluorescence
Studies to confirm co-localisation of Iba-1 and MMP-1 were performed using 
double immunofluorescence. Deparaffinized and rehydrated 5 μm tissue 
sections were subjected to antigen retrieval utilising a steamer in citrate buffer 
(pH 6.0). Sections were then treated with 10% normal goat serum (Vector 
Laboratories) in PBS for 30 minutes to quench the non specific staining. After 
16-20 hours incubation with anti-MMP-1 antibody at 4oC the slides were further 
incubated for one hour with appropriate secondary antibody conjugated to a 
fluorescent dye (1:200 dilution, Alexa Fluor 488, Invitrogen). After incubation 
with 10% normal goat serum in PBS, the anti Iba-1 antibody was applied for two 
hours at 4oC. Slides were incubated with the secondary antibody conjugated to 
a second fluorescent dye (1:200 dilution, Alexa Fluor 555, Invitrogen) for one 
hour. Between each step in the staining procedure, sections were washed with 
PBS three times for five minutes. To reduce autofluorescence caused by 
lipophilic lipofuscin-like compounds tissue sections were treated with 0.3% 
Sudan Black B (BDH Chemicals Ltd, Poole, UK) in 70% ethanol. Images were 
obtained using the Nikon E1000M imaging fluorescence microscope (Nikon, 
Japan) and a QICAM digital camera (QImaging, Surrey, BC, Canada) and 
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analysed using Image Pro Plus software (Media Cybernetics, Bethesda, MD, 
US). For negative controls primary antibodies were omitted. 
Ethical consent was obtained from the Hammersmith Hospitals Research Ethics 
Committee for the use of archived biopsies. Tissue samples were provided by 
the Human Biomaterials Resource Centre at Imperial College Healthcare NHS 
Trust.
Detection of nuclear NF?B & AP-1 DNA binding by ELISA 
To investigate the activation of the multiple subunits of NF?B a specific 
transcription factor assay (TransAM, Active Motif), which is five times more 
sensitive than EMSA, was performed. Nuclear extracts were added to a 96-well 
plate containing immobilized oligonucleotides encoding a consensus site 
(NF?B: 5’-GGGACTTTCC-3’). Active NF?B contained in the nuclear extract 
specifically bound to this oligonucleotide. The primary Abs used to detect p50, 
p52, p65, RelB, or cRel recognise an epitope accessible only when the active 
form of these factors is bound to its target DNA. An HRP-linked secondary 
antibody was added and the colour change determined by spectrophotometry at 
450 nm (Bio-Tek). Competition experiments demonstrated specificity of binding 
by adding 20 pM/well of either wildtype or mutated NF?B oligonucleotide before 
assaying with the p65 antibody and demonstrating loss of binding with wildtype 
but not mutated construct. Similarly the AP-1 subunit kit used the 5’-TGAGTCA-
3’ AP-1 consensus site. Primary antibodies were to JunB, cJun, JunD, FosB, 
cFos, Fra-1 and Fra-2. 
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Promoter Reporter analysis 
Microglial cells were seeded in 12-well plates at 50,000 cells/cm2 in DMEM 
1640 containing 3 mM glutamine, 10% FCS (Biosera), and 10?g/ml ampicillin. 
For kinetic experiments cells were co-transfected 24 hours later in serum-free 
medium with 0.8?g of MMP-1 promoter DNA construct (-4372 bp upstream of 
transcription start site) inserted into the firefly luciferase expression plasmid 
pGL3 (a gift from Professor Ian Clarke, University of East Anglia, Norwich, UK) 
and 0.08?g of control reporter plasmid, PRLTK, constitutively expressing low 
level Renilla luciferase activity, all suspended in 2.4?l of FuGene HD (Roche, 
Lewes, UK). Cells were stimulated after 12 hours and the luciferase activity of 
extracts was measured using the Dual-Luciferase Reporter Assay System 
(Promega, Southampton, UK) analysed with a luminometer (L-Max Lucy 2, 
Molecular Devices, Sunnyvale, CA, US). Renilla luciferase activity was used to 
normalise firefly activity to control for transfection efficiency. 
Deletion and mutation constructs 
A series of deletion constructs decreasing in size from -3830 to -517 bp (Ian 
Clark) and the full length wild type promoter (-4372 bp) were used to assess 
regional promoter activity. Two mutation constructs of the full length promoter 
were used to assess specific cis-acting element activities. For the one 
consensus NF?B site a mutation was made between -2886 to -2878 bp (From 
5’-ATGGAAAAA-3’ to 5’-ATGGAACCC-3’) and one of the six AP-1 sites at -
1949 to -1955 (From 5’-TGAGTTA-3’ to 5’-TGATTTA-3) [324]. 
94
Chapter 2 – Materials & Methods 
Phospho-MAP kinase Array 
In order to take a comprehensive approach to the investigation of signalling 
pathways that might be involved in MMP-1 and 3 secretion a Human Phospho-
MAP kinase Array kit (R&D systems) was used to investigate MAP kinase 
pathways. 60 mm dishes of confluent microglia were stimulated with CoMCont 
or CoMTb for 30 minutes (without a wash step as initial experiments showed 
this increased basal p38 phosphorylation). After rinsing in 1ml cold 1x PBS, 
cells were lysed using Lysis Buffer 6, pipetted up and down and transferred to a 
pre-cooled microtubule. Samples were rocked on ice for 30 minutes and then 
frozen at -80oC. On the day of analysis total protein concentration was 
measured by Bradford assay (Biorad) as described above. The array was used 
to measure the relative level of phosphorylation of MAP kinases and related 
serine/threonine kinases. Arrays were blocked for an hour with Array Buffer 1, 
whilst 250 μg lysate was prepared by adding it to Array Buffer 1 in a 1:5 ratio 
(lysate:Array Buffer 1) to a final volume of 1.5 mls. After adding this lysate/Array 
Buffer 1 mix to blocked membranes they were incubated overnight at 2-8oC on 
a rocking shaker. The following day each membrane was washed three times in 
5 mls wash buffer and 1.5 mls 1:1000 diluted biotinylated antibody cocktail 
added to each membrane for two hours on a rocking shaker. Three further 
washes were performed and a 30 minute incubation in 1:2000 streptavidin-HRP 
performed. After three washes the membrane was developed with the ECL 
system (GE Healthcare) and a digital image taken (UVP). Six positive controls 
are incorporated onto the membrane. The digital image was then analysed 
using Scion Image Analysis software (NIH Image version 1.61) and the mean 
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intensity calculated for CoMCont and CoMTb. Data are presented as the 
difference (± SD) between mean intensities.
Analysis of CSF MMPs/TIMPS in TBM – Chapter 6 
Please see chapter 6 for further specific methodology for the analysis of CSF 
specimens from TBM patients. 
Statistics
Data are presented as means (± SD) of three samples and represent 
experiments performed in triplicate on at least two separate occasions, unless 
otherwise stated. Paired groups were compared with the Student t-test. Multiple 
intervention experiments were compared by a one-way analysis of variance and 
Tukey’s correction for multiple pairwise comparisons, with equal variance tested 
by Levene’s test. A p<0.05 was taken as significant. Error bars in figures 
represent standard deviations unless stated otherwise. All analysis was done 
using SPSS software (version 15.0, SPSS corp, Chicago, IL, US). 
Ethics
The research ethics, safety and genetic modification committees of all 
institutions involved in the research approved the protocols described herein. 
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Chapter 3 – MMPs/TIMPs, NF?B and cellular networks
Introduction 
Global analysis of microglial MMP/TIMP expression in TB and 
investigation of the control of MMP-1 expression and secretion 
In order to investigate the hypothesis that microglia control the CNS immune 
response to M.tb and investigate intracellular signalling pathways I had to 
develop an in vitro model of CNS TB. M.tb is known to infect CNS cells such as 
microglia and astrocytes directly, but networks involving infiltrating M.tb infected 
monocytes are also likely to be important for MMP-driven CNS TB 
immunopathology based on published data [156, 221]. Microglia secrete a wide 
range of MMPs in response to inflammatory stimuli such as LPS, but a 
complete analysis of MMP/TIMP expression has never previously been 
performed in the context of TB.  
Therefore I set up the cellular model so that could I could test the various 
interactions between the key cells in CNS TB. Initially it was important to take a 
broad look at all MMPs/TIMPs to decipher which specific enzymes should be 
looked at in more detail. Thus I performed gene expression profiling of all 23 
MMPs and 4 TIMPs in collaboration with Dylan Edwards and Caroline 
Pennington at the University of East Anglia, who provided primers, probes and 
expertise. This suggested that MMP-1 and MMP-3 were the critical microglial 
MMPs in CNS TB and therefore the control of their expression and secretion 
was investigated in depth: data are presented in this and the following chapter. 
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In vivo correlation of the cellular model was sought through the use of 
immunohistochemistry. As monocyte-microglial networks appeared to be central 
to MMP secretion I checked the specificity of this finding. I have generated data 
on astrocyte-microglial, as well as microglial-microglial, interactions and show 
that these networks do not drive MMP secretion in the same way as monocytes 
networks do. 
Gene expression is controlled by a large number of transcriptional activators 
that bind to the 5’ upstream promoter region of genes to enhance transcription 
by RNA polymerases. NF?B is known to be a central controller of MMP gene 
transcription and the MMP-1 promoter is known to have only one NF?B
consensus site [194, 324]. Transcription factors rarely act in isolation and 
another key pro-inflammatory transcription factor implicated in control of MMP 
secretion is AP-1 [325]. Therefore control of gene expression focused on these 
two molecules. 
In this chapter therefore I demonstrate that cytokine networks, specifically 
between infiltrating monocytes and microglia, acting via NF?B and AP-1, are 
critical in controlling MMP-1 expression and secretion in CNS TB.  
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Results
MMP gene expression profiling in M.tb-infected and CoM stimulated 
human microglia 
Gene expression of all 24 human MMPs and four TIMPs was analyzed by 
reverse transcription (RT)–PCR in unstimulated, M.tb, CoMCont and CoMTb-
stimulated microglia at 24 h. M.tb was at an MOI of 10. CoMTb up-regulated 
MMP-1 3.4-fold over control, MMP-3 3.0-fold over control, MMP-9 2.2 over 
control (all p<0.05, summarised in figure 6). CoMTb also up-regulated MMP-8 
6.2-fold over control and MMP-10 5.3-fold over control but these results were 
not significant. M.tb only up-regulated MMP-27 26-fold over control. CoMCont 
and CoMTb suppressed MMP-24 expression by 40% (p<0.05). A 36% (but non-
significant) fall in MMP-2 was also observed between control and CoMTb. 
MMP-7, -20, -21, -26 and -28 expression was not detected. 
The data in figure 6 show changes in MMP mRNA, normalized to 18S rRNA 
and expressed as fold change over control thus they indicate relative not 
absolute levels of gene expression in microglia. The CT at which PCR 
amplification enters the logarithmic phase indicates levels of gene expression 
so CT data was used to compare absolute levels of different genes, where a low 
CT value indicates high level gene expression (Figure 7). Of the MMPs up-
regulated by CoMTb MMP-1 and -3 were the most highly expressed with mean 
CT thresholds of 22.9 (± 0.6) and 24.8 (±1.4) respectively (p=0.003 and p=0.03 
for t-test between CoMCont and CoMTb), whereas MMP-8, -9, -10 reached only 
moderate levels with CT all over 25 (p=0.05 for MMP-9 and p=0.01 for MMP-10
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Chapter 3 – MMPs/TIMPs, NF?B and cellular networks 
for t-test between CoMCont and CoMTb). The CT for M.tb stimulated MMP-27 
expression was very low at 36 suggesting the fold value was biased by a very 
low control denominator value. CT values for all stimuli for MMP-24 were similar 
(median 30.6, range 30.0 – 30.8). The main changes in MMPs are summarised 
in table 4. 
Table 4. Summary of main findings from global analysis of MMPs/TIMPs 
High basal expression MMP-14, TIMP-1 
Increased by CoMTb MMP-1, 3 & 9* MMP-8 & 10†
Decreased by CoMTb MMP-24‡, TIMP-2, 3 & 4†
Increased by M.tb MMP-27‡
Not detected MMP-7, 20, 21, 26 & 28 
        * p<0.05; † p=ns; ‡ CT value very low. 
Conclusions from global analysis of MMPs 
Therefore after analysis of the direct and indirect networking effects of M.tb
driven expression of all 23 known MMPs and 4 TIMPs in human microglia using 
both 18s corrected and quantitative CT data significant up-regulation of MMP-1 
and 3 were identified as the key findings and subsequently investigated in 
depth.
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Monocyte-microglial networks drive MMP-1 secretion from human 
microglia more potently than M.tb infection 
Secretion of MMP-1 was then analysed by casein zymography confirmed with 
western blotting to investigate whether increased gene expression resulted in 
greater enzyme activity. M.tb up-regulated MMP-1 in a dose dependent fashion 
to a maximum of 4.1 fold over control at an MOI of 10 (p<0.01, Figure 8A). 
However, CoMTb drove MMP-1 secretion more potently with a 20.6 fold 
increase in secretion over CoMCont (p<0.01) and 3.7 fold greater than M.tb
(p<0.01, Figure 8A). Western blotting confirmed that the bands seen on casein 
zymography were MMP-1 (Figure 8A). In dose response experiments analysed 
by Luminex a 1:5 dilution of CoMTb resulted in 49.9 (±5.3) ng/ml MMP-1 
secretion (equivalent to 143.3 ± 45.2 units of caseinolytic activity on casein 
zymogram) at 72 hours and was therefore used in all subsequent experiments 
(p<0.01, Figure 8B). Kinetic studies of MMP-1 expression demonstrated that 
mRNA had started to rise by 6 hours and had peaked by 48 hours with a 23.4 ± 
4.7 fold up regulation of mRNA over time 0 control samples (p<0.01, Figure 
8C). In kinetic studies MMP-1 secretion was up-regulated by 24 hours but 
continued to increase until 96 hours (Figure 8D). At 72 hours (the subsequent 
time point for secretion experiments) MMP-1 was 67.0 ± 23.7 units of 
caseinolytic activity. 
Microglial-microglial and astrocyte-microglial networks do not drive 
MMP-1 secretion 
M.tb is known to infect and replicate in macrophages, including microglia the 
resident macrophages of the CNS, and has been described infecting about 15%  
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Chapter 3 – MMPs/TIMPs, NF?B and cellular networks 
of astrocytes in vitro [156]. Therefore whether M.tb acted via networks other 
than infiltrating monocytes in the model of CNS TB was investigated. CoATb, as 
well as appropriate control conditioned medium, was prepared from primary 
human astrocytes from two donors but did not stimulate MMP-1 secretion 
(Figure 9). Similarly microglial condition medium, CoMicTb, did not up-regulate 
MMP-1 secretion (data not shown).
Chamber slide analysis of M.tb and microglial cell association 
I was concerned that the negative findings with CoMicTb and those in the initial 
global MMP analysis presented in figure 6 and 7 might be as a result of M.tb not 
infecting the microglia as they were a transformed cell line. Therefore I 
performed chamber slide M.tb infections of microglia at an MOI of 10, with 
modified Kinyoun staining and found 36.1% (±13.8) of cells associated with 
M.tb. For comparison I also infected macrophages with M.tb and found 59 ± 
5.7% bacilli associated at an MOI of 1. Confocal microscopy with GFP 
expressing M.tb confirmed that microglia were associated with intracellular 
bacilli (Figure 10). 
Immunohistochemistry: MMP-1 is expressed in microglia in patients 
with CNS TB 
To determine the clinicopathological significance of our cellular findings MMP-1 
immunohistochemical analysis of five brain biopsies from non-
immunosuppressed patients with histologically proven CNS TB was performed. 
An antibody to ionised calcium-binding adaptor molecule 1 (Iba-1), a known 
macrophage/microglial marker, was used to co-localise microglial MMP-1 
expression [326]. Two positive control patients were analysed, who had  
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Chapter 3 – MMPs/TIMPs, NF?B and cellular networks 
undergone temporal lobectomy for intractable epilepsy, a condition known to 
induce extensive activation of microglia. Tissue from beyond the epileptic focus 
at the excision margin was examined. Two negative control tissues examined 
were from post-mortem, macroscopically normal brains, from subjects with no 
history of neurological or infectious disease. 
Iba-1 immunoreactivity was strong in both parenchymal brain tissue and TB 
granulomas (Figure 11A). MMP-1 was expressed in resident tissue associated 
microglia compared to the granular layer neuronal cells (Figure 11B). 
Examination of Iba-1 positive granuloma associated microglia/macrophages 
(Figure 11C) demonstrated that MMP-1 immunoreactivity was strongest in the 
centre of the granuloma (Figure 11D). Hematoxylin and eosin staining and a 
representative negative control (omission of primary antibody) are shown for 
comparison (Figure 11E & F). Astrocytes and neurons did not demonstrate 
staining for Iba-1 or MMP-1 in any specimens. Positive controls demonstrated 
that although some microglial and capillary endothelium MMP-1 
immunoreactivity was seen this was to a lesser degree than was observed in 
CNS TB (data not shown). Negative controls showed some background 
immunoreactivity due to non-specific lipofuscin-antibody binding (a post-mortem 
artefact) but no specific binding (data not shown). In order to confirm co-
localisation of MMP-1 in microglia immunofluorescence was performed for Iba-1 
and MMP-1 (Figure 11G-I). Immunofluorescence confirmed that the MMP-1 
immunoreactivity observed above was expressed specifically in microglia. In 
summary immunohistochemistry demonstrated that in CNS TB microglia
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Chapter 3 – MMPs/TIMPs, NF?B and cellular networks 
express MMP-1 and that this immunoreactivity is more pronounced towards the 
centre of the TB granuloma. 
TIMP expression and secretion by M.tb-infected and CoM stimulated 
human microglia 
In contrast to the global analysis of MMPs (Figure 6 and 7) where MMP-1 gene 
expression was increased, CoMTb did not alter TIMP-1 expression and reduced 
TIMP-2, -3 and -4 expression by 68%, 64% and 56% respectively, although 
non-significantly (Figure 12A). The mean CT values between stimuli for 
individual TIMPs were similar but at different levels between TIMPs (Figure 7 
bottom): TIMP -1 (median 21.5, range 20.9 – 22.1), TIMP-2 (26.5, 25.8 – 27.5), 
TIMP-3 (26.3, 26.1 – 27.4) and TIMP-4 (31.8, 31.6 – 32.1). The main changes 
in TIMPs are summarised in table 4 above. 
TIMP-1 secretion was measured by ELISA and was confirmed to be at high 
concentrations, consistent with gene expression. It was not affected by different 
stimuli with control secretion of 31.9 ± 3.2 ng/ml representative of the four 
stimuli values (Figure 12B). In contrast CoMTb suppressed TIMP-2 secretion 
29% compared to CoMCont (p<0.01, figure 12C) confirming the expression 
data. TIMP-3 and 4 secretion were not assessed.  
Fractionation of CoMTb reveals CoMTb-dependent microglial cell 
MMP-1 secretion is mediated via a >10 kDa protein  
A holistic approach to the identification of the possible mediators of up-
regulation of MMP-1 in CoMTb was taken. Fractionation of CoMTb into two 
aliquots by molecular weight was performed. Aliquots of <10kDa and >10kDa
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Chapter 3 – MMPs/TIMPs, NF?B and cellular networks 
fractions were used to stimulate microglia at the same concentration as CoMTb 
(Figure 13A). The >10kDa fraction up-regulated MMP-1 secretion to 56.8% of 
the CoMTb value. 
TNF-? is necessary but not sufficient to reproduce the effect of 
CoMTb
As the >10 kDa fraction reproduced some of the effect of CoMTb I hypothesised 
that the pro-inflammatory cytokine TNF-? (molecular weight ~17 kDa) might be 
mediating the effect of CoMTb. Therefore CoMTb was pre-incubated with 
increasing doses of anti-TNF-? antibody (Peprotech, Rocky Hill, NJ, US). Anti-
TNF-? abolished the effect of CoMTb in a dose dependent manner (Figure 
13B). However, addition of recombinant TNF-? even at 100 ng/ml only restored 
MMP-1 secretion to 32.9% of CoMTb (Figure 13C). 
As synergy between TNF-? and secreted mycobacterial products leading to 
MMP secretion has previously been shown both TNF and Tb supernatant were 
used to stimulate cells [258]. Tb supernatant was generated by sterile filtering 
mid-log growth phase M.tb culture through an Anopore 0.2?m membrane 
(Whatman). The same volume of M.tb filtrate present in CoMTb was used to 
stimulate microglia (Figure 13D). Although there was a moderate increase in 
MMP-1 secretion (over and above the summated individual values of TNF-?
and Tb supernatant) to 54.2% of CoMTb this was not statistically different from 
TNF-? 100ng/ml alone. In addition the amount of TNF-? in three donor CoMTb 
batches was measured by ELISA and found to be 22.9 (± 5.0) ng/ml, thus 1:5 
diluted CoMTb only contains about 5 ng/ml TNF-?. TNF-? 10 ng/ml and Tb sup 
only produced 6.5% MMP-1 secretion compared to CoMTb. 
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Chapter 3 – MMPs/TIMPs, NF?B and cellular networks 
IL-1? is critical for the monocyte-microglial network driving MMP-1 
secretion
IL-1? is also a 17 kDa protein but is at much lower concentrations in CoMTb 
than TNF-? therefore the role of IL-1? in MMP-1 secretion was investigated 
using receptor antagonist (IL-1Ra, Peprotech) [327]. IL-1Ra abolished MMP-1 
secretion in a dose dependent manner (Figure 14A) but only to 15.4 ± 7.4 units 
of caseinolytic activity (63% reduction, p<0.01). Add back experiments with IL-
1? alone did not increase secretion of MMP-1 over basal levels (Figure 14B).
IL-1? and TNF-? (at concentrations found in CoMTb) were used to stimulate 
microglia to investigate whether synergy between these two cytokines 
accounted for all the effect of CoMTb (Figure 14C). TNF-? 10 ng/ml alone 
stimulated 28.4 (±8.6) units of caseinolytic activity (p<0.05 cf CoMTb). IL-1? and 
TNF-? together stimulated 52.4 (±21.1) units of caseinolytic activity. In figure 
14B IL-1? 1 ng/ml stimulated only 1.7 (±1.2) units of caseinolytic activity. 
However, as the confidence intervals were wide for these experiments the 
difference between TNF-? alone and in combination with IL-1? did not reach 
significance. In addition IL-1? and TNF-? together did not stimulate MMP-1 
secretion to the same magnitude as CoMTb, which gave an additional 24.0 
units of caseinolytic activity. 
Analysis of Conditioned Media by Luminex 
In order to try to unpick the final components of CoMTb that were responsible 
for MMP-1 secretion CoMCont (n=4 donors) and CoMTb (n=6 donors) were 
analysed using the Luminex platform. By using a low reading 8 point standard 
curve the lower level of sensitivity for these analytes were all < 1 pg/ml. The
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Chapter 3 – MMPs/TIMPs, NF?B and cellular networks 
results are summarised in figure 15 for analytes in the ng range and in table 5 
for those in pg range. 
In the nanogram range unstimulated monocytes (i.e. CoMCont) had significant 
basal secretion of IL-1 Ra 3.0 (±2.4) ng/ml, CXCL8 (IL-8) 3.7 (±4.3) ng/ml and 
CCL4 (MIP-1?) 1.0 (±0.8) ng/ml. In the pg range CCL2 (MCP-1) 92.6 (±82.2) 
pg/ml, CCL3 (MIP-1?) 129.8 (±232.3) pg/ml and CCL5 (RANTES) 89.7 (±104.6) 
pg/ml were secreted. Stimulation of cells with M.tb (i.e. CoMTb) led to 
significant increases in the concentration of IL-1? to 3.9 (±1.2) ng/ml (p<0.01), 
CXCL8 10.5 (±4.1) ng/ml (p<0.05), TNF-? 8.1 (±1.8) ng/ml (p<0.01), CCL4 2.2 
(±0.6) ng/ml (p<0.05) and CCL2 492.2 (±263.9) pg/ml (p<0.05). Although IL-2, -
4, -17, IFN-? and CXCL-10 (IP-10) were significantly increased in CoMTb (all 
p<0.01) their overall concentrations remained very low. IL-1Ra, IL-10, CCL3 
and CCL5 levels did not change significantly in response to M.tb stimulation. 
Pertussis toxin does not affect MMP-1 secretion 
As a number of important chemokines had been identified in the Luminex 
analysis of CoMTb, cells were pre-incubated with pertussis toxin, a GPCR 
inhibitor that inhibits chemokine signalling. No change was seen in MMP-1 
secretion with pertussis pre-incubation (Figure 16).  
In addition recombinant oncostatin M (a member of the IL-6 family), and IL-6 
neutralising antibody pre-incubation with CoMTb did not affect MMP-1 secretion 
(data not shown). IL-12 and 18 were not investigated. 
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NF-?B and AP-1 regulate CoMTb-induced microglial MMP-1 
promoter activity and secretion 
MMP-1 but not TIMP-1 or TIMP-2 contains an NF-?B consensus site in its 
promoter which may account for the differential regulation of gene expression 
observed [324]. To investigate the role of NF-?B in microglial MMP-1 secretion 
in response to CoMTb, kinetic analysis of the DNA binding activity of the NF-?B
subunits p50, p65, RelB, c-Rel and p52 in nuclear extracts was performed 
(Figure 17A-E). At 1 hour post stimulation with CoMTb there was a 2.0 fold 
increased in p50 DNA binding compared to CoMCont stimulated cells, with 
maximal activity seen at 4 hours. CoMTb induced a 3.1 fold increase in p65 
DNA binding at 1 hour. RelB reached a maximal 2.0 fold increase in DNA 
binding at the 4 hour time point. No change in the activity of c-Rel or p52 was 
observed. A sustained increase in DNA binding of p50, p65 and RelB subunits 
was still observed at the 24 hour timepoint, especially for the RelB subunit. 
Nuclear p65 kinetics was further investigated in a short timepoint kinetic 
experiment (Figure 18A). This demonstrated that p65 was detectable in the 
nucleus by 10 minutes and reached a peak at 30 minutes with sustained activity 
over 4 hours as previously seen. NF-?B activity is normally regulated by 
cytoplasmic I?B proteins. Degradation of cytoplasmic I?B? (Figure 18B) 
occurred by 10 minutes in CoMTb stimulated cells, with resynthesis by 60 
minutes. CoMCont did not affect I?B? degradation. Helenalin, an irreversible 
p65 alkylator, blocked nuclear translocation of p65 and p50 to below basal 
levels (Figure 18C), suggesting p65-p50 heterodimers are involved in MMP-1 
mRNA expression. The importance of the NF-?B pathway was confirmed by 
118
119
??????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????? ???????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????? ??????????? ???
?????????????????????????????????????????????? ????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????? ??????????????????????????????????????????????????????????????
????? normalised to ComCont 0 hrs??????????????????????????????????????????????????????????????????????? ??????
??????????????????????????????????????????????????????????????????????
???????
?????
?????
? 8 ???? ?? ??
?????
1
1
?
 N
F?
?
??
??
??
???
???
??
??
??
??
??
? 8 ???? ?? ??
?????
???????
?????
???
1
?
3
 N
F?
?
??
??
??
???
???
??
??
??
??
??
?
1
? ?
? 8 ???? ?? ??
?????
1
?
3
 N
F?
?
??
??
??
???
???
??
??
??
??
??
???????
?????
???
1
???
1
?
 N
F?
?
??
??
??
???
???
??
??
??
??
??
? 8 ???? ?? ??
?????
1
???????
?????
?????? ?
1
?
 N
F?
?
??
??
??
???
???
??
??
??
??
??
???????
?????
???
? 8 ???? ?? ??
?????
1
??
??
??
??
??
120
??????????????????????????????????????????????????
?
?????
???????
0   10   30  60 120  240 0   10   30  60 120  240????
????????????
??
????
?
??
?
??
??
??
??
??
??
??
?
???
???
??
?
??
??
??
??
0 30 60 90 120 ??? 180 210 240
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
??????? ?????
??
1
2
3
??????? ????? ???????????
?????????????
??
??
??
??
??
??
??
??
?
???
???
??
1
2
3
4
?
6
?
?
?
??
??
??
??
??
??
??
??
??
?
??????? ????? ??????????
??????????
??
???????????????????????????????????????????????????????????????????????????????????????????????????????? ?????????
???????????????????????????????????????????????????????????????????????????????????????? ??????????????? ????????
????????????????????????? ??????????????????????????? ????????????????????????????????????????????????????????????????
????????? ??????????????????????????????????????????????????????????????????????????????????????????? ???????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????? ???????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????? ?????????
?????? Data were analysed by one-way analysis of variance, followed by Tukey’s multiple comparison.
Chapter 3 – MMPs/TIMPs, NF?B and cellular networks 
 using SC-514 (Calbiochem) an IKK-2 inhibitor and showing suppression of 
CoMTb induced MMP-1 mRNA expression (Figure 18D) similar mRNA results 
for helenalin were observed (data not shown). 
To investigate the functional importance of the increase in nuclear p65 cells 
were pre-incubated with helenalin or SC-514 and MMP-1 secretion was 
measured (Figure 19A & B). In a dose dependent manner both compounds 
reduced MMP-1 secretion to basal levels. No change in cell viability was 
observed in these experiments as measured by trypan blue exclusion.
Since IL-1? was found to be important in CoMTb mediated up-regulation of 
MMP-1 secretion the role of the IL-1? stimulated transcription factor AP-1 was 
investigated by performing DNA binding experiments for the JunB, cJun, JunD, 
FosB, cFos, Fra-1 and Fra-2 subunits. At the 1 hour time point a 111.5% rise in 
cJun (p<0.05) and 83.4% rise in FosB (p<0.05) DNA binding was seen over 
CoMCont stimulated cells (Figure 20A). The 6 hour timepoint was also analysed 
and showed very similar results (Figure 20B) although the differences were not 
significant because of wide confidence intervals.  
The full length wild type MMP-1 promoter (4372 bp up stream of transcription 
start site) and six 5’ deletion constructs were transiently transfected into 
microglial cells linked to a luciferase reporter to analyse promoter dynamics in 
response to CoMTb stimulation (Figure 21A for promoter schematics). Kinetic 
experiments were performed with the full length promoter (Figure 21B). CoMTb 
increased promoter activity above CoMCont levels by 1.6-fold at 10 h, 2.0-fold
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at 24 h, and 1.33-fold at 32 h thus the 24 hour timepoint was used in 
subsequent experiments. Then the series of 5’ deletion constructs showed a 
drop in promoter activity between -2942 and -2001 bp upstream of the 
transcription start site (Figure 21C). Using mutation constructs of the known NF-
?B and one of the six known AP-1 consensus sites in the wild type promoter 
(Figure 21A arrows) abolition of CoMTb stimulated promoter activity to 22.5% 
±4.7 (p<0.01) and 30.4% ±6.4 (p<0.01) of wild type activity was seen (Figure 
21D).
Immunohistochemistry for p65 and cJun 
To confirm the in vivo relevance of our cellular findings immunohistochemistry 
was performed on CNS TB and appropriate positive and negative control brain 
biopsies for p65 and cJun. Tissue associated microglia were immunoreactive 
for cytoplasmic p65 (Figure 22A), with granuloma associated 
microglia/macrophages demonstrating strong nuclear p65 immunoreactivity 
(Figure 22B arrow, enlarged in C). Some lymphocytes and capillary endothelial 
cells, but not cerebellar granular layer cells, were immunoreactive for p65 in 
CNS TB (Figure 22A). Neither astrocytes, neurons nor areas of necrosis were 
immunoreactive for p65. In positive control specimens only capillary endothelial 
cells were immunoreactive for p65. There were numerous Iba-1 positive 
activated microglia in these positive control specimens which were not 
immunoreactive for p65 (data not shown).
Some cJun immunoreactivity was seen in the cytoplasm of tissue associated 
microglia (Figure 22D & E). However, there was strong nuclear cJun 
immunoreactivity in microglia/macrophages surrounding the central area of  
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necrosis in TB gramulomas (Figure 22F). In summary increased p65 and cJun 
immunoreactivity was observed in a gradient from parenchymal brain tissue 
surrounding granulomas with cytoplasmic staining, increasing towards the 
centre of the granuloma where staining was nuclear and principally in 
microglia/macrophage cells. 
Discussion
In this comprehensive study of MMP and TIMP gene expression in human 
microglia I have demonstrated that M.tb networks potently increased MMP-1, -
3, -9 expression and moderately increased MMP-8 and -10 expression. CoMTb 
also suppressed MMP-24 expression significantly and MMP-2 moderately. 
Direct infection with M.tb appeared to affect cells very little with a rise in MMP-
27 the only significant finding. A number of MMPs were not detected with any of 
the stimuli suggesting that the spectrum of MMP expression observed is a TB 
specific finding in microglia. MMP-1 is a potent collagenase and was up-
regulated with both the stromelysin MMP-3, capable of activating MMP-1, and 
the gelatinase MMP-9, able to degrade collagen breakdown products of MMP-1. 
Thus this suggests that the host CNS response to M.tb infection is driven by 
infiltrating infected monocytes and that the individual microglial MMPs 
expressed represent a complete spectrum of enzymes necessary for extensive 
tissue destruction. As noted in table 3 these three MMPs have a number of 
substrates specific to the CNS: MMP-1 degrades molecules such as brevican 
and tenascin, MMP-3 and 9 can degrade myelin and tight junction proteins, 
MMP-1 and 3 are both pro-apoptotic to neurons [268, 328].  In addition TIMP -1 
expression remained unchanged and TIMP-2 to -4 were all reduced, suggesting 
a net shift toward a matrix degrading environment in CNS TB. 
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Increased gene expression by CoMTb drove high level secretion of MMP-1, 
confirmed in kinetic and dose response experiments. A moderate dose 
dependent increase in MMP-1 secretion was also seen with direct M.tb infection 
(4.6 fold increase). Kinetic investigations showed that MMP-1 gene expression 
was rapidly up-regulated by CoMTb. The fold up-regulation values for these 
experiments (Figure 8C) are higher than those in the global analysis (Figure 6) 
because they were normalised to a time 0 control, whereas the global analysis 
was normalised to 24 hour CoMCont MMP-1 mRNA levels. 
There are no published reports to compare these data to directly. However, 
Nuttal et al looked at MMP responses in microglia from human adult brains and 
described LPS responses in detail [263] . MMP-1, -3, -8, -10 and -12 rose 
significantly after LPS stimulation. There was an accompanying fall in MMP-2, -
15, -16 and -21. No further data on the intracellular mechanism is presented but 
the authors comment that TNF-? and IL-1? concentration also rise. Studies 
performed in rat microglia confirm that LPS up-regulated MMP-1, -3 and -8 
expression is a cross species response to LPS [329]. Elkington et al
investigated MMP expression in M.tb infected macrophages and found 
significant elevation of MMP-1, -3, -7, -10 mRNA, as well as a non-significant 
rise in MMP-8. Although not statistically significant I also found a 6.2 fold rise in 
MMP-8, suggesting that MMP-1, 3, 8 and 10 up-regulation might be a monocyte 
lineage specific response to a number of inflammatory stimuli.  
TIMP gene expression was either not affected (TIMP-1) or decreased by 
CoMTb (TIMP-2 to -4). Secretion data was analysed for TIMP-1 and -2 and 
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reflected the expression data. Thus in CNS TB MMPs are produced in excess 
of the TIMPs. Loss of neuronal TIMP staining in biopsies from CNS TB patients 
has been reported and macrophages do not up-regulate TIMPs in response to 
M.tb but there is no data in the literature regarding microglial TIMP secretion in 
CNS TB [221, 236]. 
Direct infection did not up-regulate MMPs in microglia to the same extent as 
CoMTb. Only MMP-27 expression was increased and the qRT-PCR CT value 
for this MMP was very low suggesting up-regulation was moderate and from a 
very low baseline level. Therefore I confirmed that M.tb was associating with 
microglial cells by Kinyoun staining of chamber slides. Although cell associated 
M.tb was lower in microglia than less heavily infected monocytes the rates were 
comparable to the literature. Rock et al reported that 76% of human foetal 
microglia were infected by H37Rv M.tb [156]. The lower rate reported in this 
work may be because the microglia were a transformed cell line that have 
previously been reported to have a lower phagocytic ability than primary cells 
[316]. Confocal microscopy confirmed that cell associated M.tb was intracellular 
in many cells, but quantitative analysis was not carried out. Whether this means 
that resident microglia are less good at being professional phagocytes is 
unclear and warrants further work in primary cells or in vivo models. If this were 
the case it would mean that monocyte infiltration is necessary for an efficient 
host response in the CNS to M.tb. Therefore therapies based on tightening the 
BBB might be detrimental to patients with CNS TB by excluding monocytes but 
this remains speculative. Additionally the lack of MMP-1 secretion in response 
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to M.tb driven astrocyte (CoATb) and microglial (CoMicTb) networks supports a 
central role for the infiltrating monocyte. 
The cellular model predicted high level MMP-1 expression in CNS TB patients 
at the site of tissue destruction and this was observed in clinical biopsy 
specimens. Microglial markers and MMP-1 co-localised in both brain 
parenchyma and granulomas suggesting that microglia, as the effector cells of 
the CNS immune response, may be driving CNS tissue destruction by secretion 
of MMP-1.  
Next I sough to unpick the mediators in CoMTb that were driving MMP-1 
secretion by taking a global approach to analysis. Fractionation revealed all the 
activity to be due to molecules >10 kDa. TNF-? and IL-1-? were proven to be 
necessary, but not sufficient, to reproduce the effect of CoMTb in driving MMP-1 
secretion. Adding back TNF-? and IL-1-? at concentrations in excess of those in 
CoMTb was necessary to restore MMP-1 secretion to CoMTb levels. TNF-? is 
known to stimulate MMP-1 secretion from a number of different cell types, but 
often seems to need co-stimulation with another molecule. Elkington et al
reported that pulmonary epithelial cells required additional cholera toxin (a 
GPCR stimulus used as a chemokine surrogate in vitro) to up-regulate MMP-1 
secretion [204]. Zhou et al similarly suggested that monocytes required 
additional GM-CSF and O’Kane et al Oncostatin M in fibroblasts [186, 252].  IL-
1-?, however, can stimulate MMP-1 secretion alone in rabbit synovial fibroblasts 
or gastric epithelial cells [325, 330]. I did not find this to be the case as IL-1-?
only stimulated MMP-1 secretion when combined with TNF-?. Both these 
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cytokines are key inflammatory molecules and have been implicated in the 
aetiology of other diseases with extensive tissue destruction such as 
rheumatoid arthritis. However, TNF-? is vital for sustaining the host response to 
latent M.tb infection and therefore therapies reliant upon TNF-? blockade in 
CNS TB might run the risk of exacerbating infection. Indeed a randomised 
placebo controlled trial of thalidomide in paediatric TBM showed increased 
adverse events in the treatment arm and so was terminated early [47].
CoMTb is a complex mixture of host and pathogen derived factors so the small 
(albeit non-significant) increase in MMP-1 secretion with addition of Tb 
supernatant to TNF-? (Figure 12D) is of interest. M.tb is known to stimulate a 
number of innate signalling pathways, such as TLRs and mannose receptors. 
Thus stimulating cells with the combination of TNF-?, IL-1-? and Tb sup 
together may have further increased MMP-1 secretion. Investigating TLR2 
pathways involving LAM might be fruitful too as LAM has been shown to up-
regulate MMP-9 secretion in monocytic cell lines [256].
The lack of suppression of MMP-1 secretion with pertussis toxin, a 7-membrane 
span GPCR blocker (e.g. chemokines receptors), suggests that the chemokines 
up-regulated by M.tb in CoMTb, such as CXCL8 and CCL2-5 are unlikely to be 
important factors in microglial MMP-1 secretion. This is confirmed by the 
fractionation data (only molecules >10 kDa are important for MMP-1 secretion) 
as most chemokines are about 8 kDa in size. I also measured a number of 
cytokines typically produced by T-cells which were at very low (pg) levels in 
CoMTb, reflecting the purity of the monocyte preparation. Therefore I cannot 
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comment on the role of other cytokines central to the formation and 
maintenance of TB granulomas in this model. For example IFN-? can modulate 
the secretion of MMPs [252, 315]. 
As TNF-? and IL-1-? were found to be central in CoMTb stimulated MMP-1 
secretion the NF?B pathway was carefully examined. This demonstrated that 
the canonical pathway involving p65-p50 heterodimer activation of MMP-1 gene 
transcription is critical for MMP-1 secretion. First nuclear extracts were analysed 
for all five NF?B subunits but only p50, p65 and Rel-B were enhanced by 
CoMTb. This was accompanied by rapid I?B? degradation as has been found in 
other model systems [221]. NF?B has already been described as an important 
transcription factor for MMP-1 secretion in fibroblasts, where an I?B mutant 
abrogated secretion [325]. Helenalin, a sesquiterpine lactone that irreversibly 
alkylates p65 thereby sequestering it in the cytoplasm, blocked both p65 and 
p50 translocation into the nucleus suggesting p65-p50 heterodimers are central 
to control of gene transcription. These data were confirmed by using a specific 
IKK2 inhibitor SC-514 [331]. This molecule slows p65 translocation into the 
nucleus and increases p65 nuclear egress. In this model it caused a dose 
dependent reduction in MMP-1 expression and secretion. The alternative NF?B
pathway uses p52 subunit dimers derived from proteolytic cleavage of the p100 
precursor combined with cRel or RelB. RelB has been shown to be involved in 
the regulation of antigen presentation function of DCs. Here in microglial cells 
RelB was found to be up-regulated by CoMTb and is likely to have formed 
heterodimers with p50, as its other major dimer partner p52 was unchanged by 
CoMTb. The role of RelB in both TB immunology and MMP secretion is 
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unknown but RelB null mice are known to have defects in innate responses to 
pathogens such as Toxoplasma gondii [332]. There are few chemicals available 
to block RelB so its role in MMP secretion could not be ascertained further as 
techniques such as siRNA were not available. Immunohistochemistry 
demonstrated that p65 activation is a dynamic process in vivo too. Cytoplasmic 
p65 was observed in parenchymal microglia but as the centre of the granuloma 
was approached this became predominantly a nuclear phenomenon. The 
antibody used recognises the N-terminus of p65 unbound to I?B proteins so 
staining observed reflects activation of the NF?B pathway in vivo.
IL-1? is known to stimulate AP-1 activity and the MMP-1 promoter has six 
consensus AP-1 sites [324, 333]. Thus the DNA binding activity of the seven 
AP-1 subunits were analysed at one and six hours after CoMTb stimulation in 
nuclear extracts. Both time points demonstrated that c-Jun and FosB were 
elevated in microglial nuclear extracts. Data from other CoMTb stimulated cells 
suggests that the AP-1 response is cell specific. In addition to c-Jun and FosB 
pulmonary epithelial cells up-regulated cFos but in astrocytes the additional 
subunit is JunB [327, 334]. In microglia cFos was non-significantly raised but 
JunB fell. Although AP-1 is known to have a central role in LAM induced MMP-9 
secretion but there are no published data on M.tb induced, AP-1 controlled 
MMP-1 secretion [335]. Therefore the observation that nuclear cJun is seen in
vivo particularly in parenchymal microglia and strongly expressed in granuloma 
associated microglia/macrophages is a key finding from this work. 
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Promoter reporter analysis confirmed the central role of both NF?B and AP-1. 
Complete loss of promoter activity was observed with loss or mutation of the 
NF?B site at -2886 to -2878 bp.  A distal AP-1 site at -1955 to -1945 bp was 
also found to be important, although the NF?B site is likely to be dominant. 
Similar evidence demonstrating loss of MMP-1 promoter activity with deletion of 
the NF?B site in primary fibroblasts suggested that it was principally an IL-1?
responsive site [324]. TNF-? did not induce promoter activity but was necessary 
for MMP-1 secretion in synovial fibroblasts despite up-regulating nuclear 
translocation of NF?B. These data suggest that co-ordinated IL-1? and TNF-?
stimulation is required for maximal MMP-1 promoter activity in keeping with the 
CoMTb data presented here. 
In summary I have demonstrated that monocyte-dependent networks are more 
important than either direct M.tb infection or glial-dependent networks in driving 
MMP expression from human microglial cells. TIMPs were not up-regulated 
suggesting that M.tb drives uncoupled MMP secretion. In addition I have 
demonstrated that MMP-1 gene expression and secretion is mediated via IL-1?
and TNF-? activating through NF-?B and AP-1 in vitro and in vivo. This 
suggests that in CNS TB infiltrating monocytes are central in driving MMP-
mediated tissue destruction that is the hallmark of this disease. Nevertheless 
this MMP cannot act alone and MMP-3, a known MMP-1 activator, was up-
regulated to the same extent as MMP-1.
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Chapter 4 – MMPs, MAP kinases and dexamethasone 
Introduction 
In data presented in chapter 3 global analysis of all microglial MMPs/TIMPs in 
CNS TB suggested that MMP-1 and -3 are key. Data regarding the control of 
MMP-1 expression and secretion was then presented. In this chapter therefore I 
focus on the stromelysin MMP-3 as it has a different spectrum of substrates to 
MMP-1. To compliment the nuclear signalling studies presented in the 
preceding studies, the role of MAP kinases in differential control of MMP-1 and -
3 secretion has also been investigated, as there are data that these kinase 
cascades, central to cellular stress activated responses, might been amenable 
to pharmacological manipulation in the future. Dexamethasone is used as an 
adjunct to anti-tuberculosis therapy in CNS TB, where it has been shown to 
reduce mortality but the exact mechanism is currently unclear [107]. As 
corticosteroids are known to affect MMP gene transcription directly the influence 
of dexamethasone on MMP-1, -3, TIMP-1 and -2 expression and secretion has 
also been investigated.
The data presented in this chapter demonstrates that monocyte-microglial 
networks are a greater stimulus than M.tb to MMP-3 expression and secretion. 
In addition p38 MAP kinase appears to be the critical intracellular cytoplasmic 
regulator of MMP-1 and -3 secretion. Dexamethasone differentially suppresses 
MMP-1 and -3 over TIMP-1 and -2 suggesting that these molecules may hold 
the key to the mechanism of dexamethasone action in treatment of CNS TB.
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Results
M.tb infection and monocyte-microglial networks drive MMP-3 
secretion from human microglia 
Secretion of MMP-3 was analysed to investigate whether the increased gene 
expression (Figures 6 & 7) resulted in greater enzyme activity. M.tb up-
regulated MMP-3 in a dose and cell-bacillus contact time dependent fashion to 
a maximum of 2.2 fold over control at an MOI of 10 (p<0.01, Figure 23A) at 72 
hours. However, CoMTb drove MMP-3 secretion more potently (Figure 23B) 
with a 25.3 fold increase in secretion over CoMCont (p<0.01) and 14.1 fold 
greater than M.tb (p<0.01). Kinetic studies of MMP-3 expression (Figure 23C) 
demonstrated that mRNA had started to rise by 6 hours and peaked by 24 
hours with a 34.8 ± 4.8 fold up regulation of mRNA over time 0 control samples 
(p<0.01).
Astrocyte-microglial and microglial-microglial networks do not drive 
MMP-3 secretion 
As MMP-1 and -3 are often co-regulated I investigated whether M.tb acted via 
networks other than infiltrating monocytes in the model of CNS TB. CoATb, as 
well as control conditioned medium (CoACont), was prepared from primary 
human astrocytes from two donors but did not stimulate MMP-3 secretion 
(Figure 23D). Similarly CoMicTb did not up-regulate MMP-3 secretion above 
basal levels (data not shown). In addition cells were stimulated with LPS but 
they did not up-regulate MMP-3 secretion suggesting that MMP-3 secretion is a 
TB specific response in microglia (Figure 23E). 
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TNF-?/IL-1? synergy is responsible for microglial MMP-3 secretion 
Fractionation of CoMTb resulted in two aliquots <10kDa and >10kDa that was 
used to stimulate microglia. The >10kDa fraction up-regulated MMP-3 secretion 
to 37.9% more than the CoMTb effect (p<0.01) but the <10kDa fraction had no 
effect (Figure 24A). Preincubation of CoMTb and the >10kDa fraction with 1 
?g/ml anti-TNF neutralising antibody returned MMP-3 secretion to baseline 
levels. In complimentary experiments anti-TNF-? abolished the effect of CoMTb 
in a dose dependent manner (Figure 24B). However, stimulation with 100 ng/ml 
TNF-? resulted in 5.2 ± 0.6 ng/ml MMP-3 (5% of CoMTb, Figure 24C). A small 
synergistic effect with the addition of TB supernatant to 100 ng/ml TNF-? alone 
was observed. Tb supernatant alone gave 1.6 ± 0.1 ng/ml MMP-3, rising to 9.1 
± 1.3 ng/ml with TNF-? (Figure 24C).
Next the role of IL-1? in MMP-3 secretion was investigated. IL-1Ra abolished 
MMP-3 secretion in a dose dependent manner (Figure 25A) to 20.6 ± 2.7 ng/ml 
(89.6% reduction compared to CoMTb). Add back experiments with IL-1? alone 
did not increase secretion of MMP-3 over basal levels (Figure 25B). However, 
when 1 ng/ml IL-1? was used to stimulate cells with 10 ng/ml TNF-? (similar 
concentrations of these cytokines found in the analysis of CoMTb in chapter 3) 
substantial synergy was seen (Figure 25C) with 37.9 ± 3.5 ng/ml MMP-3 
secreted (63.1% of CoMTb value, p<0.05). GPCR were blocked with pertussis 
toxin but there was no influence on MMP-3 secretion (Figure 26). 
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The NF-?B pathway regulates microglial MMP-3 secretion 
To investigate the role of NF-?B in microglial MMP-3 secretion in response to 
CoMTb chemical inhibition of IKK2 and p65 nuclear translocation was 
performed. SC-514 and helenalin blocked MMP-3 secretion in a dose 
dependent manner to basal levels (Figure 27A & B). At the level of gene 
expression a similar result was found for SC-514 (Figure 27C, helenalin data 
not shown but similar). No change in cell viability was observed in these 
experiments as measured by trypan blue exclusion.  
Three 5’ MMP-3 promoter deletion constructs linked to a luciferase reporter 
were available for transient transfection into microglial cells. This demonstrated 
that CoMTb increased the 2183 bp full length promoter activity above CoMCont 
levels by 3.4-fold at 24 hours (Figure 27C, p<0.05). Two 5’ deletion constructs 
were also used. A significant rise in promoter activity was seen with the 1612 bp 
promoter compared to the full length promoter in response to CoMTb 
stimulation (p<0.01). Promoter activity was abrogated to CoMCont levels when 
the shorter 642 bp construct was stimulated with CoMTb. Unfortunately no 
further deletion constructs or point mutation constructs were available to 
conduct further analysis of these findings. 
Analysis of serine/threonine kinases in microglia 
To dissect the intracellular signalling pathways that control MMP-1 and -3 
secretion an analysis of MAP kinase pathways was performed. A 
serine/threonine kinase phosphorylation array using a commercial kit that 
targets a number of important pathways was used. At 30 minutes CoMTb
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stimulated multiple signalling pathways including ERK, p38, AKT, GSK, JNK 
and HSP-27 (Figure 28A). Densitometric analysis demonstrated that high levels 
of ERK-1/2 and AKT phosphorylation were detected in CoMCont stimulated 
cells and were increased further by CoMTb (Figure 28B). However, absolute 
increases in some p38 isoforms were particularly high. CoMTb stimulated p38?
phosphorylation 58.2 units more (311%, p<0.01) than CoMCont and p38?
phosphorylation increased by 10.2 units (154%, p<0.05). p38? and p38?
phosphorylation levels did not change. 
p38 phosphorylation kinetics 
To investigate these findings further kinetic Western blot analysis of CoMCont 
and CoMTb stimulated p38 phosphorylation in microglia was performed over 
120 minutes (Figure 28C). Minimal basal phosphorylation was seen. CoMTb 
stimulated p38 phosphorylation by 15 minutes, which had waned by 60 minutes. 
However, a second peak of phosphorylation was detected at 120 minutes. ERK 
phosphorylation was investigated at 30 minutes and confirmed high basal 
phosphorylation that was further up-regulated by CoMTb (Figure 28D, lanes 1 & 
4).
MMP-1 and -3 secretion are p38 dependent but only MMP-1 is ERK dependent 
To study the role of the p38 and ERK pathways in control of MMP-3 secretion 
specific chemical inhibitors (p38, SB203580 and ERK, PD98059) were pre-
incubated with microglia at 1 and 10 ?M prior to stimulation by CoMTb. For 
contrast MMP-1 secretion was also analysed. MMP-1 secretion was 
suppressed 45.6% by 1 ?M  and 92% by 10 ?M SB 203580 (p<0.05 and p<0.01 
respectively, Figure 29A). 10 ?M PD98059 ERK inhibition similarly decreased
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Figure 29. p38 phosphorylation is the key signalling event during MMP-1 and -3 secretion. A, p38 and ERK MAP kinase 
pathways regulate MMP-1 secretion. Microglial cells were incubated with SB203580 or PD98059 for 2 h and then 
stimulated with CoMTb. MMP-1 secretion was analysed at 72 h by casein zymography (representative gel shown), 
confirmed by Western blot and Luminex. B, MAP kinase inhibition suppresses MMP-1 mRNA accumulation. MMP-1 
gene expression was analysed by RT-PCR 24 h after stimulation with CoMTb. C, Only p38 MAP kinase regulates 
MMP-3 secretion. MMP-3 secretion was analysed at 72 h by ELISA. D, p38 MAP kinase inhibition suppresses MMP-3 
mRNA accumulation. A & C, Bars represent mean values ± SD of three samples, representative of at least duplicate 
experiments performed in triplicate. B & D, Mean values ± SD from three experiments are presented. Data were 
analysed by one-way analysis of variance, followed by Tukey’s multiple comparison. *p<0.05, **p<0.01.
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MMP-1 secretion by 71.3% (p<0.01). MMP-3 was found to be p38 but not ERK 
dependent as SB203580, but not PD98059, suppressed MMP-3 in a dose 
dependent manner (Figure 29C). 1 and 10 ?M SB203580 reduced MMP-3 
secretion by 28.8% and 83.2% respectively (both p<0.01). 10 ?M PD98059 did 
not suppress MMP-3 secretion compared to CoMTb (p=ns). 
Since ERK inhibition did not cause suppression of MMP-3 secretion the 
inhibitory effect of PD98059 on ERK phosphorylation was checked by 
phosphorylation Western blot analysis (Figure 28D). At 30 minutes basal ERK 
phosphorylation was detected (lane 1), which was not significantly affected by 
PD98059 (lanes 2 & 3). CoMTb up-regulated ERK phosphorylation (lane 4) and 
this effect was blocked by PD98059 in a dose dependent manner (lanes 5 & 6).  
MMP-1 and -3 gene expression were investigated by qRT-PCR (Figure 29B & 
D). MMP-1 gene expression was up-regulated 4.6 fold by CoMTb over 
CoMCont (p<0.05). This up-regulation was suppressed by inhibition of both the 
p38 and ERK pathways. SB203580 reduced MMP-1 mRNA expression by 
58.7% (p<0.05) and PD98059 reduced it by 25.9% although this latter value 
was not statistically significant. MMP-3 expression was only affected by p38 
inhibition, being reduced by 75.1% (p<0.01) thereby confirming the secretion 
data.
Effect of dexamethasone on gene expression and secretion of MMP-
1 & 3 and TIMP-1 & -2 
Corticosteroids are of proven clinical benefit in TBM therefore the effect of pre-
treatment with dexamethasone on expression and secretion of MMP-1, -3,
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Figure 30. Dexamethasone suppresses CoMTb-induced MMP-1 and -3 gene expression. Microglia were infected 
with M.tb at an MOI of 10 (diamond hatched shading) or stimulated with CoMTb (filled bars) with or without 
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shown. A, MMP-1 gene expression. Dexamethasone suppressed MMP-1 gene expression at 24 h in infected microglia 
to below control levels and to basal levels in CoMTb stimulated cells. B, MMP-3 gene expression. Dexamethasone 
suppressed MMP-3 gene expression to basal levels in CoMTb stimulated cells. C, TIMP-1 gene expression. 
Dexamethasone partially suppressed TIMP-1 gene expression (p=ns). D, TIMP-2 gene expression not suppressed by 
dexamethasone. Mean values ± SEM are given for three experiments performed on separate vials of cells. Data were 
analysed by one-way analysis of variance, followed by Tukey’s multiple comparison. *p<0.05, **p<0.01. E, PCR cycle 
thresholds for matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) gene expression in 
human microglia stimulated by M.tb and CoMTb preincubated with dexamethasone. The mean cycle threshold (CT) at 
which PCR amplification enters the logarithmic phase is shown for the RNA samples analysed in A-D. A low CT indicates 
high mRNA levels. Open rectangles represent low expression through shaded to solid rectangles, representing high 
expression. Of the MMPs/TIMPs down-regulated by dexamethasone MMP-1 and -3 were the most highly 
suppressed. Note: in part some of these data were presented in figure 6 & 7.
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TIMP-1 and -2 was investigated. Preincubation with dexamethasone at 0.01?M
inhibited CoMTb induced MMP-1 mRNA expression to basal levels (Figure 30A, 
p<0.01). In addition dexamethasone reduced M.tb induced MMP-1 expression 
beyond baseline to undetectable levels. Dexamethasone inhibition of CoMTb 
induced MMP-3 expression to basal levels was also observed (Figure 30 B). 
Baseline secretion of both MMPs was similarly affected by dexamethasone. In 
contrast TIMP-1 and -2 mRNA levels were not affected by dexamethasone 
(Figure 30 C & D). The quantitative CT data for this experiment was in 
accordance with the 18s corrected values (Figure 30E). Secretion data 
confirmed the expression data for all four analytes (Figure 31). MMP-1 secretion 
was suppressed further than MMP-3 but both were significantly suppressed by 
dexamethasone (Figure 31 A & B, p<0.01). In contrast TIMP-1 was not affected 
by dexamethasone preincubation (Figure 31 C). CoMTb suppressed TIMP-2 
secretion somewhat but this was not affected by dexamethasone (Figure 31 D). 
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Figure 31. Dexamethasone suppresses CoMTb-induced MMP-1 and MMP-3 secretion. Microglial cells were 
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casein zymography. B, MMP-3 secretion was analysed by ELISA. C, TIMP-1 secretion was analysed by ELISA. D, 
TIMP-2 secretion, analysed by ELISA, was suppressed by CoMTb but not restored by dexamethasone. Bars represent 
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Discussion
The gene expression profiling discussed in the chapter 3 results section 
suggested that both MMP-1 and -3 were up-regulated more than any other 
MMPs. Although MMPs have overlapping substrate affinities, a variety of MMPs 
need to be secreted into the extracellular environment to degrade both 
extracellular matrix and other substrates such as chemokines and tight 
junctions efficiently. Therefore this chapter has focused both on factors in 
CoMTb that led to increased MMP-3 secretion, as well as intracellular signalling 
events stimulated by CoMTb leading to MMP-1 and -3 secretion. MMP-3 has a 
number of CNS specific substrates: it can cause neuronal apoptosis and BBB  
breakdown in addition to activating MMP-1 [301]. There are little published 
clinical data on the role of MMP-3 in TB and no data in CNS TB. Extrapolation 
from Mmp3 null mice work performed in other models of inflammation would 
suggest that, in addition to the substrates/activities listed in table 3, MMP-3 is 
critical for leucocyte influx to areas of inflammation [336]. Modulation of the host 
inflammatory response is a realistic drug target and therefore the MAP kinase 
pathways have been explored in some depth to unpick up-stream signalling 
events leading to MMP-1 and -3 secretion. As dexamethasone is a key adjuvant 
therapy for TBM its effect on the secretion of MMP-1 and -3, as well as TIMP-1 
and -2 was investigated. 
The first observation was that M.tb infection of microglial cells up-regulated 
MMP-3 secretion in a time and dose dependent fashion despite the lack of 
change in gene expression suggesting that M.tb infected microglia are not inert. 
LPS injected directly into the brains of mice led to up-regulation of MMP-3 
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secretion well before TNF-? suggesting that innate signalling pathways 
involving TLRs lead to MMP-3 secretion [198]. However, CoMTb drove the 
secretion of MMP-3 more than 14 fold more than M.tb direct infection and this 
was also confirmed to be occurring at the level of gene transcription in kinetic 
studies. Increased MMP-3 secretion has been described in response to LPS 
stimulation in mice, rat and human microglia [220, 263, 329]. However, MMP-3 
secretion in human microglia appears to be a TB-specific phenomenon, as LPS 
did not up-regulate MMP-3 in this model (Figure 23E). I have not analysed 
TLR4 expression on the microglial cells used in these experiments, but microglia 
are known to express TLR4 [142, 143]. In the same way as described for MMP-
1, networks involving astrocytes and microglia did not influence MMP-3 
secretion, once again placing the monocyte as the central player in microglial 
MMP responses to M.tb driven neuroinflammation.
There was substantial synergy between TNF-? and IL-1? leading to MMP-3 
secretion. MMP-3 secretion is usually IL-1? dependent, but synergy has been 
described before in trabecular meshwork cells, orchestrated in part by TNF-?
driving increased expression of IL-1 receptors [337]. Fibroblast MMP-3 
secretion requires synergy between TNF-? and Oncostatin M  [186]. The point 
of synergy between TNF-? and IL-1? in microglia remains to be elucidated. 
The NF?B pathway was found to be important for MMP-3 expression and 
secretion, as chemical blockade with helenalin and SC-514 abrogated both 
responses. Unlike MMP-1 the published literature has suggested that there are 
no true NF?B consensus sites in the MMP-3 promoter [333]. A down-regulatory 
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effect of p50-p65 NF?B subunits binding at the stromelysin IL-1 responsive 
element found between -1614 and -1595 bp upstream of the transcription start 
site has been described [338]. The literature fits with the finding in this work of a 
derepressor of promoter activity between the -1612 and -642 promoter 
constructs, but not the NF?B chemical inhibition data. Nevertheless, involvement 
of NF?B in up-regulation of MMP-3 secretion has been described in human 
macrophages and rabbit foam cells using NF?B knockdown by over expression 
of I?B? [339]. Perhaps NF?B is having an indirect effect by up-regulating AP-1 
subunits, known to have NF?B sites in their own promoters, as AP-1 is known to 
be important in regulation of MMP-3 gene expression. Once activated these AP-
1 subunits could then secondarily activate MMP-3 transcription [340]. Further 
work to unpick these mechanisms might include EMSAs with NF?B subunit 
supershifts, or anti-NF?B subunit chromatin immunoprecipitation with 
subsequent RT-PCR using MMP-3 promoter specific primers designed for non-
consensus NF?B binding sites identified using a blast search of the promoter. 
Further work on investigating the derepressor in the MMP-3 promoter is also 
warranted using mutation constructs of potential derepressors, such as PEA3 
binding sites. 
Next I investigated the role of MAP and serine/threonine kinases in control of 
MMP-1 and -3 secretion by use of a commercial array. This demonstrated that 
ERK and the Akt pathways were active in resting cells. These pathways are 
responsible for cell turnover and therefore high basal expression in cell lines is 
common. Although there was some up-regulation of phosphorylation of these 
pathways with CoMTb, the p38 pathway, in particular the p38? and ? subunits, 
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stood out as the principle target of CoMTb induced signalling. This was 
confirmed with kinetic studies, where biphasic phosphorylation of p38 was 
observed. No specific subunit analysis was performed because the antibody 
used recognises epitopes common to all four p38 subunits. M.tb has also been 
shown to drive p38 phosphorylation in microglia directly. Yang et al
demonstrated that sonicated M.tb stimulated p38 phosphorylation in a TLR2, 
dectin-1 independent manner [157]. However, I did not use this profiling kit to 
investigate which components of CoMTb are required specifically for p38 
phosphorylation, but it is reasonable to assume that the TNF-? and IL-1?
synergy observed acts at this point, as synergy driving MMP-3 secretion has 
been reported as acting at this level previously [337]. Those authors reported 
that the p38? and p38? subunits were important, not p38?, as was the principle 
finding in this study. p38? appears to be a critical regulator of monocyte lineage 
inflammatory responses. Conditional knockout of p38? in murine macrophages 
differentially affects bacterial phagocytosis and LPS-induced TNF-?, but not IL-6,
secretion via the attenuation of the transcription factor cAMP response element-
binding protein (CREB), but not the NF?B, pathway [341]. Finally there is now 
evolving evidence that p38 inhibition may have a therapeutic role in the 
treatment of cerebral ischaemia, where it reduces both neuronal death and 
microglial activation [342].
The high ERK basal phosphorylation up-regulated by CoMTb observed in the 
MAP kinase array was confirmed, as was the efficacy of the inhibitor PD98059 , 
by Western blotting. Secretion of MMP-1 was found to be both ERK and p38 
dependent, but MMP-3 was only p38 dependent; thus p38 is the central cellular 
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control point for MMP-1 and -3 secretion in microglial cells. Gene expression 
data reflected the secretion data, which is somewhat surprising as p38 is felt to 
act post-translationally on mRNA stability, as has been shown for MMP-1 in 
fibroblasts [343]. mRNA stability was not assessed in this work, but would add 
valuable information to the data presented thus far. 
Dexamethasone suppressed MMP-1 and -3 gene expression and secretion 
without affecting TIMP-1 and -2. The mechanism for the beneficial adjuvant 
effect of dexamethasone in reducing mortality in TBM is unknown, but total 
protein was significantly reduced in the CSF by study drug recipients [50]. This 
was not due to an alteration in BBB permeability, as measured by the albumin 
index (ratio of CSF to serum albumin), so a reduction in MMP concentration 
could have contributed to this. In addition, measuring CSF parameters of 
inflammation does not equate to equivalent parenchymal fluxes of mediators. 
Microglial pro-inflammatory responses have been shown to be dexamethasone 
sensitive before. Rock et al showed that M.tb induced TNF-? and IL-1?
concentrations were suppressed by the same dose of dexamethasone used in 
this study (10-8 M). Harris et al and Elkington et al showed that astrocyte MMP-9 
and macrophage MMP-1 respectively, but not TIMPs, were modulated by 
dexamethasone pre-incubation. How dexamethasone does this is not clear, as 
MMP promoters are not as rich in glucocorticoid response elements as other 
genes [206]. Thus modulation of the p38 pathway, critical to microglial MMP-1 
and -3 secretion, by MAPK phosphatase-1 (a corticosteroid induced enzyme 
that opposes that action of p38 MAP kinase) is a possibility, but I was unable to 
perform experiments to confirm this mechanism [215, 344]. 
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In summary I have shown that M.tb infected monocyte networks and direct 
infection are both strong stimuli to MMP-3 secretion. This is mediated by 
synergy between TNF-? and IL-1?, acting principally via p38 MAP kinase. In 
addition, dexamethasone potently suppresses MMP-1 and -3 gene expression 
and secretion, reversing the CNS matrix degrading phenotype stimulated by 
CoMTb. This chapter adds to the literature surrounding the mechanism of tissue 
destruction in CNS TB and offers credible drug targets for future therapies. 
However, understanding the effects of targeting pathways such as p38 MAP 
kinase on other mediators controlled by it will be necessary. 
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Introduction 
The preceding chapters have focused on up-regulation of MMPs, particularly 
MMP-1 and -3, in the context of CNS TB. MMP-1 is a potent collagenase, 
cleaving fibrillary collagen exclusively at the Gly775-Leu/Ileu776 peptide bond and 
is activated by MMP-3. Both were up-regulated far more by CoMTb than M.tb.
Nevertheless even together they cannot degrade all components of the ECM. In 
this respect the gelatinases, MMP-2 and -9, are of particular interest as they 
can further degrade collagen that has been cleaved by MMP-1. Gelatinases 
have well described and important roles in ECM turnover as they are 
quantitatively the most abundant MMPs secreted in most situations. MMP-2 is 
constitutively expressed at high levels by many cells and pro-peptide activation 
is felt to be the main mechanism of MMP-2 control. MMP-9 has been implicated 
in the pathogenesis of many inflammatory diseases including CNS TB [313]. In 
addition up-regulation of the expression of MMP-9 was noted in the global 
analysis of MMPs/TIMPs. However, the overall flux of MMP concentrations 
within an inflammatory environment is likely to be an important factor in 
determining net changes in proteolytic activity within any compartment. 
Therefore this chapter focuses on the observation that microglial MMP-2 
secretion was suppressed by monocyte derived TNF-? acting via p38 and NF?B
signalling to the level of gene transcription. A possible non-apoptotic role for 
caspase 8 in this pathway is suggested by preliminary data. 
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Results
MMP-2 secretion suppressed by CoMTb more than M.tb
Microglia were stimulated with 1:5 CoMCont, CoMTb or M.tb at MOIs of 0.1, 1.0 
and 10. MMP-2 secretion was analysed by zymography and confirmed by 
Luminex (Figure 32A). There was a 12.8 and 31% reduction in MMP-2 secretion 
due to direct infection of microglia at an MOI of 1 and 10 but CoMTb caused a 
72.8% suppression of MMP-2 secretion (p<0.01). Kinetic analysis confirmed 
that this suppression was evident by 24 hours and sustained over 96 hours 
(Figure 32B). Analysis of mRNA by qRT-PCR demonstrated that CoMTb was 
acting at the level of gene expression as mRNA levels were suppressed by 50% 
(Figure 32C). This was a specific effect between monocytes and microglia as 
conditioned media from M.tb infected primary human astrocytes (Figure 32D) 
and microglia (CoMicTb, data not shown) had no effect on MMP-2 
concentrations.
Only TNF-? in CoMTb is responsible for suppression of MMP-2 
secretion
TNF-? has been described as a mediator of MMP-2 suppression in astrocytoma 
cells [193]. Therefore CoMTb was pre-incubated for two hours with increasing 
doses of TNF-? neutralising antibodies before being used to stimulate microglia 
(Figure 33A). MMP-2 secretion was restored in a dose dependent manner. 
Therefore recombinant TNF-? was added to cells at 1, 10 and 100ng/ml. 100 
ng/ml was able to suppress MMP-2 secretion by 61.0%, the same extent as 
CoMTb (Figure 33B, p=ns for comparison of CoMTb and TNF-?). However,
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Figure 32. MMP-2 secretion and gene expression is suppressed by CoMTb. A, Microglial cells were stimulated with 
CoMTb or infected with M.tb. 72 h supernatants were analysed by Luminex and gelatin zymography. B, Kinetics of 
MMP-2 secretion analysed by gelatin zymography (representative zymogram shown). C, MMP-2 gene expression is 
suppressed by CoMTb. mRNA from microglia stimulated for 24 h was analysed by RT-PCR, normalised to 18S RNA 
and expressed as fold change relative to 24 h CoMCont mRNA. The mean ± SD from three experiments are shown 
analysed by Student’s t-test. D, Astrocyte-microglial signalling networks do not suppress MMP-2 secretion. Conditioned 
medium from primary human astrocytes was prepared from control (CoACont) and M.tb infected cells (CoATb) and 
used to stimulate microglia 1:5. 72 h cell culture medium was analysed by gelatin zymography. A, B & D, Bars represent 
mean values ± SD of three samples, representative of at least duplicate experiments performed in triplicate. Data were 
analysed by one-way analysis of variance, followed by Tukey’s multiple comparison. *p<0.05, **p<0.01.
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analysis of CoMTb presented in chapter 3 confirmed it contained only ~8 ng/ml 
TNF-? therefore the role of secreted M.tb antigens that are in filtered CoMTb by 
the addition of Tb supernatant (Tb sup) was investigated. Although Tb sup had 
been found to be important in the control of secretion of MMP-1 and -3 in 
chapters 3 and 4 no synergy was found between TNF and Tb sup (Figure 33C). 
Unlike live M.tb, Tb sup alone did not suppress MMP-2 secretion (data not 
shown). Pre-incubating cells with IL-1Ra in increasing doses or stimulation of 
cells with recombinant IL-1? did not suppress MMP-2 secretion in the same way 
as CoMTb (Figure 34A & B). In addition cells were pre-incubated with pertussis 
toxin for two hours in order to block GPCR before the addition of CoMTb. No 
effect on CoMTb suppression of MMP-2 secretion was found (data not shown). 
p38 MAPK controls TNF-? mediated MMP-2 suppression 
As TNF-? is known to signal via MAP kinase signalling pathways cells were pre-
incubated for 2 hours with specific chemical inhibitors for the p38 (SB230580) 
and  ERK (PD98059) pathways (Figure 35). Inhibition of the p38 pathway led to 
a loss of CoMTb mediated MMP-2 suppression. 1 ?M  SB230580 caused MMP-
2 secretion to return to the same level as CoMCont and 10 ?M SB230580 
caused a 228% increase in MMP-2 secretion over CoMCont (p<0.01). In 
contrast ERK inhibition at 1 ?M PD98059 led to a further 6.1% decrease in 
MMP-2 secretion over and above the 31.2% due to CoMTb (p<0.05 for CoMTb 
to Control group comparison). 10 ?M PD98059 caused a significant further fall 
in MMP-2 secretion of 76.6% compared to CoMCont (p<0.01), although 
statistically this was not lower than CoMTb alone. 
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NF?B nuclear signalling controls MMP-2 secretion 
As the CoMTb down-regulatory signal was found to be via the TNF-?/p38
pathway (Figure 35), mediated by a fall in mRNA (Figure 32C), the NF?B
pathway was studied to unpick further the mechanism of MMP-2 suppression. 
Helenalin restored MMP-2 secretion to basal levels (Figure 36A). Chemical 
inhibition of IKK2 with SC-514 led to a dose dependent loss of CoMTb mediated 
MMP-2 suppression (Figure 36B). This was supra-maximal at 5 ?M, 220.7% 
higher than CoMCont and 423.8% higher than CoMTb (both p<0.01). No 
supramaximal secretion was seen with helenalin but it was toxic to cells at more 
than 1 ?M if used in secretion experiments as cells were exposed to it for a 
prolonged period of time. 
Dexamethasone does not control MMP-2 suppression 
Pre-incubation of cells with 0.01 ?M dexamethasone, that had previously 
suppressed MMP-1 and -3 secretion, had no effect on CoMTb mediated MMP-2 
suppression (data not shown). 
Caspase 8 inhibition restores MMP-2 secretion to control levels 
To investigate the mechanism of CoMTb induced MMP-2 suppression cells 
were pre-incubated with a caspase 8 inhibitor (z-IETD-fmk, Sigma) and 
stimulated after two hours. As expected CoMTb suppressed secretion of MMP-
2 by 33% (p<0.01). A dose dependent increase in MMP-2 secretion was 
observed with increasing concentrations of caspase 8 inhibitor, returning 
secretion to basal levels with 1 ?M inhibitor (Figure 37). 
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Immunohistochemistry 
To confirm the importance of the in vitro p38 findings phospho-p38 
immunohistochemistry was performed on the five CNS TB brain biopsies and 
appropriate controls as described in the preceding chapters. This demonstrated 
that microglial nuclei were more immunoreactive for phosphorylated p38 than 
cytoplasm (Figure 38).
Technical aspects of quantifying MMP-9 secretion  
As CoMTb induced MMP-9 gene expression was statistically up-regulated in the 
initial MMP screen (Figure 6 & 7) MMP-9 secretion was investigated. Initial 
experiments appeared to confirm that CoMTb up-regulated MMP-9 secretion. 
However, when 1:5 CoMTb itself was analysed it was found to contain high 
concentrations of MMP-9. This meant that looking for increases in microglial 
MMP-9 secretion over and above that already in CoMTb (or decreases 
expected in blocking experiments) was extremely difficult. Interpretation of 
MMP-9 secretion in microglia using this model system was not possible. Of note 
no MMP-1 or MMP-3 was detected in CoMTb. 
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Figure 38. Microglia express phosphorylated p38 in patients with CNS TB. Brain biopsies from five patients with 
CNS TB and two positive and negative controls were immunostained for p38 as described in materials and methods 
chapter. Areas of immunoreactivity appear as brown against the blue counterstain. A, Nuclear p38 immunoreactivity 
is seen in microglia, principally on the left hand side of the figure (original magnification x40). B, negative control 
(omission of primary Ab) from tonsillar tissue used as positive control for p38 staining (original magnification x20).  
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Discussion
In this chapter I have explored the mechanism driving the observation that 
CoMTb down-regulated MMP-2 in microglial cells. I have demonstrated that this 
occurs via an M.tb infected monocyte network involving TNF-?, p38 MAP kinase 
and NF?B. In addition a role for Caspase 8 is indicated. MMP-2 is frequently 
constitutively expressed at high levels in many normal physiological states 
principally because the gene promoter does not have a TATA box [206]. MMP-2
up-regulation is described in the CSF of TBM patients compared with controls 
or patients with non-infectious neurological conditions in two case series [288, 
312]. Although MMP-2 was detected by immunohistochemistry in the meninges 
of CNS TB patients it was not seen in parenchymal cells suggesting that tissue 
specific down-regulation may be occurring in vivo [288]. It is felt that control of 
MMP-2 activity is achieved by restricting the activation of the secreted pro-
enzyme. This occurs via a mechanism involving a molecule of both MMP-14 
and TIMP-2 binding a molecule of proMMP-2 and presenting it to another MMP-
14 molecule for proteolysis of the pro-domain [345]. However, in this chapter I 
have described how MMP-2 down-regulation in microglia is controlled at the 
level of gene transcription. Outside of the context of carcinomas down-
regulation of MMP-2 is rarely reported. 
MMP-2 secretion was suppressed by CoMTb more profoundly than by M.tb
alone. This suppression commenced as early as 24 hours. It was then 
sustained up to the 96 hour timepoint. Suppression of secretion was shown to 
be due to suppression of MMP-2 mRNA expression. As in the preceding 
chapters monocyte networks appear to be key as astrocyte conditioned medium 
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did not affect MMP-2 secretion. Only TNF-? in CoMTb was responsible for 
down-regulation of MMP-2 secretion supported by anti-TNF-? neutralising 
antibodies and add back experiments. This is in keeping with a report from Qin 
et al who observed a similar phenomenon in astroglioma cells mediated by 
TNF-? and regulated at the level of gene transcription but not by changes in 
mRNA stability [193]. The negative data from blocking IL-1? and pertussis toxin 
is consistent with their findings.
Investigation of the ERK and p38 MAP kinase pathways demonstrated p38 acting
as a brake to MMP-2 secretion. Addition of 1 ?M SB203580 restored the MMP-2
concentration to CoMCont levels but 10 ?M SB203580 led to supra-maximal secretion
of MMP-2. The p38 MAP kinase pathway is already known to be a critical regulator of 
inflammatory processes [346]. p38 acts as a brake in a similar way in pulmonary 
epithelial cells, where it is the switching point for divergent TNF-? driven MMP-1 and 
TIMP-1 secretion [204]. The exact mechanism of how p38 acts is not clear either
here or in the literature. Microglial mRNA data for SB203580 inhibition of CoMTb 
stimulation has not been presented but it might be expected to show restoration of
MMP-2 mRNA to CoMCont levels. However, as p38 is also known to act 
post-transcriptionally on mRNA stability, therefore future work would have to 
include kinetic actinomycin D chase experiments to investigate this proposed 
mechanism.
Blockade of the NF?B pathway with SC-514 restored MMP-2 secretion to 
supramaximal levels over controls in the same way that p38 inhibition did. This 
suggests that both p38 and the NF?B pathway are restricting MMP-2 secretion 
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from microglia in basal conditions as well when stimulated by CoMTb. Although 
TNF-? mediates its pro-inflammatory activity via the NF?B pathway down-
regulation by the same pathway is well described [347]. TNF-? mediated down-
regulation of apolipoprotein E mRNA in adipocytes has been shown to be an 
NF?B dependent process, with p50 siRNA reversing the inhibition [348]. This 
suggests that investigation of p50 homodimer binding to the MMP-2 promoter 
by chromatin immunoprecipitation assays might be the next step although the 
literature does not support a consensus site for NF?B in the MMP-2 promoter.  
However, NF?B has non-DNA binding mechanisms for suppressing 
transcription. NF?B dependent inhibition of MMP-2 has been described in 
hepatic stellate cells in vitro. Curcumin, a naturally occurring NF?B inhibitor, 
was shown to increase basal expression of MMP-2, via decreased nuclear p65 
but no further data on the mechanism was presented [349]. In p53 (a 
transcription factor) negative tumour cells, p65 mediated suppression of p21 
gene induction. However, in tumour cells expressing p53, competition between 
p53 and p65 for a limited pool of the coactivator p300/CBP was proposed as the 
mechanism for the loss of p65 mediated suppression observed [350]. In human 
monocytes a similar phenomenon was described, this time with CREB and p65 
both competing for CBP, rescued by over expression of CBP [351]. Thus I 
hypothesise that CoMTb driven nuclear p65 competes for p300/CBP coactivator 
protein complexes with transcription factors known to be necessary for 
constitutive MMP-2 gene expression such as Sp-1, Sp3 and AP-2 [352].
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This may also explain the role of p38 MAP kinase in MMP-2 repression. p38 (?
and ? subunits) can feed into the NF?B pathway by forming part of the p65 
transcription complex [353]. After p65 release from phosphorylated I?B proteins, 
in certain circumstances cytoplasmic p38 binds to the p65 nuclear localisation 
sequence prior to its translocation to the nucleus. Knockdown of p38 then 
specifically affects NF?B dependent genes such as CXCL8. Additionally p38 
has been described as the regulator of p65 phosphorylation. Phosphorylated 
p65 is a more potent stimulus to gene transcription. p38 phosphorylation of the 
nuclear located mitogen and stress activated kinase-1 (MSK-1) led to p65 
phosphorylation in RAW264.7 murine macrophages [354]. Unfortunately MSK-1 
was not on the phosphoarray presented in chapter 4, but there was a non-
significant increase in phosphorylation of the closely related MSK-2 (Figure 28).  
Finally caspase 8 inhibition also restored MMP-2 secretion in a dose dependent 
fashion, but not to supramaximal levels as p38 and NF?B inhibition had done. 
These data suggest that proteolytic cleavage activity of caspase 8 is inhibitory 
to MMP-2 secretion. Caspase 8 is an aspartate specific cysteine protease that 
is the most receptor proximal caspase associated with initiation of apoptosis. 
Subsequently apoptosis is executed by caspase 8 cleaved molecules such as 
caspase 3. The caspase 8 inhibitor used (z-IETD-fmk) can block the release of 
cytochrome c as well as the activation of caspases 9 and 3 by its inhibition of 
caspase 8 [355]. Proteolytic cleavage of kinases and signal transducers by 
caspases is usually an inactivation step during apoptosis. However, some 
kinases such as MEK kinase-1 are activated by caspase mediated cleavage 
[356]. More specifically p38 signalling was essential for caspase 8 activation 
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linked to M. avium-induced death signalling in macrophages. This is cell specific 
because in some tumour cells treatment with SB203580 and expression of a 
dominant negative form of p38 did not affect caspase 8 activation [357]. Finally 
in neutrophils p38 can directly phosphorylate and inhibit the activity of caspase 
8 and thereby hinder neutrophil apoptosis [358].
Non-apoptotic roles for caspase 8 in cell proliferation, differentiation, cytokine 
release and NF?B activation have already been described [359]. Caspase 8 
mediates TNF-? activation of NF?B via a p38 independent pathway. In HeLa 
and HEK293 cells caspase 8 forms a complex with TRAF2, a TNF-? receptor 
adaptor molecule, and Flice-associated huge protein (FLASH) [360]. The 
mechanism of how this complex leads to IKK? and ? degradation and NF?B
nuclear translocation is not known. It is also cell type dependent as other 
authors have described a role for caspase 8 in T-cell receptor and LPS not 
TNF-? mediated NF?B activation in T-cells [361]. 
Inhibition of caspase 8 could have led to suppression of microglial apoptosis 
thereby increasing the number of cells secreting MMP-2 but this was not 
analysed. CoMTb mediates significant up-regulation of MMP-1 and -3 secretion 
and TIMP-1 secretion continues at a high level suggesting that apoptosis is not 
a significant factor in this model. In addition activation of the canonical NF?B
pathway is a recognised anti-apoptotic stimulus. Of interest would be to inhibit 
Caspase 8 in CoMTb stimulated cells and measure MMP-2 mRNA levels, p38 
phosphorylation and nuclear p65 translocation. Caspase 8 activation could be 
measured by Western analysis of cell lysates too [252]. 
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In summary I have shown that M.tb infected monocyte networks involving TNF-
?, p38 MAP kinase, NF?B and caspase 8 act to suppress MMP-2 secretion in 
microglial cells. This serves to remind that it is the overall balance of MMPs and 
TIMPs within the inflammatory milieu that will affect the absolute level of matrix 
degradation occurring. 
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Introduction 
The preceding chapters have concentrated on analysis of data generated from 
an in vitro model of CNS TB with in vivo confirmation from biopsy specimens. 
Thus findings reflect microglial specific processes to a larger extent. However, 
TBM is a meningoencephalitis and so analysis of CSF should reflect total net 
secreted MMP/TIMP load from all CNS cells such as endothelium, astrocytes, 
microglia, neurons and infiltrating leucocytes. As suggested by data in chapter 5 
the flux of MMPs/TIMPs is as important as changes in individual molecules due 
to potential substrate overlap. In addition, over time the quantity and phenotypic 
quality of cells involved in any inflammatory circumstance will change leading to 
alterations in MMP/TIMP concentrations. I now present longitudinal analysis of 
archived CSF samples from TBM patients that I performed at the Wellcome-
Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam in 
collaboration with Dr Guy Thwaites (Imperial College).
Previously it has been shown that adjunctive dexamethasone, administered with 
anti-tuberculosis drugs, improved the outcome of adults with TBM [107], but the 
mechanism underlying this effect is not understood. Dexamethasone did not 
have any significant effect on CSF white cell infiltration or cytokine expression in 
93 patients recruited to the original clinical trial [50]. A subset of patients had 
serial brain magnetic resonance imaging which suggested dexamethasone 
might decrease the incidence of hydrocephalus and infarction [95]. However, no 
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study has clearly demonstrated the mechanism by which dexamethasone 
reduced case-fatality from TBM. 
In this study, I measured serial CSF concentrations of the MMPs/TIMPs 
identified as key in TB in a sub-set of adults with TBM recruited to a randomised 
controlled trial of adjunctive dexamethasone [107]. MMP-9 has already been 
identified as important in CNS TB [221, 313]. MMP-1, -2, -3, -8, -9 and -10 were 
identified in the global analysis presented in the preceding chapters. 
Macrophages infected with M.tb secreted MMP-7, in addition to MMP-1, in a 
cellular model of TB [236]. As CSF will only contain secreted molecules TIMP-3, 
which is membrane associated, was not analysed, but TIMP-1, 2 and 4 were. 
The aim was to investigate the relationship between dexamethasone treatment, 
CSF MMP/TIMP expression and clinical outcome. 
Methods 
Study participants and setting 
I studied a subset of patients from a previously reported randomised, double 
blind, placebo-controlled trial of adjunctive dexamethasone for the treatment of 
TBM in 545 Vietnamese adults [107]. Disease severity at admission was 
defined by the Glasgow coma scale (GCS). Assessment of GCS was performed 
by summation of clinical assessment of eye opening (awarded 1-4 points), best 
verbal response (1-5 points) and best motor function (1-6 points), where lower 
values indicate more severe neurological dysfunction [362]. Disease severity 
was also assessed using the United Kingdom Medical Research Council grade 
(UK MRC) for TBM [363]: patients in grade I had a GCS of 15 (fully conscious) 
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and no focal neurological signs; patients in grade II had a GCS of between 11 
and 14 and/or focal neurological signs; and patients in grade III had severe 
coma with a GCS of less than 11. 
To be eligible for selection for this study patients had to have been recruited at 
the Hospital for Tropical Diseases (HTD), Ho Chi Minh City, have a 
microbiologically confirmed diagnosis of TBM (Mycobacterium tuberculosis
cultured from the CSF), negative HIV-1 & -2 antibodies, and at least two serial 
CSF specimens taken within the first 60 days of treatment (when 
dexamethasone was stopped) available for analysis, unless they had died 
within this period.
Ethics
The ethical and scientific committees of all institutions approved the study and 
written, informed consent to participate in the study was obtained from the 
patients or their relatives. 
Treatment and specimen collection 
Adults were allocated randomly to start dexamethasone sodium phosphate or 
placebo as soon as possible after the start of four drug anti-tuberculosis therapy 
as previously described [107]. Briefly, adults with grade II or III disease  
received intravenous study drug for 4 weeks (week 1 0.4 mg/kg/day); week 2 
0.3 mg/kg/day, week 3 0.2mg/kg/day, week 4 0.1 mg/kg/day), then 4 weeks of 
tablets starting at 4mg total dose per day, reducing by 1mg per week until zero. 
Those with grade I disease received 2 weeks of intravenous study drug (week 1 
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0.3 mg/kg/day, week 2 0.2 mg/kg/day) then 4 weeks of tablets (week 3 0.1 
mg/kg/day; then 3mg total per day reducing by 1mg per week until zero). 
Serial CSF samples (frozen at -70oC) and routine clinical investigations were 
collected as part of normal clinical care pre-treatment and on study days 3, 7, 
30, 60 and 270.
Assessment of the clinical and CSF inflammatory response to treatment 
The primary outcome of the trial was death or severe disability 9 months after 
randomisation and was assessed blind to the treatment allocation [107]. 
Likewise, treatment allocation was unknown to those assessing conventional 
and experimental CSF inflammatory responses. CSF white cell count, protein, 
glucose and lactate concentrations were determined by standard methods. 
Blood brain barrier integrity was assessed by measurement of paired CSF and 
plasma albumin concentrations by standard methods. The albumin index was 
calculated using the formula [albumincsf]/[albuminplasma] [52]. The concentrations 
of CSF cytokines (IFN-?, TNF-?, and the interleukins -1?, -6, -8, -10, and 
12p70) were determined by cytometric bead array assay (BD Biosciences) as 
described [50].
MMP and TIMP concentration measurement 
MMP-1, -2, -3, -7, -8, -9 and -10 and TIMP-1, -2 and -4 were measured by 
ELISA (R&D Systems) according to the manufacturer’s instructions. The lower 
level of sensitivity for the ELISAs were 156 pg/ml for MMP-1 and 7, 78 pg/ml for 
MMP-2 and 10, and 31 pg/ml for MMP-3, 8, 9, TIMP-1, 2 and 4. Samples with 
high MMP/TIMP concentrations were diluted as appropriate. Values below the 
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level of detection were assigned an arbitrary value halfway between zero and 
the lower level of sensitivity.  
Statistical analysis
Continuous variables were compared by Student’s t-test if normally distributed 
and Mann-Whitney U test if non-normally distributed. Where more than two 
groups were compared the Kruskal-Wallis test was used for non-parametric 
data. Categorical data were compared using Fisher’s exact test or the ?2 test. 
All p-values were two sided and a value of <0.05 was taken as significant. 
Baseline MMPs and TIMPs were analysed by univariate analysis to examine 
relationships between presenting clinical features and outcomes. Continuous 
variables were modelled using linear regression and binary outcomes using 
forward and backward likelihood ratio logistic regression. The changes in 
MMP/TIMP concentration between pre-treatment and follow-up samples were 
calculated using repeated measures ANOVA with dexamethasone as a 
covariate. All analyses were performed using SPSS version 15.0 (SPSS Corp).  
Results
37 patients, of whom 18 received dexamethasone, satisfied the study entry 
criteria and their baseline characteristics and laboratory parameters are 
summarised in table 6. These were similar between the two study groups. 
Patient median age was 29 (interquartile range [IQR] 21 - 41.5) years and 22/37 
(59%) were female. On admission patients were febrile with a median GCS of 
13 (IQR 11-15). In addition 14/37 (38%) had at least one cranial nerve palsy, 
5/37 (14%) had hemiparesis but only 1/37 (3%) had paraparesis. At the end of 
treatment a combined poor outcome (death or severe disability) was seen in 
179
 Chapter 6 – Analysis of CSF MMPs/TIMPs in TBM 
8/37 (22%) and 5/37 (14%) of patients died. Baseline CSF laboratory findings, 
which are summarised in table 7, were similar between the two groups except 
there was a raised CSF opening pressure in the dexamethasone-treated group 
(p=0.05). In total 141 of 185 (76%) CSF specimens taken were available for 
analysis of longitudinal changes in MMPs/TIMPs concentrations. 66/94 (70%) 
were from placebo and 75/91 (82%) from dexamethasone group patients; a 
mean of 3.8 (+/-1.2) samples per patient. Sample exhaustion accounted for the 
missing specimens. 
Table 6. Baseline demographics, presenting features and clinical outcome 
of study patients.
Variable*# Placebo Dexamethasone 
Number (n) 19 18
Age (yr) 31 (23.0-44.0) 25 (19.25-40.5) 
Gender (M:F) n 7:12 8:10
TBM grade n (%)    I 2 (10.5) 6 (33.3) 
  II 11 (57.9) 7 (38.9) 
   III 6 (31.6) 5 (27.8) 
Weight mean (sd, kg) 49.3 (8.5) 48.4 (6.5) 
Temperature oC 38.7 (38.0 - 39.3) 39.0 (38.0 - 39.5) 
GCS at presentation 13 (10-14) 13.5 (10-15) 
Duration of symptoms (days) 17 (12-21) 17 (12-26.25) 
HIV negative n (%) 19 (100) 18 (100) 
Cranial Nerve Palsy n (%) 8 (42.1) 6 (33.3) 
Hemiparesis n (%) 2 (10.5) 3 (16.7) 
Paraparesis n (%) 0 (0) 1 (5.6) 
Death n (%) 3 (15.8) 2 (11.1) 
Combined poor outcome n (%) 4 (21.1) 4 (22.2) 
* Values are median (IQR) or number (percentage) unless stated otherwise. 
# No significant differences between groups. 
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Table 7. Baseline CSF parameters of study patients. 
Variable* Placebo Dexamethasone 
Number (n) 19 18
Opening pressure (cm)# 18.0 (16-32) 33 (19.25-39.0) 
Total WCC (cells/?l) 470 (130-625) 250 (147-613) 
Neutrophils (%) 30 (18-43) 40 (24.5-67.5) 
Neutrophils (cells/?l) 93 (25-251) 101 (38-281) 
Lymphocytes (%) 70 ( 57-82) 60 (42-75.5) 
Lymphocytes (cells/?l) 210 (125-398) 164 (86-312) 
Protein (g/L) 160 (102-300) 200 (150-297) 
Lactate (mmol/L) 6.2 (4.6-8.1) 6.6 (5.2-8.9) 
Glucose ratio – CSF/blood 0.17 (0.09-0.30) 0.25 (0.14-0.34) 
Albumin ratio – CSF/blood (%) 1.12 (0.58-2.84) 2.03 (0.65-2.73) 
* Values are median (IQR) unless stated otherwise. 
# p=0.05 for group comparison. 
The relationship between baseline CSF MMP and TIMP concentrations, pre-
treatment disease features and clinical outcome 
Baseline pre-treatment concentrations of MMPs and TIMPs are summarised in 
table 8. MMP-2, -3 and -9 concentrations were detectable in all 30 pre-
treatment CSF samples and MMP-8 concentrations were detectable in 29 
(97%). CSF concentrations of MMP-1 and -7 were only detectable in 9 (30%) 
patients and MMP-10 in 10 (33%) patients. All 30 patients had detectable TIMP-
1 and -2 and 29 (97%) patients had detectable CSF TIMP-4.  
Baseline MMP and TIMP concentrations stratified by TBM grade were analysed 
but no significant relationships were found (Figure 39). Therefore I investigated 
the relationship between increasing severity of coma (i.e. lower GCS) and CSF 
MMP/TIMP concentrations (corrected for CSF white cell count) by linear 
regression. The final model (table 9) showed higher MMP-9 and TIMP-1 
concentrations were significantly correlated with higher coma score (lower coma 
severity, both p<0.05), and MMP-3 showed a strong trend in this direction
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Figure 39. CSF MMP(A)/TIMP(B) concentrations vary by severity of coma at presentation. CSF samples were analysed 
by ELISA and are presented stratified by MRC TBM coma grade (where I is mild and III severe coma). Outliers are 
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Table 8. Baseline CSF MMP/TIMP concentrations*.
Variable Placebo Dexamethasone 
Number (n) 15 15
MMP-1 (ng/ml) 0.13 (0.13-0.49) 0.13 (0.13-0.24) 
MMP-2 (ng/ml) 47.0 (37.5-53.2) 42.2 (33.3-48.7) 
MMP-3 (ng/ml) 1.22 (0.80-1.46) 0.97 (0.27-1.66) 
MMP-7 (ng/ml) 0.078 (0.078-0.079) 0.078 (0.075-0.12) 
MMP-8 (ng/ml) 18.9 (10.9-28.4) 12.6 (7.9-28.6) 
MMP-9 (ng/ml) 108.3 (37.8-226.5) 110.8 (93.4-269.2) 
MMP-10 (ng/ml) 0.04 (0.04-0.11) 0.04 (0.04-0.11) 
TIMP-1 (ng/ml) 248.6 (116.2-421.1) 180.1 (83.9-241.0) 
TIMP-2 (ng/ml)# 31.6 (28.2-38.6) 23.0 (20.9-29.6) 
TIMP-4 (ng/ml) 0.43 (0.32-0.47) 0.49 (0.32-0.87) 
            * Values are median (IQR) unless stated otherwise. 
            # p=0.01 for group comparison. 
(p=0.07). CSF MMP-8 and TIMP-2 were inversely associated with coma score 
(both p<0.05).  Baseline higher MMP-8 and lower MMP-9 concentrations also 
predicted combined poor outcome in multivariate analysis of all MMPs/TIMPs 
and CSF WCC (MMP-8: OR=85, p=0.03 [95% CI 2, 4218] and MMP-9: 
OR=0.02, p=0.04 [95% CI 0.0003, 0.8]).
Table 9. Summary of multiple linear regression - MMPs/TIMPs that predict 
more severe coma (lower Glasgow Coma Score) on clinical presentation 
with TBM. 
Unadjusted Multiple regression analysis 
Variable
Coeff. (95% CI) P coeff. (95% CI) P
MMP-3 0.03 (-2.3, 2.4) 0.98 3.2 (-0.3, 6.8) 0.07
MMP-8 -37 (-95, 20) 0.19 -258 (-445, -70) 0.009
MMP-9 -19 (-62, 23) 0.37 190 (37, 344) 0.02
TIMP-1 1.0 (-0.8, 2.8) 0.27 2.7 (0.7, 4.8) 0.01
TIMP-2 -0.9 (-3.3, 1.5) 0.45 -7.6 (-12.5, -2.8) 0.03
Variables entered into model: MMP-1, -2, -3, -7, -8, -9, -10 & TIMP-1, -2, -4 adjusted for CSF WCC  
(R2 =0.45, ANOVA p=0.01 for final model). 
I found no other significant relationships between pre-treatment MMP/TIMP 
concentrations and combined poor outcome, mortality, cranial nerve palsy, 
hemiparesis and paraparesis on admission by multivariate analysis, although 
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there was a significant relationship between lower pre-treatment MMP-2 
concentrations in CSF and hemiparesis (p=0.02) on univariate analysis. There 
was no relationship between duration of symptoms and MMP/TIMP 
concentrations.
MMP non-secretion and disease severity at clinical presentation 
21/30 (70%) pre-treatment CSF samples were from patients with undetectable 
CSF MMP-1. 14 of these 21 patients (67%) also had undetectable MMP-7 and 
of these 14 patients 8 (57%) had undetectable MMP-10. These 8 patients were 
categorised as “non-secretors” and compared to the remaining 22 “secretors” 
by TBM grade. Non-secretors made up 0/6 (0%), 3/15 (25%) and 7/9 (78%) of 
patients with grade I, II and III disease respectively (p=0.003). There was no 
significant difference in CSF white cell or neutrophil count between groups to 
explain the discrepancies in MMP secretion. An exploratory univariate analysis 
revealed a significant relationship between non-secretors and admission GCS 
(OR=1.6, p=0.02 [95% CI 1.1, 2.2]) and a trend with combined poor outcome on 
admission (p=0.08). There was no significant relationship between non-
secretors and survival, cranial nerve palsy, hemiparesis or paraparesis on 
admission. Multivariate analysis with age, sex, GCS, combined poor outcome 
and CSF white cell count within the model showed GCS as the only 
independent predictor of failure to secrete detectable CSF MMP-1, -7, and -10 
in the model. 
The influence of dexamethasone on CSF MMP/TIMP concentrations 
22 patients had both a pre-treatment and at least one paired ‘early’ follow up 
sample available for analysis, taken a median 5 days (range 3-8) into anti-
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tuberculosis treatment. Where two samples were available from this period the 
results from the earlier one were used in analysis. CSF MMP-9 concentrations 
were significantly lower in the early follow-up samples of patients given 
dexamethasone compared to placebo (p=0.01, Figure 40), confirmed by 
repeated measures ANOVA with CSF white cell count as a covariate (p=0.002). 
3/11 (27%) patients in the placebo group had a fall in their CSF MMP-9 
concentration and 9/11 (82%) of the dexamethasone group (p=0.03) between 
pre-treatment and the early follow-up sample. However, there was no significant 
relationship between those patients whose CSF MMP-9 fell and outcome. 
There was a similar but less marked effect of dexamethasone on MMP-8 
concentrations.  A trend for lower CSF MMP-8 concentrations in the 
dexamethasone arm (p=0.08) was not significant in the repeated measures 
ANOVA. No other significant relationships were found at this or any later time 
points for any other MMP/TIMP and treatment group. MMP-9 concentrations at 
later time points were not statistically different between the two groups. Day 270  
Table 10. Day 270 CSF MMP/TIMP concentrations. 
Variable CSF Concentration [median (IQR)]* P value#
MMP-1 (ng/ml) 0.13 (0.13 - 0.13) 0.34
MMP-2 (ng/ml) 36.7 (33.0 - 50.7) 0.26
MMP-3 (ng/ml) 0.26 (0.12 - 0.45) <0.001
MMP-7 (ng/ml) 0.08 (0.07 - 0.11) 0.63
MMP-8 (ng/ml) 0.03 (0.03 - 0.03) <0.001
MMP-9 (ng/ml) 4.7 (0.9 - 12.2) <0.001
MMP-10 (ng/ml) 0.04 (0.04 - 0.05) 0.20
TIMP-1 (ng/ml) 23.9 (15.2 - 36.0) <0.001
TIMP-2 (ng/ml) 26.4 (23.1 - 37.4) 0.82
TIMP-4 (ng/ml) 2.1 (1.4 - 3.1) <0.001
             * Data are presented unstratified for treatment group, n=19. 
             # Comparison to baseline value in table 8. 
185
186
Chapter 6 - Analysis of CSF MMPs/TIMPs in TBM
*
p=0.01
Pre-treatment Early follow-up
M
M
P
-9
 (n
g/
m
l)
0
100
200
300
400
Figure 40. Dexamethasone reduces CSF MMP-9 concentrations in early follow up samples. Paired CSF samples from 
patients with tuberculous meningitis were taken pre-treatment and at early follow up, a median 5 days (range 3-8) into 
anti-tuberculosis therapy, and analysed for MMP-9 concentration by ELISA. Patients who received placebo (P, light grey 
bars, n=11) had significantly higher MMP-9 concentrations in their early follow-up CSF samples than those who received 
dexamethasone (D, dark grey bars, n=11). The black line represents the median value and the box the interquartile range. 
Whiskers represent 1.5 times the interquartile range away from the box. Groups were analysed by the Mann-Whitney U 
test. *, p=0.01.
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MMP/TIMP concentrations and their statistical change from baseline are 
summarised in table 10. Of note MMP-3, -8, -9 and TIMP-1 fell and TIMP-4 rose 
significantly over the course of 9 months anti-tuberculosis treatment.
The relationship between CSF WCC and MMP-9 concentrations 
Neutrophils play a key but possibly under-recognised role in host defence to 
mycobacteria and release preformed MMP-9 from granzymes to cross the BBB 
[364, 365].  CSF MMP-9 concentration and neutrophil count were correlated on 
analysis of all samples (R2 = 0.19, p<0.001). There was a significant correlation 
between MMP-9 concentration and CSF WCC (R2=0.31, P=0.004) in all early 
follow-up samples and a stronger correlation with CSF neutrophil count (Figure 
41, R2=0.52, P<0.001) which was dexamethasone independent.  
The relationship between MMP-9 and other CSF inflammatory parameters 
BBB disruption is potentially related to MMP activity [300], but I could find no 
relationship between the albumin index and CSF MMP/TIMP concentration. I 
found significant correlations between CSF total protein (the only CSF analyte 
to fall significantly due to dexamethasone [50]) and MMP-9 (R2 = 0.18, p<0.001) 
concentrations. When treatment groups were analysed separately 
dexamethasone significantly strengthened the relationship between MMP-9 and 
total protein concentrations (placebo R2 =0.05, dexamethasone R2 = 0.41, 
p=0.004). I could find no relationship between MMP-9 and TIMP-1, or their ratio 
and clinical outcome. 
I then explored the relationship between CSF concentrations of TNF-?, IFN-?,
IL-6, IL-8, IL-10 (data not presented) and MMP-9 in all specimens and found
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Figure 41. CSF MMP-9 concentration and CSF neutrophil count are significantly correlated in early follow up samples. 
Early follow-up CSF samples, taken a median of 5 days (range 3-8) into anti-tuberculosis treatment, from patients with 
tuberculous meningitis were analyzed for correlation between absolute neutrophil count and MMP-9 concentration 
(measured by ELISA). The R  value for Spearman’s correlation was 0.52 (p<0.001). Patients who received placebo are 
represented by light grey circles and dexamethasone by dark grey circles.
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only IL-10 and MMP-9 to be correlated (R2 = 0.22, p<0.001). Concentrations of 
IL-1? and IL-12p70 levels were below the level of detection in all but 6 and 8 
specimens respectively so were not analysed. I looked specifically at baseline 
and early follow-up samples but did not find other significant relationships. 
Discussion
In this study I have examined the role of MMPs/TIMPs in the immunopathology 
of TBM in patients and the influence dexamethasone has on their secretion. I 
demonstrated a significant relationship between MMP-8, -9, TIMP-1 and -2 and 
the severity of coma at presentation and MMP-8 and -9 with death or severe 
neurological disability by 9 months of treatment. There were strong correlations 
between CSF MMP-9 and the CSF concentrations of neutrophils, and total 
protein, but not pro-inflammatory cytokines. Dexamethasone decreased CSF 
MMP-9 concentrations early in the course of treatment and may represent one 
mechanism by which corticosteroids improve outcome. Higher CSF MMP-9 
concentrations before the start of treatment were associated with better 
outcome. Dexamethasone did not influence the CSF concentrations of other 
MMPs/TIMPs.
The CSF concentrations of MMP-2, -3, -8 and -9, and TIMP-1, -2 and -4 were 
elevated in all patients with TBM before the start of treatment. When corrected 
for CSF white cell count, concentrations of MMP-8 and -9 and TIMP-1 and -2 
were significantly associated with severity of coma at presentation. Higher CSF 
MMP-9 concentrations were associated with less severe coma before anti-
tuberculosis treatment and a lower incidence of death or disability by the end of 
treatment. CSF MMP-8 and -9 concentrations were up-regulated in patients with 
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pyogenic bacterial meningitis and high MMP-9 concentrations were associated 
with poor outcome [285]. In a previous retrospective study that compared adults 
with TBM to those with viral or bacterial meningitis, and controls, increased CSF 
MMP-9 concentrations were related to increased disease severity and case-
fatality, confirmed by others in studies of TBM alone [288, 313]. Taken together, 
the data from this and previous studies demonstrate that MMP-9 has a key role 
in the pathogenesis of TBM.  MMP-9 may have both protective and detrimental 
clinical effects. Inhibition of MMPs by doxycycline in mice decreased 
pneumococcal CNS immunopathology, but MMP-9 knockout mice with 
experimental bacterial meningitis had reduced host defence mechanisms to the 
same pathogen [172, 289]. Murine studies suggest MMP-9 is important in host 
defence to M. tuberculosis. Macrophages from mice resistant to M. tuberculosis
produce more MMP-9 mRNA in response to intracellular infection than 
susceptible mice [366]. Non-specific MMP inhibition blocked early dissemination 
of M. tuberculosis and MMP-9-knockout mice had both reduced pulmonary 
recruitment of macrophages and poorer granuloma formation [190].
These data suggest the majority of early CSF MMP-9 is released from 
neutrophils. Other studies have reported strong correlations between MMP-9 
and neutrophils in viral meningitis and with total white cells in TBM [284, 312]. 
Neutrophils release large amounts of preformed MMP-9 in response to many 
inflammatory stimuli, which may explain the lack of correlation observed 
between CSF MMP-9 and the pro-inflammatory cytokines measured [367]. The 
role of the neutrophil in the pathogenesis of tuberculosis is not well understood. 
Peripheral neutrophil counts have been inversely related to risk of tuberculosis 
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in tuberculosis contacts and neutrophil depletion ex vivo impaired the ability of 
whole blood to restrict mycobacterial growth via depletion of secreted anti-
microbial peptides [365]. A report that neutrophil derived anti-microbial peptides 
are released in response to M. tuberculosis infection but not expressed in the 
tuberculous granuloma is consistent with the proposed early role for neutrophils 
in tuberculosis [368]. In addition, adults with TBM and a high proportion of 
neutrophils in the CSF have an increased chance of survival [52]. 
Consistent with the finding of decreased CSF MMP-9 concentrations in patients 
with more severe coma, non-secretors of MMP-1 (a collagenase), MMP-7 (an 
elastase) and MMP-10 (a stromelysin) were also associated with more severe 
coma at presentation. MMP-1 and -7 are present in pulmonary TB granulomas 
and M. tuberculosis-infected macrophages up-regulate expression of MMP-1, -7 
and -10 mRNA in vitro [236]. However, TBM is an encephalomyelitic process 
and dissociation between parenchymal and secreted MMPs may account for 
their lower levels in the CSF [369]. Immunohistochemical analysis of brain 
biopsies in chapter 3 suggested that the parenchymal TB granuloma is 
abundant in MMP-1. Alternatively, there is evidence that severe TBM may be 
associated with a relative immune-paresis, or cellular exhaustion as has been 
described in measles [370].
MMP-3 concentrations decreased 4-fold during treatment and I found a strong 
trend towards higher MMP-3 levels predicting more severe coma score on 
presentation. MMP-3 expression and secretion was up-regulated in microglia 
(chapter 4) suggesting they are a likely source of CSF MMP-3. MMP-3 mRNA is 
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known to be up-regulated in TB infected macrophages, but astrocytes have 
previously been shown not to be a source of MMP-3 in CNS TB [221, 236]. No 
data exist for oligodendrocytes. An LPS/MMP-3 knock-out mouse model 
showed less BBB disruption suggesting a role for MMP-3 in neuroinflammation 
[301]. MMP-3 cleaves myelin basic protein and MMP-3 release from apoptotic 
neurons activates microglia, perhaps suggesting a mechanism of enhancing 
further MMP secretion [269, 371]. TIMP-1 levels fell from a high baseline level 
10-fold during treatment but were still elevated at the end of treatment. TIMP-1 
is constitutively expressed by a number of CNS cells (including microglia and 
astrocytes) and elevated CSF concentrations have been reported in patients 
with viral and eosinophilic meningitis [219, 221, 284]. Although neuronal 
associated TIMP-1 is down-regulated in immunohistochemical studies of 
parenchymal cerebral TB CSF concentrations in TBM are higher than in viral, 
but not bacterial, meningitis [221, 313].  TIMP-4 concentrations increased 
greater than 4-fold during treatment. Similarly suppressed baseline CSF TIMP-4 
has been reported in eosinophilic meningitis [219, 372]. TIMP-2 concentration 
was elevated at baseline and levels did not change during longitudinal analysis 
consistent with constitutive expression as described [221].
Lower baseline MMP-2 concentration was associated with a significant risk of 
hemiparesis suggesting that the down-regulation presented in the cellular data 
(chapter 5) is important in vivo. Evidence from a study of experimental olfactory 
nerve injury in mice suggests that MMP-2 has a role in neuronal regeneration 
[373]. Peak MMP-2 levels corresponded to the onset of neural repair. Hence 
lower MMP-2 concentrations maybe detrimental to patients due to defective 
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healing rather than as a consequence of direct neuronal damage as suggested 
for MMP-1 and -3. 
Dexamethasone, the only known effective adjuvant to anti-tuberculosis 
chemotherapy, significantly reduced MMP-9 concentrations in early follow-up 
samples. Dexamethasone may improve outcome by influencing MMP-9 
secretion. I was not able to show a direct relationship between those with 
reduced post-treatment MMP-9 concentrations and improved outcome, but this 
study was not powered to confirm such an effect. No effect was observed at 
later time-points or on the other MMPs/TIMPs studied. Limitations in 
methodology may partly explain this observation. I used ELISAs that detected 
both active and pro-MMP-9 thus cannot differentiate between biologically active 
and inactive or degraded MMP-9 [320]. Differences in the activity of MMP-9 
(assessed by zymography) have been reported in experimental pyogenic 
meningitis where treatment with antibiotics alone increased CSF MMP-9 
activity, but dexamethasone co-administration suppressed this effect [292]. 
Additionally differential effects of dexamethasone suppressing TNF-? and IFN-?
driven MMP-9 secretion, but leaving TIMP-1 and -2 secretion unchanged in M.
tuberculosis-stimulated human astrocytic cells have been described [221, 315].
Given the strong correlation between CSF neutrophils and MMP-9 
concentrations I investigated the influence of dexamethasone on CSF 
neutrophil numbers, but did not observe any differences between the treatment 
groups at any time point. However, dexamethasone may affect function rather 
than absolute numbers [107]. Corticosteroids can rapidly prevent neutrophil 
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degranulation independently of effects on protein synthesis [374]. The restricted 
release of neutrophil derived proteins in dexamethasone treated patients may 
have contributed to the significant reduction in CSF protein observed in the 
dexamethasone group in the previous study involving a larger number of 
patients from the same trial [50].
In summary, this chapter has identified key relationships between baseline CSF 
MMP-8, -9, TIMP-1 and -2 concentrations, severity of coma at presentation and 
clinical outcome in TBM patients. I have shown that dexamethasone may 
influence outcome from TBM by reducing MMP-9 secretion into the CSF as has 
been shown for MMP-1 and -3, but not MMP-2 in vitro. Future research needs 
to delineate the roles of neutrophils and their MMPs in TBM more clearly. 
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The experiments presented have investigated the hypothesis that
that microglia control the CNS immune response to M.tb infection via the 
production of a different spectrum of MMPs compared to monocytes, 
macrophages and other glial components. By performing global analysis of all 
MMPs/TIMPs in human microglia in response to M.tb infection and M.tb infected 
monocyte-microglial networking (CoMTb) I found that MMP-1, -3 and -9 gene 
expression were significantly up-regulated only in CoMTb stimulated cells. 
MMP-8 and -10 were up-regulated to a lesser degree. In contrast TIMP-1 to -4 
expression was either static or suppressed by the same stimuli. Conditioned 
media from both microglia and primary astrocytes did not up-regulated MMP 
secretion in the same way as CoMTb suggesting that microglia require 
monocyte activity to be a source of MMPs. There is published evidence that the 
astrocyte response to M.tb infection is not as robust as that from microglia or 
monocyte in terms of cytokines and MMPs but investigations of 
oligodendrocytes are lacking [156, 221]. Thus cells of monocyte lineage, both 
monocytes and microglia, appear to be the critical cells orchestrating the CNS 
immune response to TB. 
After confirming MMP-1 and -3 expression were accompanied by secretion and 
observed in vivo in patient biopsies or CSF I attempted to unpick the 
components of CoMTb that were responsible for MMP-1 and -3 secretion. 
There was a difference between these two key MMPs. Although both were 
TNF-? and IL-? requiring neither cytokine alone could reproduce the effect of 
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CoMTb at working concentrations found in it. Significant synergy existed 
between TNF-? and IL-? leading to MMP-3, but not MMP-1, secretion. 
Nevertheless there was a missing factor in CoMTb which I was unable to find. 
This may have been filtered M.tb antigens although the data supporting this 
were not conclusive. Kinyoun staining and confocal microscopy helped confirm 
that differences in MMP gene expression seen between direct infection and 
CoMTb stimulated cells were not simply due to lack of phagocytosis of bacilli, 
although the cells used did not perform as well as the published microglial 
literature in this respect.
In depth analysis of nuclear signalling events that led to MMP-1 secretion 
suggested that p50-p65 heterodimers of NF?B and cJun/FosB AP-1 subunits 
are rapidly recruited to the promoter, leading to up-regulation of MMP-1 gene 
expression. Some of this work was also performed in a more limited way for 
MMP-3. I then focused upon the ERK and p38 MAP kinases, identified as key in 
a global analysis of serine/threonine kinase pathways activated by CoMTb. The 
proteome profiler array and subsequent experiments demonstrated that the 
p38? pathway is critical for MMP-1 and -3 gene expression and secretion. As 
dexamethasone is used as an adjuvant to anti-tuberculosis therapy in TBM I 
investigated its effect on MMP-1 and -3 secretion foreshadowing the clinical 
study presented in the final results chapter. This demonstrated that both MMP-1 
and -3, but not TIMPs, were suppressed by dexamethasone at the level of gene 
transcription.
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As the flux of MMPs is likely to be important in vivo due to substrate overlap I 
next investigated the mechanism of CoMTb mediated MMP-2 suppression. This 
was driven by a TNF-?/p38/NF?B/caspase 8 pathway, but due to time 
constraints I was unable to demonstrate convincing links between the individual 
components of the pathway identified. Additionally technical difficulties (namely 
the high MMP-9 content of CoMTb) made further analysis of the interesting 
dynamic whereby MMP-9 is up-regulated at the same time as MMP-2 is down-
regulated impossible within the timescale of the thesis.
Analysis of CSF specimens from patients with TBM confirmed that the MMPs 
identified in the in vitro model were present at elevated concentrations in most 
TBM patients. MMP-3, -8, -9 and TIMP-1 and -2 were predictive of coma 
severity and outcome from illness, although confidence intervals were wide. A 
prospective, appropriately powered study ought to be performed to confirm 
these findings. Additionally MMP-9 was the only MMP studied that was affected 
by dexamethasone treatment in vivo. Although MMP-9 was principally from 
neutrophils, the cellular source of the other CSF MMPs/TIMPs measured 
remains to be ascertained, but microglia are likely to contribute. This suggests 
that MMP manipulation in the clinical context may be a viable pharmaceutical 
target, although concerns about altered host response to the pathogen warrant 
further investigation in animal models first.
Therefore, in CNS TB it is likely that once bacilli reach the subarachnoid space 
or brain parenchyma, the first immune cells they will encounter will be microglia. 
There will be limited MMP-1 and -3 secretion from these cells once they have 
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phagocytosed M.tb. MMP-3 mediated MMP-1 activation will facilitate monocyte 
influx into the CNS by their action upon brain ECM (specifically fibrillary 
collagen, brevican and tenascin) and tight junction proteins like occludens 
molecules. Once infiltrating monocytes, perhaps following microglial derived 
chemokine gradients, have engulfed M.tb release of proinflammatory cytokines 
further enhances microglial MMP secretion. In addition to MMP-1 and -3 
secretion, MMP-8, -9 and -10 may be released allowing extensive ECM 
breakdown, chemokine processing and enhanced BBB breakdown. In addition 
to monocyte influx, T-cell trafficking will mean there is IFN-? secretion in the 
CNS. I have not investigated how this cytokine effects microglial MMP secretion,
but it has been reported to synergise with IL-1? to enhance MMP-9 secretion 
from astrocytes in CNS TB [315]. Microglia will then efficiently form granulomas 
with infiltrating monocytes and T-cells, during which MMP-9 function is known to 
be important [190]. Whilst the action of MMP-1 and -3 are important for these 
processes, there will be concurrent detrimental effects as these two MMPs are 
implicated in driving neuronal apoptosis. MMP-2 is the only other MMP 
reportedly able to effect this process, but I have demonstrated that it is likely to 
be down-regulated by monocyte derived TNF-?, itself pro-apoptotic to neurons. 
If patients are then commenced upon anti-tuberculosis therapy, release of M.tb
antigens will further activate monocytes and enhance microglial MMP secretion,
leading to intensified CNS inflammation and oedema, responsible for 
hydrocephalus and the deterioration sometimes seen early in therapy. It is 
tempting to speculate that the adjuvant effect of dexamethasone observed in 
reducing mortality from TBM is not only due to modulation of CSF MMP-9 
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concentrations, but also to effects on parenchymal MMP expression. As these 
MMPs may be membrane associated or simply do not spill over into the CSF 
this effect is not easily measured in patients by current technology.
In addition, by investigating intracellular signalling mechanisms I have identified 
the NF?B, AP-1 and p38 MAP kinase pathways as key to the control of MMP 
gene expression and secretion. p38 inhibitors are in the early stages of clinical 
development. However, TNF-? secretion is driven by the p38 pathway in 
monocytic cells, so a cautious optimism for their potential use must be balanced 
by intense scrutiny of their effects on host-pathogen dynamics before use in 
patients with CNS TB is attempted. However, if specific p38 subunits are 
differentially used to drive TNF-? and MMPs, then targeting them for subunit 
manipulation via small molecules might be possible [375].
In summary, this thesis identifies M.tb driven MMP secretion via NF?B, AP-1 and 
p38 MAP kinase pathways as central to the pathogenesis of CNS TB. Further 
work is warranted to delineate which MMPs specifically should be targeted to 
combat the detrimental effect of the excessive inflammation that accompanies 
the process of pathogen elimination. Perhaps by targeting the signalling 
pathways leading to MMP secretion described herein better adjuvants to anti-
tuberculosis therapy in CNS TB might be developed. 
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This work has concentrated upon developing and testing an in vitro model of 
CNS TB using cell culture and then confirmation in vivo in patient samples. 
Chemical inhibition data ought to be confirmed in primary microglia and with 
other technology such as siRNA. However, there are significant technological 
difficulties in transfecting primary monocytic cells to be overcome before this 
can become routine in the laboratory. Clinical trials of anti-MMP therapy are 
warranted. The tetracycline derivative doxycycline is known to have both anti-
MMP and anti-tuberculous activity, so potentially this drug could be used in 
patients as a therapeutic adjuvant in CNS TB. Although deciphering the 
mechanism of any observed beneficial effect would be difficult unless large 
numbers of patients were recruited to an appropriately powered prospective 
study.
Before attempting clinical trials of MMP/TIMP modulation further work ought to 
be performed in an animal model. Unfortunately the mouse model of CNS TB 
requires direct inoculation of M.tb into the brain, and the clinical phenotype of the 
ensuing disease is not the same as observed in humans. In published work 
looking at CNS TB in mice M.tb was cultured from brain homogenates, 
meningeal cellular infiltration was observed and inflammatory cytokines 
released, but mice did not die [161]. Whether this is due to enhanced iNOS 
production in murine microglia, not seen in human disease, is unclear. A recent 
report that iNOS null mice displayed a more human phenotype, dying with 
granulomatous lesions containing tubercle bacilli in histological examination of 
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the meninges may be a viable animal model worth trying. There has been no 
work using the guinea pig as a model of TBM since chemotherapy trials were 
published in the 1950s. The rabbit model of TBM is the most successful but 
suffers from a lack of molecular tools, as well as similar problems with disease 
phenotype seen in murine studies. Large primate studies, using macaques, 
would be the most likely to yield relevant results but are expensive and 
logistically difficult to do in category 3 facilities [165]. 
Nevertheless Mmp null mice, or perhaps iNOS Mmp null double knockouts, 
would compliment a study of MMP inhibition in murine TBM well. Knowing that 
Mmp9 null mice have disordered TB granuloma structure, along with the clinical 
data presented here on dexamethasone and MMP-9, makes this model 
pertinent to human disease. Unfortunately there are no data using other Mmp 
null mice in murine TB to suggest which avenue of investigation should be tried 
first. In addition murine cells do not express a functional orthologue of human 
MMP-1. However, the scavenger receptor A promoter has been linked to the 
human MMP-1 gene and inserted into the mouse genome, thus activated 
macrophages can be made to express human MMP-1, a subject of ongoing 
research in my host laboratory. p38? null mice do not survive gestation but
there are macrophage conditional knockouts which could be used to test 
whether loss of TNF-? secretion in response to M.tb occurs in vivo, as well as 
whether abrogating this pathway affects pathogen killing [341]. In addition this 
model, along with cellular studies, could be used to look at the mechanism of 
p38 control of MMPs by investigating gene stability, transcription factor 
phosphorylation and p38-p65 complexes.
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This study has not addressed the impact that HIV is likely to have on MMP 
secretion in CNS TB. TB in HIV patients is frequently not accompanied by 
inflammation until ART is commenced, clinically apparent as immune 
reconstitution syndrome (IRIS). HIV can infect microglia and adjuvant 
dexamethasone showed marginal benefit in HIV positive patients with TBM 
[107]. Thus any data generated from similar studies to those presented here 
would add valuable information to the current literature. 
In summary these studies have identified that microglia secrete MMPs in vitro
and in vivo. CSF examination shows MMPs are key regulators of inflammatory 
processes in TBM. Further delineation of the control and roles of MMPs, as well 
as the influence of HIV, in CNS TB pathogenesis by the use of animal models 
and new technology would aid the planning of large prospective clinical trials of 
MMP modulation. 
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ADAM A  dysintegrin and metalloproteinase 
ADAMTS A dysintegrin and metalloproteinase containing thrombospondin 
repeats
AP-1/2 Activator protein-1/2 
ARE  AU-rich element 
BBB  Blood brain barrier 
BCG  Bacille Calmette-Guerin 
BM  Bacterial meningitis 
BSA  Bovine serum albumin 
cAMP  Cyclic adenosine monophosphate 
CBP/p300 CREB binding protein/p300 
CMI  Cell mediated immunity 
CNS  Central nervous system 
CREB  cAMP response element-binding protein 
CSF  Cerebrospinal fluid 
DAB  3, 3’-Diaminobenzidine  
DC  Dendritic cell 
DMEM Dulbecco's modified essential medium 
DNA  Deoxyribonucleic acid 
DPX  Di-n-butylPhthalate 
ECM   Extracellular matrix 
ERK  Extracellular signal-regulated kinase 
FCS  Foetal calf serum 
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GM-CSF Granulocyte macrophage colony stimulating factor 
GPCR  G-protein coupled receptors 
GRO?  Growth-related oncogene alpha 
HBSS  Hank's balanced salt solution 
HIV  Human immunodeficiency virus 
HPA  Health Protection Agency 
Iba-1  Ionized calcium-binding adaptor molecule 1 
IFN?  Interferon gamma 
IGRA  Interferon gamma release assay 
IkappaB Inhibitor kappa B 
IL-  Interleukin 
JAK  Janus kinase 
JNK  c-jun N-terminal kinase 
LAM  Lipoarabinomannan 
LP  Lumbar puncture 
M.tb  Mycobacterium tuberculosis 
MAP kinase Mitogen activated kinase 
MCP-1 to 3 Monocyte chemoattractant protein-1 to 3 
MDR-TB Multidrug resistant tuberculosis 
MHC  Major histocompatibility complex 
miRNA Micro RNA 
MMP  Matrix metalloproteinase 
MODS Microscopic observation drug sensitivity assay 
MOI  Multiplicity of infection 
mRNA Messenger RNA 
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MS  Multiple sclerosis 
MSFM Macrophage serum free medium 
NFkappaB Nuclear-factor kappa B 
OD  Optical density 
PBMCs Peripheral blood mononuclear cells 
PCR  Polymerase chain reaction 
PEA3  Polyomavirus enhancer activator 3 
PF4  Platelet factor 4 
PGL  Polyketide synthase-derived phenolic glycolipid 
RNA  Ribonucleic acid 
RPMI  Rosswell Park Memorial Institute 
SAPK  Stress activated protein kinase 
SDF-1  Stromal cell-derived factor-1 
SDS-PAGE Sodium dodecyl sulphate - polyacrylamide gel electrophoresis 
SNP  Single nucleotide polymorphism 
SP-1/3 Specificity protein-1/3 
STAT  Signal transducers and activators of transcription 
TB  Tuberculosis 
TBM  Tuberculous meningitis 
TGF-? Transforming growth factor beta 
TIMP  Tissue inhibitor of metalloproteinase 
TLR  Toll-like receptor 
TNF-?  Tumour necrosis factor alpha 
TST  Tuberculin skin test 
WHO  World Health Organisation 
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XDR-TB Extreme drug resistant tuberculosis 
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